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ABSTRACT 
Stroke is a significant cause of disability in the population. When the arm is affected by 
stroke, functional recovery may be poor. The use of robotic aids to enhance arm recovery 
is a novel treatment adjunct.  There is a growing support for using robots as an adjunct to 
therapy but there has been little translation from research into clinical use. 
The investigations reported in this thesis aimed to bridge the gap between research and 
clinical use of these devices. To achieve this,five stages were carried out: 
 Firstly a systematic literature review of outcomes measure used for the upper limb was 
conducted.to establish the most reliable, valid and responsive scales. This review found a 
battery of measures (ABILHAND, CHAI, STREAM, FMA, ARAT, EQ5D, DASH, NIHSS). 
An evaluation of 125 consecutive acute stroke patients established the proportion of 
patients that potentially benefited from rehabilitation using a robotic device. This found that 
around 50% of subjects could use a robotic aid and that it was practically feasible to carry 
out the intervention. 
A pilot RCT performed on 37 participants using the battery of measures found a significant 
difference with use of the robotic device on the ABILHAND, This was not seen with the 
other measures, however there was a trend towards improvement in motor performance 
and function in the robotic group. In depth interviews with participants found subjects 
perceived gains with using the robot but fatigue stopped them using it for longer periods. 
Psychometric analysis of the outcome measures used found difficulties with the 
instruments in reflecting clinically change. 
The studies showed that a robotic device could be used practically; however stratifying 
subjects into arm severity would help provide further information over who could benefit 
from the intervention. Identifying appropriate ways of measuring changes that are clinically 
meaningful would also be beneficial. 
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1.1 INTRODUCTION 
Robotic aids may enhance upper limb motor recovery after stroke through repetitive, task-
specific training.  There is a growing research regarding the use of these aids as an 
adjunct to therapy. However unanswered questions remain, especially as currently the use 
of these devices have had little integration into clinical practice.  
This thesis describes studies which aim to address some of the gaps in the current 
literature particularly around the practical implementation of this novel therapy. The 
research presented in this thesis was completed between 2008 and 2011. 
A broad overview of the literature relating to stroke, the upper limb, and specifically its 
recovery after stroke is presented in this chapter (Chapter  One).  This chapter also 
considers the types of therapy intervention for the upper limb after stroke.  Chapter Two 
then presents a specific literature review on the use of robotic devices in upper limb 
rehabilitation. The aims, research questions, and hypotheses are set out in Chapter Three 
of the thesis. 
The original research is in four parts.  Firstly, a systematic literature review was completed 
to establish the most appropriate upper limb outcome measures to evaluate upper limb 
recovery with use of a robotic device. This is described in Chapter Four.  A recruitment trial 
(Phase I study) to evaluating the amount of participants who could potentially use the 
device and define inclusion and exclusion criteria technique was completed in an acute 
stroke population.  Details of this are given in Chapter Five.  A preliminary Randomised 
Control Trial to evaluate the effect of a novel robotic device (ReachMan) is described in 
Chapter Six.  A quantitative study to investigate participants perception of the robotic 
device was carried out in parallel to the RCT and is described in Chapter Seven. A 
psychometric analysis of the outcome measures used in the study was performed and a 
detail description of this for two of the measures used is given in Chapter eight. Finally, 
these interrelated strands are brought together in the discussion (Chapter nine) and 
conclusions of this thesis. 
 
1.2 BACKGROUND AND LITERATURE REVIEW 
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This chapter will firstly present a background and literature review on stroke. The aim is to 
place the research initially in a broader context, by discussing the nature and impact of 
stroke. This chapter will provide an introduction to the effects of stroke on individuals, and 
current theories of brain reorganisation will be discussed. Specific emphasis on the impact 
of stroke on the upper limb and recovery of the upper limb will be considered. The 
theoretical underpinning of the therapies that are employed in stroke rehabilitation will also 
be discussed.  This will provide a background into the development of using robotic 
devices as a novel therapy adjunct in upper limb rehabilitation. 
 
1.3 STROKE 
1.3.1 DEFINITION 
Stroke has been described as a “Brain Attack” 1. This definition has been used in the 
National Stroke Strategy 1to signify that stroke is a medical emergency requiring 
immediate attention. Stroke is due to the loss of blood supply to a part of the brain in a 
similar way that the loss of blood supply to the heart muscles leads to a “heart attack”. The 
definition of stroke given by the World Health Organization is, “rapidly developing clinical 
signs of focal (or global as in coma or subarachnoid haemorrhage) disturbance of cerebral 
function, lasting more than 24 hours or leading to death with no apparent cause other than 
vascular origin” 2.  
Blood supply to the brain may be disrupted in one of two ways: either a thrombus formed 
in situ or originating elsewhere blocks a blood vessel (ischaemic stroke), or a blood 
vessels ruptures (haemorrhagic stroke). The type of stroke can be reliably determined only 
by neuroimaging 3. The results of this disruption of blood supply is that an area of brain 
tissue is rendered inactive or may die. The volume of brain tissue affected together with 
the lesion location will govern the nature, severity and duration of symptoms.  Another 
source of variation in the impact of stroke is the fact that precise details of brain 
architecture will vary between individuals.  Stroke is therefore an extremely heterogeneous 
condition. Any aspect of brain function may be affected by stroke; and the physiological 
and psychological responses to the damage are wide ranging making it difficult to 
generalise about the stroke population. The heterogeneity of the condition also makes the 
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identification of appropriate treatments and research into the efficacy of these treatments 
problematic, as a treatment that works well for one person may be ineffective for another .  
Where the symptoms of a stroke last less than 24 hours the event is described as a 
Transient Ischaemic Attack (TIA or ‘mini-stroke’)4. This is often the forerunner of a more 
major event, with a 20% risk of a full stroke within four weeks of a TIA 4. 
The use of the terms acute, sub-acute and chronic in reference to time elapsed since 
stroke are not used consistently in the literature.  In view of this the definition of the terms 
used in the Royal College of Physicians’ guidance5 will be assumed throughout the thesis: 
• Acute (or early): the period up to seven days after stroke 
• Sub-acute: one to 26 weeks after stroke (first six months) 
• Chronic:  six months or more after stroke 
1.3.2 EPIDEMIOLOGY 
The National Audit Office (NAO) 6estimates that 110,000 strokes and 20,000 TIAs occur in 
England each year. Stroke is now the second most common cause of death globally7 , and 
accounts for 9% of death in England each year6 Feigin et al (2014) 9 note that international 
stroke mortality rates have declined in recent years, the absolute number of people 
whohave a stroke every year, stroke survivors, related deaths, and the overall global 
burden of stroke (DALYs lost) are great and increasing. A study by Lee et al (2011)10  
reports that incidence and mortality rates for stroke in England have decreased over the 
ten years between 1998-2008, with the incidence of stroke in the UK  falling by 29%. 
Lovelock et al  11 analysed the incidence of intracerebral haemorrhage (ICH) in the 
population of Oxfordshire over a 25 year period. They found that although ICH related to 
hypertension reduced over the period, incidence of ICH in older people had increased 
possibly due to an increase in the use of antithrombotic drugs. They suggested that the 
incidence of ICH may therefore increase with the ageing population. Feigin et al (2014) 9 in 
a global systematic review spanning 40 years, found a non-significant reduction in ICH in 
developed countries , whereas the incidence of subarachnoid haemorrhage had remained 
stable. 
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Stroke occurs in all age groups, but primarily affects older people, with three quarters of all 
first strokes occurring after the age of 65 8. Bonita(1992) 12 reports that almost one in four 
men and one in five women aged 45 can expect to have a stroke if they live to 85.   
Prevalence (number of people with stroke at a given time) was calculated by Feigin et al 
(2013)13. Data from nine studies gave a range of the prevalence for people over 65 years 
between 46.1 and 73.3 per 1000 population (men 58.8 to 92.6: women 32.2 to 61.2). 
1.3.3 BURDEN OF STROKE 
There are significant personal, social and health costs associated with stroke. There are 
more than a million people living with the consequences of stroke in the UK. 14   It is 
estimated that half of these individuals are dependent on others for everyday activities 6. 
Stroke has been reported to be the seventh leading cause of disability–adjusted life years 
(DALYs) in the developed world 2 and fifth in the developing world .15 The National Stroke 
Strategy 1 reports that stroke is the single largest cause of adult disability in the UK .   
The accurate diagnosis, investigations and management of stroke should lead to a better 
outcome for individuals affected 3. The National Stroke Strategy 1has been adopted in the 
UK with the aim of preventing stroke and treating strokes more effectively. Not only is 
there a moral imperative to provide optimum prevention and after care, but it also makes 
economic sense. It is estimated that stroke costs the NHS and the economy about £7 
billion a year: £2.8 billion in direct costs to the NHS, £2.4 billion of informal care costs (e.g. 
the costs of home nursing borne by patients’ families) and £1.8 billion in income lost to 
productivity and disability6. These statistics underlie the major cost to individuals with 
stroke in terms of lost independence, and to their families and communities in respect to 
the assistance that stroke survivors need in the long term. 
 
1.3.4 AETIOLOGY 
Strokes are caused as a result of blood vessel occlusion, hence the main risk factors for 
stroke are also risk factors for atheroma and heart disease16 . Warlow et al (2003)17 
estimated that in the white population, half of all ischaemic strokes are due to 
arteriothrombitic disease, a further 20% being caused by emboli arising from the heart, 
and approximately 25% being due to occlusion of one of the deep perforating arteries 
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leading to lacunar stroke.  There is a steeper relation between stroke and blood pressure 
than for ischaemic heart disease 17 , with 65% of people with stroke having hypertension10. 
In contrast with heart disease there is no proven association between plasma cholesterol 
concentrations and stroke. The main risk factors for stroke are illustrated in Table 1.1. 
Strokes are usually the result of a combination of risk factors coming together rather than 
any single one 16  
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Table  1.1: Major risk factors of stroke age  
Hypertension 
Smoking 
Diabetes mellitus 
Atrial fibrillation 
Heart disease 
Dyslipedaemia 
Alcohol 
Obesity 
Symptomatic and asymptomatic carotid stenosis 
Drug misuse 
Adapted from Losseff et al (2009) 16 
 
1.3.5 DIAGNOSIS OF ACUTE STROKE 
 
Acute stroke is a medical emergency and the longer treatment is delayed, the less scope 
there is for benefit from treatment (leading to the term “time is brain”.) The main form of 
diagnosis is via clinical questioning and assessment. However, Ricci et al (1993) 18 found 
that in general medical and emergency department settings up to 20% of patients with 
suspected stroke turned out to have another diagnosis. Brain imaging is the only reliable 
method to distinguish a haemorrhage from an infarct 3 and this distinction is important as 
treatment such as aspirin and thrombolysis are dangerous to give when haemorrhage has 
occurred. In 2005 , NAO (2005)6 found that less than 20 per cent of stroke units had 
access to scans within three hours of admission. This led to the National Stroke Strategy 1 
calling for an overhaul of stroke services in the UK to enable immediate transfer to a 
hospital with 24 hour hyperacute services. London now has eight hyper-acute stroke units 
treating all stroke patients in the first 72 hours after a stroke. These units provide expert 
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triage, clinical assessment, urgent brain imaging, intravenous thrombolysis if appropriate 
and prompt access to acute stroke unit and early multidisciplinary assessment. 
Furthermore, admission to a hyperacute unit can allow investigation and treatment of high-
risk patients with TIA within 24 hours which could produce an 80 per cent reduction in the 
number of people who go on to have a full stroke 1. A recent study investigating the impact 
of this centralized approach to acute stroke care in London found a reduced mortality for a 
reduced cost per patient, with these hyperacute units19. 
1.3.6 MANAGEMENT OF ACUTE STROKE 
 
Stroke was seen as untreatable, however over the last 20 years this has changed to being 
seen as a condition where there is now a range of options for acute inventions, which have 
been shown to improve outcome 16 .  Intensive physiological and neurological monitoring 
in the early phase of a stroke supports early treatment that halts stroke progression and 
prevents more brain cells being damaged 1. In the first few hours after stroke, measures 
are designed to restore blood flow (reperfusion), preserve the ischaemic penumbra 
(neuroprotection) and prevent early recurrence (aspirin treatment)  16 .  
Three main Cochrane reviews have supported three interventions for acute stroke care: 
organized stroke care20, early administration of aspirin for almost all patients with acute 
ischaemic stroke21, and intravenous thrombolysis for select patients with acute ischaemic 
stroke.22  A recently updated Cochrane Review 20 included a meta-analysis of studies of 
stroke unit care and strongly supported them for acute treatment.  It concluded that the 
numbers needed to treat to get one additional “good” outcome were low (33 for survival, 
20 to regain independence and 20 to return home). Two large randomized trials have 
shown that aspirin, given within 48 hours of onset, has a small but significant benefit in 
reducing the rate of recurrent ischaemic stroke23;24.Although this benefit appears small, in 
the UK it is estimated that if everyone in the UK with stroke were given aspirin with 48 
hours of onset (after CT scan to exclude haemorrhage), then more than 1000 people 
would be saved from death or disability every year 1 
Thrombolysis therapy is a novel development in stroke medicine and is not without 
controversy25 The thrombolytic or “clot-busting” drug alteplase (rt-PA) has been tested in  
clinical trials in ischaemic stroke since the 1990s The NINDS study26 showed that one in 
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eight people benefited from being thrombolysised within three hour onset of symptoms, 
making a full or nearly full recovery. Treatment was associated with a chance of fatal 
intracranial haemorrhage and treatment was in highly selected patients26. Guidelines vary 
as when to administer the drug due to limited trial evidence. The IST3 trial 27in May 2012 
found that thrombolysis within 6 h improved functional outcome. This benefit did not seem 
to be reduced in  people who were over 80 years old. In the UK, recent reports illustrate 
that the thrombolysis rate has increased from 1.8% in 2008 to 5% nationally in 20105.The 
Department of Health has suggested that if this were increased to 10% over 1,000 people 
would regain independence rather than die or be severely impaired28. The NAO 28 
estimated that the net saving to the Health Service of implementing this would be £16 
million per annum.  
Physiological abnormalities including increased temperature, low blood oxygenation, 
altered blood pressure and high blood sugar levels often occur after stroke17 . Within the 
setting of a stroke unit, patients are monitored closely and appropriate interventions are 
given to prevent or treat those physiological abnormalities and other complication 29 
At present rehabilitation, rather than, say, drug treatment is the main strategy for driving 
recovery after stroke. The great promise of many pharmaceutical interventions (such  as 
amphetamines) has yet to be realized 30.  A recent study investigated the use of fluoxetine 
with physiotherapy suggested enhanced motor recovery after 3 months, however further 
work is needed to investigate the effect of this drug treatment. 31This is in sharp contrast to 
the striking benefits seen with techniques such as brain care (described above) and 
thrombolytic therapy whose primary aim is to prevent damage from occurring in the first 
place.  A study from Canada 32  investigated over a five year period at the impact of 
thrombolysis on progress through inpatient rehabilitation, found no evidence to suggest 
that it contributes to greater functional improvement.  
1.3.7 EFFECTS OF STROKE (GENERAL) 
 
A significant proportion of those who have a stroke will die within the first month. Feigin et 
al (2009) 8 report that the case fatality ranged from 17% to 30% (25-35% ICH , 25-35% 
SAH and 13-23% in ischaemic stroke ) in high-income countries. Much higher percentages 
of deaths occur early post stroke in people who have had haemorrhages in low-income 
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countries (30-48% ICH, 40-48% SAH). Warlow et al (2003)17  suggest that death 
immediately after stroke is most often due directly to the brain lesion, either causing a 
mass effect or disrupting vital centres. Death occurring later are likely to be due to 
complications such as pulmonary embolism or infection 33. 
 However, as most patients with stroke survive the initial injury, the biggest consequence 
on patients and family is usually through long-term impairment, limitations of activities and 
reduced participation7 .  Lawerence et al (2001) 34 reported the prevalence of acute 
impairments in a large population of first-ever strokes.  Table 1.2 lists the most commonly 
occurring deficits as seen in this study. A recent sentinel audit5  also reported similar 
prevalence of impairments 
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Table 1.2: Impairments associated with stroke 
Impairment % of the stroke population 
affected 
Upper limb weakness 77.4 
Lower limb weakness 72.4 
Urinary incontinence 48.2 
Impaired consciousness 44.7 
Dysphagia .44.7 
Impaired cognition 43.9 
Dysarthria 41.6 
Upper limb sensory deficit 30.3 
Lower limb sensory deficit 27.2 
Visual field neglect 26.1 
Dysphasia 23.0 
Visual neglect 19.8 
Sensory inattention 19.4 
Gaze paresis 18.4 
Ataxia 7.23 
Deficits that are independently associated with death and severe disability 
at three months after stroke. Data taken from Lawerence et al (2001) 34 
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As is clear from the above data, the most common and widely recognised impairment 
caused by stroke is motor impairment. However other important functions may be affected 
by stroke. 
Neglect primarily affects those with right hemisphere lesions 35. A range of features may be 
present with either sensory or motor systems, or both, being affected. Spatial neglect has 
visual and non-visual components, affecting extrapersonal and/or personal space. Neglect 
may also be linked to attention deficits 36 , and may impair an individual’s ability to engage 
in rehabilitation activities leading to a poor prognosis 37 . 
Sensory loss or diminution of sensory perception may also be caused by stroke. The 
detection of pain, temperature, touch or proprioception may be affected, and the 
interpretation of sensory information (eg stereogenisis, textual  discrimination ), may be 
impaired 38. Altered sensory perception may have a detrimental impact on an individual’s 
ability to use their arm and so impede recovery. For example, in a study of upper limb 
recovery ,Feys et al (2000) 39 found that proprioceptive loss was prognostic of poor 
outcome.  
 Cognitive deficits resulting from stroke can have devastating impact on both patients and 
their families 40 . Studies report that up to 65% of stroke survivors demonstrate new onset 
or worsening of cognitive impairments after stroke 41. Stroke-related cognitive deficits 
interfere with functional recovery and may influence an individual’s ability to engage in 
rehabilitation. 
Other functions such as swallowing, communication, perception, depression, fatigue and 
continence may be affected by stroke and again can interfere with functional recovery and 
the potential benefits of rehabilitation. 
All the above impairments can impede on the rehabilitation process and impact on the 
potential for recovery. This thesis will now, however focus specifically on the upper limb 
post stroke. 
1.3.8 PHYSICAL EFFECTS OF STROKE ON THE UPPER LIMB 
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Motor deficits of the upper limb following stroke may range from total paralysis to partial 
paresis. Authors 42;43suggest that there are three main components of compromised motor 
control following stroke these include: weakness, impaired inter-segmental coordination, 
and hyperreflexia or spasticity: 
Muscle weakness in the upper limb after stroke may be due to alterations in neural drive 
as a result of superspinal changes to the alpha motor neuron pool at a spinal segmental 
level, structural changes and atrophy in sketal muscle in response to impaired muscle 
activity and reduced activity can also cause weakness. In addition the stroke population 
tends to be older in age and so will also have normal muscle changes associated with 
older age. This may compound on any effects of the stroke. There is a growing body of 
evidence that suggests that weakness plays a significant role and contributes directly to 
compromised motor function post-stroke43;44 Canning et al(2004) 45 and Harris and Eng 
(2007), 44 for example, found that loss of strength is a major contributor to physical 
disability following stroke, and Shelton et al(2001) 46 found a significant relationship 
between the severity of motor impairment and functional recovery.   
Impaired inter segmental co-ordination has been extensively described47-49  Causes for this 
are likely to be multifactorial: there may be contributions from a decrease in pre-synaptic 
and reciprocal inhibition50;51, reorganisation at cortical or spinal level in response to 
lesion52, change in the descending pathway used to carry the signal to move53;54 and 
alterations in stretch reflex threshold 47may also contribute. Impaired co contraction has 
particularly been described around the shoulder and elbow joints during attempts to 
reach47;55. Authors comment that subjects are constraint to a smaller number of 
stereotypical movement patterns, particularly after severe stroke, with abnormal patterns 
such as unwanted elbow flexion, with shoulder abduction or forward flexion55;56.  There is 
much debate in the literature to the extend which co contraction is a separate phenomenal 
from spasticity47;56 
The most common definition of spasticity is that by Lance (1980)57 as “a velocity-
dependent increase in tonic stretch reflexes with exaggerated tendon jerks, resulting from 
hyper-excitability of the stretch reflex” With the growing body of evidence into spasticity 
this definition is argued to be not fully accurate and does not reflect the clinically 
presentation of spasticity. 58 
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Pandyan and collegues (2005)59 argue that spasticity is not a pure motor disorder and  is 
not caused solely by hyper-excitabilty of the stretch reflex. They propose the following 
broader definition of spasticity: “Disordered sensori-motor control, as a result from an 
upper motor neuron lesion presenting as intermittent or sustained involuntary activation of 
muscles.” 
 It is difficult to measure and scales exist for the assessment of muscle tone; however, the 
reliability and validity of these have been contentious60,61. In a study of the cause of 
contractures after stroke, Ada et al (2006)62, found that spasticity was the major 
contributing factor to the development of contractures in the first weeks after stroke, but 
that after four weeks weakness was the most significant factor. 
Sensory modalities (e.g. pain, temperature, proprioception, vibration, light touch) can be 
affected by stroke and the loss may be partial or complete, 38 Sensory deficits can have a 
profound impact on the function of the limb 63. In addition to the loss of sensory input, the 
interpretation of sensory information (e.g. stereognosis) can be affected by stroke and this 
may cause a reduction in function 64.  
Stroke may cause a range of types of perceptual neglect.  In such cases, an individual 
may have a poorly functioning arm and hand, despite good muscle strength, due to poor 
awareness of its existence 63.  Additionally, neglect can lead to mechanical trauma as the 
limb may be kept in a poor position.  This may result in further complications, including 
pain and apraxia. 
The prevalence of shoulder pain has been described as well-known impairment after 
stroke 65. The incidence of upper limb pain has been reported to vary widely from 9% to 
40%.  Some prevalence estimates as high as 84%.65 There are multifactoral reasons for 
shoulder pain: Mechanical damage (e.g. shoulder subluxation) may be a secondary 
consequence of stroke, which can lead to shoulder impingement  66. Pain can also be of 
central origin and, as with mechanical pain, may lead to protection and disuse of the limb 
67
. Post stroke shoulder pain contributes to longer hospitalization times 66 and is associated 
with depression68  and decreased quality of life69 . Loss of or a reduction in arm motor 
function at the onset of stroke or during the rehabilitation phase have been shown to be 
predictors of the development of poststroke shoulder pain70;71. Shoulder pain also has 
been reported to be more frequent or intense among persons with left-sided hemiparesis 72 
38 
 
65
. Reduced shoulder ROM in the hemiparetic side of persons with shoulder pain is 
observed within the first weeks after the onset of stroke 73 and tends to worsen during the 
first months65;73 
1.3.9 RECOVERY POST STROKE 
Recovery of function after stroke is variable and depends on the nature and extent of the 
stroke and the characteristics of the individual affected, such as pre-existing impairments 
and co-concurrent disease. Early recovery following stroke is understood to be due to the 
resolution of cerebral swelling, reperfusion of the ischaemic penumbra and gradual 
reversal of diaschisis74. Later recovery is believed to be due to capacity of the brain for 
reorganisation of neural networks (neuroplasticity) in response to the damage and 
behavioral compensation (including those encountered in rehabilitation) 75;76 and  And  
activity dependent plastic change 
The impact of a person’s age (as opposed to age-associated co-morbidity) at the time of 
stroke, on recovery is controversial.  Black-Schaffer and Winston (2004)77 performed a 
study involving almost 1,000 people looking at  the effect of age on outcome. They found 
that in the higher functioning subjects (Functional Independence Measure (FIM) score of 
over 80) age did not predict outcome.  The older subjects in this group achieved the same 
functional gains as the younger cohort.  In the more impaired group the older subjects did 
not make as good a functional recovery by discharge as their younger counterparts.  The 
authors suggest that recovery may be as good in this group in the longer term but that they 
may need a longer period to reach the same point. 
There are three neuroplastic phenomena that occur in the nervous system following a 
lesion, which facilitate structural and functional reorganisation78;79.These include 
denervation super sensitivity, collateral sprouting and unmasking of silent (latent) 
synapses. 
Denervation super sensitivity occurs when there is a loss of input from some brain regions. 
An increased release of transmitter substances causes a heightened response to 
stimulation. 80  Post-synaptic target neurons become hypersensitive to the transmitter 
substance, increasing the number of receptor sites. Collateral sprouting appears in the 
cells surrounding the lesion, where collateral dendrites make connections with those 
synapses lost by cell necrosis  .81 Experiments in animals have found unmasking of silent 
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synapses occurring when previous non-functioning neurons are accessed to form new 
connections. 82 83These studies have also found that changes within the structure of the 
nervous system can be organised or disorganised producing adaptive or maladaptive 
sensorimotor behaviour, which can promote or be detrimental to recovery. 76;84   
In addition to neural reorganisation, individuals may employ compensatory strategies to 
maximise their function. Enriched environments giving subjects greater than normal 
stimulation has been shown, at the right time, to promote significant neuroplastic changes 
and improvement in functional outcomes. 85 86 
 Although many of the studies that have contributed to the current understanding on 
neuroplasticity have come from animal studies, it is likely that the complex 
interconnections of the human brain are disrupted in a similar way to those of primates 87. 
Brian imaging studies support Nudo 76;84 and others work. Baron 88, for example, describes 
the expansion of areas of the Primary Motor Cortex (M1) adjacent to a stroke, possibly due 
to the unmasking or disinhibition of latent connections or recruitment of areas not normally 
associated with the function. Plasticity may be influenced by behaviours and it has been 
postulated that early repetitive practice of any task may be associated with improved 
outcome due to plasticity.89  
Ward (2011)90 reports that in the early stages after stroke sensorimotor tasks using the 
paretic arm and hand lead to activation in many areas of the brain, including the primary 
motor, premotor and supplementary motor cortices of both hemispheres.  People who 
have poor recovery continue to demonstrate this diffuse pattern of activation, whereas 
those with better 91recovery show a more normal pattern, usually limited to the ipsilesional 
hemisphere.   
 
1.4 UPPER LIMB RECOVERY 
Upper limb recovery after stroke is still unacceptably poor92 . Reports in the literature vary 
as to the proportion of patients who actually recover upper limb function. Gowland et al 
(1982)91 investigated the prognosis outcome of 223 stroke patients. They found that only 
5% of the patients regained arm function. Dean and Mackey (1992) 93however reported 
that 52% of subjects they studied regained upper limb function. Broeks et al (1999) 67 
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found a similar percentage (50%). Kwakkel et al 92 however found only 11.6% of the stroke 
subjects they investigated gain upper limb functional use. These longitudinal studies all 
used different sample sizes, inclusion criteria, durations of treatments and outcome 
measures.  However regardless of these differences, these studies all indicate a poor 
recovery of arm and hand use following stroke. This is seen even more so in comparison 
to the number of patients who gain lower limb recovery and the ability to walk, with studies 
reporting 70/80% of patients being able to walk 17.93Although, the lower limb recovers more 
completely than the upper limb, clinically there is interdependence between the upper and 
lower limb. 94  An improvement in the ability to use the upper limb in a reach task is linked 
to the ability to use the lower limb for support and balance. 95  
It is hard also to define what constitutes “good recovery” in the upper limb post stroke.  
Studies that have found improvement in arm function  at an impairment level do not 
necessarily directly link to a functionally meaningful change.96;97: Winstein et al (2003) 97. 
comment that the relationship between impairment, participation, and activity limitation are 
complex and affected by numerous modifying factors.. People with stroke themselves 
have reported difficulties with arm movements, although they were measured clinically as 
having no arm impairments 96;Furthermore studies 67;97 have also suggested that functional 
motor recovery of the UL tends to occur later in the rehabilitation period. 
1.4.1 REASONS FOR POOR UPPER LIMB RECOVERY. 
There is no clear evidence that identifies the reasons for the poor recovery of the arm 
following stroke, although a number of theories have been identified. To place these in 
context, it is helpful to explore the functions and use of the arm in everyday tasks.  
1.4.2 THE UPPER LIMB 
The hand and arm have an extensive range of functions, including the movement and 
manipulation of objects; communication and expression through gesture and touch; tactile 
sensation and exploration; and aiding balance and locomotion.  In terms of manipulation, 
the unique flexibility of the human hand (especially as provided by the opposable thumb) 
allows a myriad of both power and precision grips. Although other species are able to use 
their hands to hold objects, their manipulative ability is compromised by the need for the 
limb to be involved in locomotion 98.  
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The range of movement provided by the shoulder complex, elbow, radio-ulnar and wrist 
joints allows the upper limb to reach objects at some distance from the body and in many 
directions. Stability at the trunk and around the joints is important to enable the transport of 
objects and this is provided primarily by muscles and ligaments 98. The joints of the upper 
limb act as a complex to reach and manipulate objects. Grip is shaped as the hand is 
transported towards an object 99 .The position of the digits is adjusted during reaching to 
provide a grasp shaped to allow the target to be encompassed. The forces coordinated by 
the hand are coordinated with those of the arm in order to lift and transport the object. 
There are a remarkable number and range of grips available which have been 
documented in detail by a number of authors 100 101 ,in general they are classified as power 
grips and precision grips.  Although standard grips have been described, each individual 
may use idiosyncratic or improvised grips, and actions may not always be completed in the 
same way 98 Additionally, dominant and non-dominant hands may be specialised for 
different tasks: for example the dominant hand is often used for more precise actions and 
non-dominant for stabilising or supportive actions 94 
When reaching for an object it can be observed that the path along which the hand moves 
usually approximates a straight line between start and end points. This requires 
simultaneous coordination of changes in angles of wrist, elbow and shoulder joints and 
takes into account kinematic factors and torques.  Morasso (1981) 102 in a “Manipulandum 
Study” found that spatial paths had straight lines and the velocity profile had a smooth 
single peaked form regardless of direction. The functions of the hand and arm are as much 
sensory as motor94, tactile and pressure sensors provide precise information about the 
texture, temperature, shape, size and weight of objects.  This allows us to distinguish 
between different shape and size coins without looking and objects in the dark. The hand 
acts as an exploratory sensory organ in that it can move towards, or seek out, stimuli, 
unlike the eye or ear which merely responds to stimuli reaching them 103. 
The hand and arm are also used as a means of communication. Touch and gesture 
convey a variety of messages to others and provide a means to demonstrate emotion 
(such as a slap or a shaken fist, thumbs up), a sign (beckoning, waving) or a command. 
Paralinguistic signs also accompany speech.  
The arms are involved in posture, when balance is compromised, the arms play a 
stabilizing and supportive function and if balance is lost, the hands are used to form a new 
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base of support94. Postural adjustments occur prior to during arm movements and this has 
been reported to occur when reaching for objects in standing, sitting and pointing94.  
Most commonly performed activities are performed bimanually (such as feeding, dressing, 
brushing teeth and washing). This involves complex interactions between the two limbs 
with co-ordination of both. Consequently, the implications of not being able to use an arm 
following stroke has broader implications. The inability to feed oneself or to use utensils in 
an appropriate way, and require assistance to wash and dress can be socially 
incapacitating and may also be embarrassing or humiliating.  
The aging process causes “normal” changes to occur in reaching, grasp and manipulation 
104
.Reaching movements have been found to be slower in over 65 and this is thought to 
relate to slowness in central processing, with slowing in performance on reaching 
movements being greater for complex tasks than simpler ones94 . Carmeli et al 2003104 
report a decline in hand function after the age of 65 and relate this to changes in the 
musculoskeltetal, vascular and nervous systems. Grip strength decreased with increased 
age 105and sensory thresholds increase 106.These “normal” changes may also be 
accompanied by other pathologies such as osteoarthritirs which may also affect hand 
function. As stroke predominantly affects the older population, these “normal” age related 
changes are likely to be present in many people prior to their stroke. 
1.4.3 SUGGESTED THEORIES FOR THE REASONS FOR POOR UPPER LIMB 
RECOVERY. 
Multiple causes may explain poor recovery in the upper limb and this will now be explored. 
They include: 
• Complexity of upper limb function 
• Site and size of the lesion post stroke 
• Learned non use 
• Secondary complications 
• Hand dominance 
• Amount of time spent on upper limb rehabilitation. 
1.4.4 COMPLEXITY OF UPPER LIMB FUNCTIONS 
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As described in section 1.4.2, the upper limb is involved in an extensive range of functions.  
Desrosiers et al (2003)107  suggest that functional motor recovery of the UL tends to occur 
later in the rehabilitation period. This may be due to the greater degree of sensory 
integration and fine motor control required for manual dexterity rather than gait.  This may 
also be a contributing factor to the poorer functional recovery seen in the upper limb 
following stroke. Broeks et al(1999) 67 report that patients four years after stroke described 
loss of arm function to be a major problem, despite their being assessed in standard tests 
as having “reasonable” upper limb function.   While patients can walk with relatively large 
lesions and impairments, a functioning upper limb requires a greater degree of 
improvement, as it comprises a complex integration of muscle activity 108 109   
1.4.5 SITE AND SIZE OF THE LESION POST STROKE 
The size and site of the lesion post stroke has been postulated as a possible reason for 
poor recovery in the upper limb post stroke. The higher prevalence of Middle Cerebral 
Artery (MCA) than Anterior Cerebral Artery (ACA) stroke, may explain the greater 
proportion of patients in whom the arm is more severely affected than the leg 110  
Shelton and Reding (2001)46 found in a study of 41 stroke subjects that recovery of the 
upper limb was more likely by the time of discharge in those with purely cortical strokes  
(supplementary motor area (SMA), premotor area (PMA) or motor cortex (MI)) rather than 
those with strokes in either the corona radiata or internal capsule.  They propose that 
subcortical strokes may have a devastating impact on function as they affect the 
descending motor pathways as they converge to leave the brain, so that more fibres can 
be damaged.  Feys et al (2000) 39et al found a similar correlation between lesion location 
and recovery at 2 months after stroke, in 45 subjects. They found that recovery at twelve 
months was found to be predicted more accurately by clinical tests of motor activity. Feys 
et al  ; (2000)39 noted that recovery tended to be slower in the case of subcortical strokes. 
This may explain the finding of Shelton and Reding (2001) 46 whose final outcome was on 
discharge (with an average length of stay of 62 days).  Schiemanck et al (2008) 111.and 
Puig et al (2011) 112found similar associations with poorer arm function with more loss of 
ipsilesional tract integrity at the level of the posterior limb of the internal capsule.  
Numerous studies propose that a patient has better prospects for upper limb recovery if 
TMS can elicit motor-evoked potentials (MEPs) in affected upper limb muscles within the 
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early days of stroke113. Although, some individuals with no upper limb MEPs may still 
recover some manual dexterity 114 . Using TMS, together with the use of brain imagery 
findings have led to studies predicting the potential for upper limb recovery in the early 
days post stroke 113;115. These studies are however preliminary in nature, using a small 
number of patients and have used patients lacking cognitive difficulties.  
Corticospinal tract integrity (as measured by  Diffusion Tensor Imaging) has been seen to 
be a key prognostic indicator. Stinear et al (2007) 54 found that  functional potential in 
chronic stroke patients was dependent  on corticospinal tract integrity. Subsequent work  
112
 
116
 have also found this to be true. 
 
1.4.6 LEARNED NON-USE 
From the earliest stages after a stroke, an individual will adapt to the changes brought 
about by it. This may be seen in the assumption of new postures or in the use of a non-
dominant hand to complete functional tasks. This compensation for loss of function is likely 
to drive neural reorganisation and lead to the reinforcement of the pathways that support 
compensatory movements 117. In some cases this will interfere with recovery of normal 
function. Taub et al (1999)118 considers that people with stroke may develop  ‘ learned 
non-use’ . It is proposed that some of the decrease in hand and arm function after stroke is 
not directly related to impairments such as loss of muscle strength. Instead, it is 
suggested, repeated failed attempts to use the hand and arm lead to the individual 
adopting movement strategies that do not involve the affected limb 118. This would result in 
weakness due to non-use and therefore further limit the use of the limb. Sunderlad and 
Tuke (2005)119  question whether ‘learned non-use’ is merely that the difficulty of using the 
affected limb leads to a preferential use of the other limb, despite an ability to use it. This 
could be an adaptive response brought about by choice not to use the limb. 
 
1.4.7 SECONDARY COMPLICATIONS 
However, other impairments such as spasticity, sensory deficits, spatial neglect, cognitive 
impairments, dyspraxia, and ataxia also impact on the functional ability of the UL. (These 
have been described in more detail in sections 1.3.7). Secondary effects such as soft 
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tissue shortening, pain or learned non-use (discussed above) may also result in reduced 
UL function. 
1.4.8 HAND DOMINANCE 
Hemisphere dominance is an extensive and complex topic which is beyond the scope of 
this thesis. However, it is important to note that it may be a factor affecting upper limb 
function after stroke. In many individuals a strong preference for the use of one hand is 
apparent, and the functional uses of the dominant and non- dominant hands differ 120. This 
may influence an individual’s motivation for using the affected limb. 
1.4.9 TRUNK AND UPPER LIMB POSTURAL CONTROL 
Efficient control of posture is important for upper limb function 121 and the upper limb may 
play a minor role in controlling posture. In order for the arm to be able to move away from 
the body to reach a target, the body must be stable enough not to require support from the 
upper limb. Weakness of trunk muscles may therefore lead to the upper limb being used to 
support the body against gravity, and so make it unavailable for any other function. 
Similarly, weak trunk muscles may make it impossible for an individual to move the body 
towards and object, so decreasing the functional range of reach. 
Studies investigating stroke survivors’ ability to reach have described multiple 
discrepancies from the strategies used in normal subjects. 122 Analyses have found that 
people after stroke demonstrated longer, more segmented, more variable movement and 
larger movement variables.122  Furthermore stroke survivors used compensatory trunk 
movements for forward transport and hand orientation123. 
The use of trunk restraint has been shown to result in an immediate improvement in active 
range of movement and co-ordination in moderate to severely affected stroke subjects49. 
1.4.10 AMOUNT OF TIME AND PRACTICE SPENT ON THE UPPER LIMB IN 
REHABILITATION. 
In acute settings there may be a pressure for early discharge of the patient, and there is 
some evidence in favour of the policy of early discharge with support 124 The role of the 
stroke unit therapist may therefore be to educate the patient and prevent upper limb 
complications rather than to provide rehabilitation to promote recovery of the limb. Therapy 
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often focuses on standing and walking, providing more opportunities to use the lower limbs 
in bilateral, weight bearing functional tasks such as walking and stair climbing, to allow 
safe discharge home.125Time for arm and hand training can be for very short periods 87. 
This finding is supported by a study comparing the activities of patients in five acute stroke 
units, in which Berhardt et al (2007) 126 found that in the first fourteen days after stroke only 
four to eleven minutes each day were spent  on upper limb activities. Hammett (2010)127 
also found that therapists working in two acute stroke wards recorded spending only 10 
minutes daily on UL rehabilitation.  
There has been in recent years a growing number of Early Supported Discharge Teams 
(ESD) emerging as a means to deliver therapy post stroke. Evidence from randomised 
controlled trials indicates that Early Supported Discharge services can significantly reduce 
the length of inpatient stay 128. However there has been variation in what defines an ESD 
service and the criteria for acceptance of a patient by such a team.  The 2010 Care Quality 
Commission audit 136 for stroke highlighted that only 18 per cent of these services have 
appropriate staffing.  A potential issue may be that time for intensive hand and arm training 
may not be available with this lack of staffing. Furthermore patients who only have arm 
problems may miss out or be lost to the service.  
An observationnal study in American and Canadian rehabilitation centres found that the 
amount of practice in post stroke rehabilitation was substantially smaller than those used 
in the animal studies of successful motor learning 129 . Work by Kimberly et al (2010) 
130also investigated at the amount of repetitions patients performed in therapy sessions 
and found them also to be small in number in comparison to animal studies . No direct 
work has  investigated at how much repetition of movement is needed .in stroke patients to 
demonstrate functional improvements and evidence is unclear exactly how many 
repetitions are necessary for functional improvements to occur. However, the indication 
from research in animals and humans suggest that hundreds of repetitions are necessary 
in the upper limb for successful cortical reorganisation. 
Stroke patients themselves report that they feel that upper limb rehabilitation and recovery 
is an important but neglected issue in acute stroke rehabilitation 131:132.Barker and Brauer 
(2005)132investigated the stroke survivor’s perspective of upper limb recovery in a 
qualitative study involving interviews and focus groups with stroke survivors and their 
spouses. Stroke patients frequently questioned why the emphasis in acute rehabilitation 
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was placed on the lower limb, and walking in particular. Turton and Pomory (2002) 87 also 
express this view commenting that the potential for improvement may be lost due to 
inadequate upper limb training.  
 
1.4.11 SUMMARY OF REASONS FOR POOR RECOVERY OF UPPER LIMB 
FUNCTION 
As highlighted above there are a variety of factors which have been postulated to impact 
on upper limb recovery post stroke and may also explain the poor recovery seen. Many of 
these are not influenced by rehabilitation, for example the site and size of lesion are major 
determinants of outcome.  Nevertheless, there is a belief that inadequate upper limb 
training may impact on the potential for recovery post stroke and that greater intensity of 
therapy brings about greater benefits.   
The rest of this chapter will now focus on the evidence base investigating rehabilitation of 
the upper limb after stroke.  
 
1.5 REHABILITATION FOR THE UL AFTER STROKE  
1.5.1 REHABILITATION AFTER STROKE 
Rehabilitation is defined by the WHO (2009) 133as “processes intended to enable people 
with disabilities to reach and maintain optimal physical, sensory, intellectual, psychological 
and/ or social function.” Despite the successes of acute stroke management, such as 
thrombolysis, rehabilitation, rather than drug treatment is the main strategy for driving 
recovery after stroke 134 135. For patients, rehabilitation is fundamentally a process of 
relearning how to move in order to carry out their needs successfully 136. 
In terms of specific rehabilitation interventions, the evidence base presents us with many 
gaps with only a few trials completed for any one intervention category or at different 
stroke delays 137 . Barriers to evaluating the most effective interventions include the 
heterogeneity of the stroke population, the variety of stroke settings, variations in time of 
intervention and wide variation in outcome measures used, as well as small sample 
populations and methodological flaws in the published studies.   
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Furthermore, Wade138 argues that rehabilitation is a ‘process’ involving many overlapping 
components and that all of these together may produce effects greater than the sum of 
their parts. Added to the difficulty in evaluating the most effective intervention is the impact 
of a patients independent activity and the influence of family and friends.   
 
1.5.2 CURRENT THERAPY APPROACHES 
A specific therapy in rehabilitation- physiotherapy for stroke consists of a number of 
approaches with no conclusive evidence to support the use of one over another 139;117. 
Physiotherapy interventions following stroke  have often been referred to as a ‘ black box’ 
140
,with little available knowledge of which specific component of the intervention provided 
following stroke are responsible for the changes and improvements observed. 
(Physiotherapy techniques used for upper limb are seen in Table 1.3). This also hampers 
the analysis of the effectiveness of interventions when using ‘conventional therapy’ as a 
comparison/ control. The studies which are described in Chapter five and six of this thesis 
address the problem of the definition of treatment by making use of detailed treatment 
schedules, both to record experimental intervention and the conventional therapy that 
subjects receive (see Appendices 1 and 11) 
 
1.5.3 CONVENTIONAL THERAPY 
As mentioned above, conventional therapies (those used in routine clinical practice) used 
in upper limb rehabilitation following stroke use a package of different treatment activities 
and are difficult to describe 141 It is known that the content of conventional therapies differs 
between clinical settings and over time 140. Traditionally the physiotherapy approach 
favoured in the UK has been that of neurodevelopmental physiotherapy, pioneered by 
Bobath, although physiotherapists report using an eclectic approach142. Two recent 
systematic reviews have concluded that further investigation into the efficacy of the Bobath 
concept is required 143;144; with there being ongoing debate currently regarding these 
conclusions. 
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1.5.4 REPETITIVE TASK PRACTICE 
Current approaches to upper limb recovery emphasise the need for intensity and 
progression of treatment. Retrospective reviews of physiotherapy in stroke suggest that 
increased intensity is beneficial. 145;146  Task related training, in which movement related to 
functional activity is directly trained has shown better results than impairment focused 
programs 89. In a Cochrane systematic review, French et al (2010) 147 conclude that task 
specific training can result in functional activity gain, which although modest in degree, 
appears to be clinically meaningful. However, the evidence for UL interventions was less 
clear due to insufficient good quality RCTs and difficulties in evaluating repetitive task 
training in clinical trials as in practice many rehabilitation interventions include complex 
and mixed interventions.  Key elements of task specific training seem to be intensity, 
variability, repetition, specificity, motivation, and salience of the task to be practiced 148. 
Training should include timely and positive feedback, but all rewards should fade over time 
to prevent unnecessary dependency 149. 
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Table 1.3 Physiotherapy Techniques used post Stroke 
Co
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Sensory re-
education 
Systematic 
sensory 
stimulation  
Soft tissue 
mobilisatio
n / 
realignment 
Facilitation 
of muscle 
activity / 
movement 
Strength 
training 
Repetitive 
active exercise 
with increasing 
resistance 
Task specific 
training 
Active goal-
directed 
exercise  
O
th
er
 
te
ch
n
iq
u
es
 
u
se
d 
fo
r 
th
e 
u
pp
er
 
lim
b 
 
Balance and 
mobility 
tasks 
incorporatin
g upper limb 
activity 
Mental 
imagery 
Cognitive 
practice of 
motor tasks  
 
Bimanual 
practice 
Rehearsal 
of 
movements 
requiring 
the use of 
both arms 
to promote 
normal 
inter-
hemispheric 
co-
ordination  
Constraint 
Induced 
Movement 
Therapy 
(CIMT) 
Constraint of 
ipsilesional 
arm 
Repetitive task 
specific 
practice with 
other arm 
Splinting 
Maintenance 
of range of 
movement 
using external 
support 
Serial casting 
to improve joint 
range of 
movement 
Robotics 
Use of 
mechanical 
devices to 
guide and 
assist or 
resist practice 
of motor tasks 
Biofeedbac
k 
Provision of 
an auditory 
or visual 
response to 
a movement 
Functional 
Electrical 
Stimulation 
(FES) 
Electrical 
stimulation 
of muscles 
to coincide 
with 
voluntary 
contraction 
Transcutaneo
us Electrical 
Nerve 
Stimulation 
(TNS) 
Electrical 
stimulation – 
usually 
sensory 
Transcranial 
Magnetic 
Stimulation 
(TMS) 
Magnetic 
impulse over 
motor cortex to 
stimulate 
muscle 
contraction 
Mirror 
therapy 
Use of mirror 
box to provide 
Virtual 
reality 
Task 
specific 
Observatio
n to imitate 
Mirror motor 
neurons 
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an illusion of 
movement of 
the paretic 
limb 
practice 
using 
computer 
generated 
settings 
activated to 
stimulate 
areas of the 
CNS used 
when 
moving 
oneself 
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1.5.5 CONSTRAINT-INDUCED MOVEMENT THERAPY 
The most promising interventions for upper-limb (arm) function seems to be constraint-
induced movement therapy (CIMT), for which there has been a substantial number of 
trials.63 In the case of CIMT, this may be due to the intensive functional retraining element 
rather than the constraint of the non-paretic limb 150 151.There is ongoing debate about the 
contribution of the various elements of CIMT and studies are currently investigating the 
various aspects of this therapy 152 .The application of CIMT is normally limited to people 
with some active wrist and finger extension 153.  This therapy is therefore not suitable for 
people with moderate to severe arm paresis.  Moreover, studies also suggest that stroke 
survivors with severe UL paresis are frequently excluded also from task-oriented training 
because they have insufficient movement to actively perform a motor skill 154. 
1.5.6 TIMING OF THERAPY 
The appropriate timing of therapeutic intervention has been debated 87. This is due to 
animals studies that suggested that intensive therapy early after a lesion may be 
detrimental due to excessive demands made upon insufficiently recovered or oxygenated 
tissue 155. A recent  study of intensive therapy to the arm in the early stages post stroke151 ( 
CIMT) also echoed those seen in the animal studies, with a worse outcome than either 
smaller doses of the therapy or a smaller dose of conventional therapy  However reviews 
suggest that more therapy is better in the acute phase 156 and that potential for 
improvement may be lost due to inadequate training in what may be a ‘critical period for 
recovery’ 87 in the early weeks post stroke, suggesting 4 weeks post stroke. However it 
should also be noted that some people may not tolerate intensive therapy in the acute 
phase 157;158. 
 
1.5.7 THERAPEUTIC DOSE 
Dose finding is a relatively novel concept in physiotherapy research.  Studies analysing 
therapies rarely mention how the amount of therapy provided was determined prior to the 
study 
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The absence of dose-finding studies in therapy trials may be because therapy is generally 
viewed to be a ‘good thing’ with few (if any) harmful effects.. The frequency and duration of 
treatment intervention in studies of therapy is often based on that used in other studies or 
what is practically possible in routine clinical care 107.   Custom and practice, whereby all 
patients entering a stroke unit receive ‘some’ physiotherapy has become established.  As 
already noted, studies of stroke therapies suggest that more therapy in the acute stages is 
better 146, although, in her review of the literature, Cooke ( 2010)159 found little evidence 
from the published studies to support greater intensity of therapy.  Unfortunately, studies 
do not tend to compare therapy with no treatment or a placebo, as it is considered that the 
recovery of patients would be disadvantaged by the absence of therapy in the acute stage 
after stroke 117.This however means that any improvements noted cannot be solely 
attributed to the therapeutic intervention, but may be due to other factors including 
spontaneous recovery 160 or the attention associated with treatment. At present, clinical 
guidelines recommend the provision of at least 45 minutes of therapy a day5. 
Two recent studies have evaluated dose as a precursor to randomised controlled trials 
comparing functional strength training and conventional physiotherapy for the lower and 
upper limbs.140;159  In respect of the upper limb, a single dose of conventional 
physiotherapy was surprisingly found to lead to better outcomes than a double dose of 
conventional physiotherapy 140 The best results were obtained in the Functional Strength 
Training  and conventional physiotherapy group, suggesting that the content of the therapy 
may be more important than its intensity.  However, in respect of the study of lower limb 
therapy159 , no clear difference was found between Functional Strength Training and an 
equivalent dose of, conventional physiotherapy suggesting that in this instance intensity 
may be important.   
Hunter et al (2011) 161 investigated the effect of three different doses of a sensorimotor 
stimulation therapy called Mobilisation and Tactile Stimulation (MTS). 76 patients were 
randomised into four groups-. conventional rehabilitation but no extra therapy (group one) 
with conventional therapy plus one of three daily doses of MTS, up to 30 (group two), 60 
(group three), or 120 (group four) minutes for 14 days. The authors found that the highest 
doses was unable to be delivered, however a daily dose of between 37 and 66 minutes of 
the treatment was feasible. The study found no difference in the change in control group 
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compared with each of the three intervention groups.  This study however is one of the first 
that has investigated  different doses of therapy.  
The need for studies that clearly specify the dose of therapy required to achieve a 
particular outcome is becoming more urgent in view of the increasing pressures on therapy 
resources (e.g. time, number of therapists, pressure to reduce patient length of stay).   
Furthermore, delivering increased levels of intensity of therapy is costly and difficult to 
achieve in clinical practice.  New and innovative ways of delivering therapy are needed to 
increase both intensity and total dose, in a timely manner. 
 
1.5 ROBOTIC DEVICES IN REHABILITATION OF THE UPPER LIMB. 
The use of robotics devices as an adjunct in upper limb rehabilitation has emerged as an 
innovative means of delivering quality therapy without increasing staffing capacity or 
service costs 162; in stroke survivors with varying levels of upper limb paresis, including 
severe paresis154. 
The use of robotic devices can provide high-intensity, repetitive, task-specific and 
interactive treatment for the impaired UL163 .  This will be discussed in greater detail in 
Chapter 2 
 
1.6 CONCLUSIONS 
Stroke is a significant cause of disability in the population.  When the arm and hand 
affected by stroke, functional recovery may be poor.  This chapter has discussed possible 
reasons for why this may be the case. The site and size of lesion are major determinants 
of outcome which cannot be influenced by rehabilitation. Nevertheless, the use of 
increased intensity, with increased repetitions of movements has been seen as a way of 
improving arm movement and recovery.  The use of rehabilitation robotics has emerged as 
a means to achieve these aims and this adjunct to therapy will now be discussed.  
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CHAPTER 2: NARRATIVE SURVEY OF THE LITERATURE INVESTIGATING 
ROBOTIC DEVICES AS AN ADJUNCT TO THERAPY 
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2.1 INTRODUCTION 
Chapter One describes stroke and the impact it can have on individuals, particularly in 
relation to the upper limb. The previous chapter discussed the growing body of evidence 
which suggests that augmenting exercise therapy time early after stroke improves 
outcome. 164 This seems to be especially the case in the upper limb, where high-intensity 
and task-specific treatment consisting of active, highly repetitive movements has been 
seen to be one of the most effective approaches to recovery in arm- and hand function 
135;163;165
. Providing this augmented, high intensity therapy is labor-intensive and has 
resource issues. The use of robotic aids, as an adjunct to therapy, is a potential solution to 
the difficulties in increasing practice time. This chapter will evaluate the literature regarding 
this novel treatment adjunct in both subacute and chronic stroke patients.  The chapter will 
discuss the translation of the literature and the use of robotic devices in clinical practice. 
Consequently, this provides an introduction and discusses the research shortfalls which 
are the rationale behind the studies in this thesis. 
 
2.2 ROBOTIC DEVICES AS AN ADJUNCT TO THERAPY 
Chapter One discussed the evidence supporting increased intensity of training for the 
upper limb which has been strongly recommended. However, delivering increased time for 
practice and expertise with continued specialist guidance is beyond the scope of many 
stroke services. The use of robotic devices has emerged as a novel and innovative adjunct 
to current therapy practice. Over the past ten years there has been an exponential 
increase in the literature investigating  the use of robotic devices in the rehabilitation of 
arm function following stroke 162  
The  Encyclopedia Britannica 166 defines a robot as "any automatically operated machine 
that replaces human effort, though it may not resemble human beings in appearance or 
perform functions in a humanlike manner" 167. Robotic systems used for rehabilitation are 
called “cooperative” systems, as they are machines that assist in the retraining process94.   
The weak arm is strapped into a hand/arm support which is connected to a robotic device. 
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This means that the robot system can sense the movement of the user and uses that 
information either to passively assist, or actively resist, the patient’s movements 168 . 
Different robotic devices target different combinations of movements, but shoulder flexion 
and abduction, elbow extension and wrist and finger flexion and extension are the most 
common movements. 169 The robot is connected to a computer through which the therapist 
controls its actions. Instructions and visual performance feedback for the patient are 
provided on a computer screen. Some rehabilitation robotics incorporate computer games 
to help patients sustain motivation to practice for extended periods 169.  
 
2. 3 CLINICAL LITERATURE REGARDING THE USE OF ROBOTIC AIDS IN 
REHABILITATION. 
Due to the significant body of literature that has been published regarding robotic devices, 
limitations have been placed on the studies which will be discussed in this literature 
review.  Relevant literature pertinent to the thesis will only be included.  This chapter will 
therefore only include clinical trials that have been performed examining the use of robotic 
devices that have an “actuator” (motor). Also only clinical trials that have recruited fifteen 
or more subjects will be included, and robotic devices developed and have been studied in 
clinical trials for arm exercise post stroke. An electronic bibliographic search was 
conducted in the following databases: Medline, Embase (Excerpta Medica), CINAHL, and 
PsycINFO. The databases were searched from 1966 to 2012. Limits were placed on each 
search to exclude non-English citations and nonhuman subjects using a variety of key 
terms, including upper limb, upper extremity, arm function, stroke, cerebral vascular 
accident, robotics, robotic device. A follow-up review of references was performed to find 
relevant articles not detected in the electronic searches. Figure 2.1 illustrates this search.  
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Figure 2.1: Flow diagram of systematic literature review carried out to identify   
literature regarding clinical trials using robotic devices. 
Mapping of Topic: 
Search Terms: upper limb, upper 
extremity, arm, arm recovery, 
robotic device, robotics, stroke, 
clinical trials,   
Electronic Bibliographic 
Searches: 
Medline; EMBASE Excerpta 
Medica):, CINAL (nursing and 
therapy database);  
938 studies found in initial search 
 
 Apply Inclusion/Exclusion 
Criteria 
Inclusion: clinical trial evaluating a 
robotic device used in arm 
rehabilation following stroke,in 
adults 
Exclusion:non actuated device, not 
a clinical trial, <15 subjects in trial, 
used in children, used for 
walking,not in english. 
500 Abstracts reviewed 
472 papers failed 
criteria and rejected 
28 papers reviewed. 
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This review found in the clinical literature the results of clinical trials (who have recruited 
over fifteen subjects) using five robotic systems from the USA have been published: 
Massachusetts Institute of Technology (MIT)-Manus; Assisted Rehabilitation and 
Measurement (ARM) Guide; Mirror Image Motion Enabler (MIME),pneu- WREX and 
HandMentor . In Europe, four systems have been developed for arm exercises post stroke, 
Bi-Manu-Track ; Haptic Master; Neurorehabilitation Robot (NeReBot); REHAROB .  One 
system from Asia has been l investigated in stroke patients BFIAMT . A summary of the 
clinical literature investigating robotic aids in upper limb rehabilitation is shown in Table 2.1 
The clinical trials that have investigated the use of robotic device have all used a variety of 
different outcome measures to evaluate arm recovery.. Upper limb outcome measures will 
be discussed in detail in Chapter Four of this thesis. However, the primary outcome 
measure used in almost all of the studies is the Fugl Meyer upper limb score. The FMA 
measure consists of 33 items which are scored on a 3 point rating scale: 0=unable to 
perform, 1= partial ability to perform and 2= near normal ability to perform. The scores are 
then summed to produce a score of 66.  FMA scores have been used as a means to 
stratify differing levels of arm impairment.  However literatures vary as to scores that 
classify mild, moderate to severe disabilities. Daly et al170;171  and others164172 categorise a 
score of <20 on the FMA as severe impairment, 20-40 as moderately impaired and >40 as 
mildly impaired. 
 
2.4 STUDIES THAT HAVE INVESTIGATEINVESTIGATEED AT ROBOTIC 
THERAPY IN THE CHRONIC PHASE OF STROKE 
Most of the clinical trials focusing on robotic aids have investigated the modality in patients 
six months or more after stroke. These studies have found modest benefits with the use of 
a robotic device when compared with normal therapy. The studies carried out have been 
hampered by a small sample size, not all have used a control group, different durations of 
therapy, differing length of times using the machine, uses of a variety of outcome 
measures, and use of the robotic device in a mixture of settings. The trials also investigate 
at a variety of different robotic aids, with the majority of aids assisting with proximal 
shoulder and elbow movement.  
2.4.1 CLINICAL TRIALS USING THE MIT-MANUS ROBOTIC DEVICE 
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The largest body of clinical trials investigateing at robotic aids comes from the group at the 
Burke-Massachusetts Institute of Technology using their MIT-Manus robot and a 
commercial robot known as InMotion 2. This robotic arm moves a patient’s shoulder and 
elbows either passively, actively or in a movement triggered (‘active-assist’) mode.  The 
robot targets proximal arm movement and allows elbow and shoulder flexion and 
extension and shoulder abduction and adduction (shown in Photograph 2.1) 
 
Photograph 2.1 InMotion2  (Interactive Motion Technologies, Inc., Cambridge, 
Massachusetts), a commercial version of the MIT-Manus robot.173 
 
Initial studies in chronic patients by this group were carried out on 20 outpatients one to 
five years post stroke, who received robotic therapy three times a week for six weeks174. 
Patients in this study had moderate upper limb impairment (Mean FMA 27). The study had 
no control group and the patients were not given any “conventional therapy”. The Modified 
Ashworth Scale (MAS), Fugl-Meyer test of upper-limb function (FMA), Motor Status Scale 
(MSS) score and Medical Research Council motor power score (MRC) were used as 
outcome measures, and a statistically significant improvement in these measures was 
seen post robotic therapy.  
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The same research group from Burke- Massachusetts Institute of Technology using the 
same program and similar patient group175 , examined 42 chronic patients over six weeks, 
but also investigateed at whether the gains from the robotic therapy remained during a four 
monthly follow-up. They found statistically significant gains when compared with baseline 
after six weeks of therapy and also after four month follow-up. Similar findings were also 
seen in 34 patient followed up after a four month period 176. These studies are limited by 
their small sample size, lack of control and lack of functional outcome measures.   
Finlay et a173 have also investigated the effect of MIT-Manus robot in individuals at least 
six month post stroke. This study differed from the group’s previous work, by looking at 
subjects with more severe upper limb impairment (FMA <15) and over a shorter duration 
(three weeks as opposed to six); fifteen subjects performed eighteen sessions with the 
robot. Outcome measures included the FMA, the Medical Research Council scale for 
muscle power (MRC), the Wolf Motor Function Test (WMFT), the Stroke Impact Scale 
(SIS) and robot recorded measures. Statistically significant improvement was seen in the 
FMA and MRC scores and the quality of movement. The choice of outcome measures in 
this paper seems to be inappropriate. The authors state clearly that the main reason for 
carrying out this study was to address the role of robotic device in subjects with severe 
upper limb impairment, however they then chose an outcome measure (WMFT) that was 
devised and used specifically in constraint induced therapy studies, where typically 
impairment is mild. 
The MIT-Manus study group have also investigated the impact of their robotic aid with half 
the duration and twice the intensity177 and also looked at the specific exercises the robot 
training provides178. In both studies all subjects improved with robotic therapy and there 
seemed to be no difference in outcome depending on the type of exercise performed by 
the robot, suggesting that increased intensity has the potential to shorten the duration of 
rehabilitation. 
These studies are of interest as they suggest that the use of a robotic device can assist in 
reducing impairment six month or more post stroke. However as the treatment was not 
compared against a control group, and, or therapy it is impossible to know whether it is 
specifically the robotic device that is useful or that the subjects improved because they 
were having a form of “therapy”/repetitive practice. Furthermore, only two of the studies 
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Ferraro et al176  and Finlay et al 173  study examined the functional impact of the device and 
no patient reported measures were recorded.  
Some attempt to address the limitations of their previous work has been undertaken by the 
Burke Institute group by performing a small randomised control trial on a group of 22 
outpatients six month or more post stroke  179.  Subjects (eleven in each arm) either used a 
robotic arm three times a week or were treated by a therapist for sessions matched both in 
duration and number. Outcome measures were the FMA, MRC, MAS, SIS and Action 
Research Arm Test (ARAT). Improvements in the FMA and MRC were seen after six 
weeks of treatment, with no significant change between robotic therapy and therapeutic 
input. No change was seen with the ARAT or SIS. Improvements in the impairment 
measures remained three month post treatment. Such a finding suggests that therapy in 
some form remains beneficial in the chronic stage post stroke. This study is again limited 
by its small sample size, and absence of specific arm patient reported measures.  
Subsequent research by the MIT-Manus group includes a hand/wrist component to the 
robot to allow a “whole arm” device 174This is an important addition to the robot as the 
previous model only trained proximal movements and results in the groups studies have 
seen only proximal improvements in the FMA 180,176,181.  Krebs et al174 piloted the whole-
arm device in 47 chronic stroke subjects, using a pretest-post test comparison. The 
subjects received (as in previous studies by this group) robotic therapy three times a week 
for six weeks. The FMA was used as the outcome measure and significant improvements 
were seen post treatment. 
The “whole arm” device has been investigated in a multicentered Randomised Control 
Trial (RCT) involving 127 chronic stroke patients171. This is the largest study currently to 
have been performed looking at the use of a robotic device. Patients in this study were 
randomized into one of three groups: one group used the robot for a twelve week period 
(the patients in this group carried out three weeks of performing shoulder and elbow 
movements with the robot, three weeks of shoulder and grasp movements and three 
weeks of wrist movement), one group received one hour therapy for twelve weeks, one 
group received their “usual care”- (i.e no additional therapy)171. The primary outcome for 
the study was a change in the FMA at twelve weeks. The mean scores in this measure 
were found to be better in the robot group than the “usual care” group, but worse than that 
for the group receiving therapy. No statistical significance was found between groups. 
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However, at 36 weeks a significant difference was found between the robot group as 
compared with the usual care” group, but not with intensive therapy.  
The findings from Lo et al (2010) 171 study supports the premise that increased intensity of 
therapy can assist in improving upper limb movement. However, the study does not 
differentiate that the use of a robotic device is any better than increased therapy. The 
study had a predominance of men, and a lack of blinding in study-group assignments. The 
study also involved a selected group of veteran stroke patients visiting selected medical 
centers and this may not be able to be generalized to the wider stroke population. 
2.4.2 CLINICAL TRIALS USING THE MIME ROBOTIC DEVICE 
Another key group looking at robot-assisted therapy for the arm after stroke, use the Mirror 
Image Movement Enabler device (MIME) 182. This is a proximal arm device that allows 
reaching with shoulder flexion, abduction, adduction, external rotation, elbow extension 
and flexion.  The device has a bimanual mode, in which it moves the impaired arm to the 
mirror image position of the unimpaired limb (shown in Photograph 2.2). 
The device has been looked at in a randomized control trial of 27 chronic stroke subjects 
who received 24 one hour sessions over two months) 172 The robot group practiced 
shoulder and elbow movements assisted by the machine. The control group received 
conventional therapy and five minutes use of the robot at each treatment session. The 
FMA, Functional Independence Measure (FIM) and biomechanical measures of strength 
and kinematics were measured. The study found that the robot group had statistically 
larger improvements in the FMA. The group also had larger gains in strength and reach. At 
six monthly follow-up there was no statistically significant differences in the two groups, 
although the robot group demonstrated a non statistical improvement in the self care and 
transfer section of the FIM.  
The research group do detail which therapy was given in the “conventional therapy” arm of 
the study, although how much of the time in the therapy session the subjects practiced 
upper limb movement is unclear. As Kahn(2006) 183 comments the findings of this trial 
rather than indicating the benefits of robot therapy, may instead be an indictment of 
convention therapy which may not have maximized movement practice. However, this is 
the first study that suggests that the use of additional upper limb practice by use of a 
robotic device improves upper limb recovery more than therapy alone in chronic subjects. 
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Photograph 2.2 MIME robotic device182 
 
2.4.3 CLINICAL TRIALS USING THE ARM ROBOTIC DEVICE 
The Arm Robotic device (Assisted Rehabilitation and Measurement Guide- ARM)  is a 
linear device allowing reaching in a straight line (elbow and shoulder flexion, elbow 
extension). Kahn et al (2006)183 looked at training reach using the device in ten chronic 
stroke subjects; they also used nine matched control subjects who practiced reach without 
the robotic device. Each subject trained for twenty four, forty five minute sessions over 
eight weeks. Although both groups showed improvements in The Racho Los Amigos 
Functional Test of the Hemiparetic Upper Extremity, there was no significant difference 
between groups. This is a similar finding to the MIT-Manus group RCT171 but differs from 
the MIME trial 165 .The authors suggest possible explanations for this discrepancy, the 
movements of the robots are different, intensity of use varied and the MIME allows a 
bimanual mode of training. However, these may have also been due to the small sample 
number, and differing outcome measures, so no conclusive reason for the difference can 
be drawn.  
 
2.4.4 CLINICAL TRIALS USING THE HAPTIC MASTER ROBOTIC SYSTEM 
65 
 
This robotic device was designed by Fokker Control Systems, following an European 
Union project entitled GENTLE/s. The robot system is a haptic interface arm which de-
weights the arm, allowing shoulder and elbow flexion, extension, elbow pronation and 
supination, wrist flexion and extension.  Two studies have been reported using this 
system, using a single case study design on 20 and 31 chronic stroke subjects108;184 .The 
subjects in randomized treatment phases used the robotic system (phase B) and sling-
suspension (phase C). Each phase lasted for three weeks and subjects had 30 minutes of 
intervention three times per week. The range of active shoulder flexion, FMA and MAS 
were measured each visit. Both studies found that each subject had a varied response to 
the measurement and intervention phases; however trends suggested that the rate of 
recovery was greater during the robot-mediated therapy phase.  
These studies,108;184suggest trends towards improvement with robotic therapy, but no 
statistical significance was found and the data was found to be highly variable. Coote et 
al(2008)108  also comment that the results of their study and previous studies using the 
Haptic Master may have been hampered by the small amount of robot therapy the 
subjects received during the research trials. 
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Photograph 2.3 Haptic master robotic device 
 
 
2.4.5 CLINICAL TRIALS USING THE BI-MANU-TRACT ROBOTIC SYSTEM 
Bi-Manu-Tract is a robotic system which allows training of forearm pro-/supination and 
wrist flexion/extension and training is done bimanually185. A pilot pre-post test trial of the 
device in twelve chronic stroke subjects has been performed185 . Each subject used the 
robot for fifteen minutes five days a week for three weeks. The patients were all 
undergoing rehabilitation programs of 45 minute daily physiotherapy and occupational 
therapy in addition to the use of the robot system. Subjects were followed-up at three 
months.   The MAS and arm section of the Rivermead Motor Assessment Score were 
used as outcome measures. A significant reduction in MAS was seen with robot therapy 
but no meaningful change in the Rivermead Score was demonstrated. These effects did 
not continue at three months.  There are a number of limitations with this study: its lack of 
control; small sample size; and small duration of time subjects used the robot. 
Liao et al (2011)186 investigated the use of Bi-Manu –tract in ten participants who were 
more than six months after a stroke, compared to ten control subjects. Participants used 
the device for 90 minutes, five days a week for a four week period. The control group 
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received therapy that was designed to be dose-matched with the intervention group.  A 
statistically significant improvement was seen in the FMA measure with use of the robot in 
comparison to the control group. This study used accelerometers as a means to record 
subjects arm movements during the trial. The results of the study found that the group who 
used the robot appeared to incorporate their affected arm more in daily tasks than the 
control group.  Furthermore, a significant different was also seen in a patient reported 
outcome measure (ABILHAND).  This is one of the few robotics studies that have found 
functional improvements with use of a robotic device. Liao et al (2011)186 acknowledge that 
this finding may be due to the participants in the robotic intervention also performing 15-20 
minutes of “functional activity training”. No follow-up analysis at a different time period was 
conducted on the participations, so longer term benefits of the intervention is unclear. 
The same study group 187 have also published a pilot RCT on 18 chronic stroke subjects 
(mean 21 months post stroke) with moderate to mild upper limb impairments (mean FMA 
of 37 to 44). Participants were randomized into three groups: high intensity use of the Bi-
Manu–tract (high repetitions of movements), low intensity use of the device (lower 
repetitions of movements), or conventional therapy for 90 or so minutes, five days a week 
for four weeks. The primary outcome measure was the FMA. Analysis revealed that the 
higher intensity group showed significantly better improvements in FMA than the lower 
intensity group. The study did not measure the intensity of the conventional therapy group, 
so matched comparisons of intensity of treatment between the groups cannot be 
ascertained. In addition, although this small study randomized subjects, the higher 
intensity group had higher baseline FMA and MRC scores, which may have biased the 
outcomes. 
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Photograph 2.4 Bi-Manu-Tract 
 
2.4.6 CLINICAL TRIALS USING THE BFIAMT SYSTEM. 
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Chang et al (2007) 188 report on the bilateral force-induced isokinetic arm movement trainer 
(BFIAMT). This device assists with bilateral push and pull movements to simulate sanding 
activity, which the authors describe as a popular therapeutic activity in early rehabilitation 
188
.  They looked at using the BFIAMT in 20 subjects at least six months post stroke. Each 
subject performed a training program consisting of 30 minutes using the robot, ten minutes 
of conventional therapy for three sessions a week over eight weeks.  The FMA was used 
as the primary outcome. A statistical significance was found in the FMA and in terms of 
grip, push and pull strength following use of the aid. This study had no control group; 
furthermore subjects had conventional therapy at the same time as using the robot device 
so it is difficult to distinguish which caused the beneficial effect. In addition, the studies 
assumption that sanding activity is a common place therapy activity may be true in Taiwan 
but this has not seen to be the case in other countries, such as the UK189 . 
 
2.4.7 PNEU-WREX 
The Pneu-WREX is a robotic device which was based on another non –actuated device 
which has been studied in clinical trials called WREX190 . It allows elbow flexion/ extension, 
shoulder horizontal abduction/adduction, shoulder flexion/extension, and shoulder forward 
backward translation. The device incorporates a passive weight support mechanism, the 
device can provide assistance as needed for a patients to actively participate and be able 
to complete 3D tasks. Grasp and release hand movements are also incorporated. The 
robot has been trialed in a pilot randomized control trial of 27 subjects (thirteen subjects 
used the robot, fourteen controls).190 Subjects at least six months post stroke, who had a 
mean FMA score of 23, were seen for one hour sessions three times a week for eight to 
nine weeks. Subjects either performed a set of exercises (control group) or used the 
device. A statistical significance was seen in FMA scores in the robot group compared to 
the control group. This was not seen on three month follow up and nor was this seen in 
other more functional outcome measures such as the MAL.  
 
2.5 TO SUMMARIZE THE LITERATURE LOOKING AT ROBOTIC AIDS IN 
CHRONIC STROKE SUBJECTS. 
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This literature review highlights that a there is a growing body of literature investigating the 
use of a variety of robotic arms in chronic stroke patients. The majority of these studies 
have shown improvements in upper limb impairments with this therapy, but have been 
hampered by small sample size, lack of control, no conformity in duration and intensity of 
use of the device or outcome measures. Trials have rarely used functional outcome 
measures or patient reported measure.  It is encouraging however that the studies have 
suggested improvement in this chronic group, where recovery is seen to be slower and 
has plateaued191. The most beneficial time to introduce robotic therapy also needs 
evaluating, and it could be proposed that more benefit may be seen with this therapy in the 
acute/subacute stages post stroke. This may because as Lum et al (2006) 192 postulate the 
central nervous system may be more “plastic” in the acute phase. Furthermore, the use of 
robotic therapy may assist in the prevention of secondary maladaptive changes related to 
increased passive tissue stiffness and contracture.62  
 
2.6 STUDIES THAT HAVE LOOKED AT ROBOTIC THERAPY IN ACUTE/SUB 
ACUTE PHASE POST STROKE.  
This review will now discuss the recent research trials that have investigated the use of 
robotic devices in acute/subacute stroke population. 
2.6.1 CLINICAL TRIALS USING THE MIT-MANUS DEVICE. 
The MIT-Manus group initially began looking at their robotic aid in acute subjects. They 
have published results on 96 patients 181;193-196. All subjects were randomly assigned to a 
robot treatment or control group and were within three weeks of their first stroke with upper 
limb weakness and undergoing rehabilitation as inpatients. Subjects spend 45 minutes 
using the robot, five days a week for four weeks. Control patients used the robot without 
the motor on with them using their unaffected limb to move the affected arm one or two 
hours a week. A statistical significant improvement was found in motor power (MRC scale) 
and MSS for the elbow and the shoulder in the robot group compared with the control 
group. The FIM was found to significantly improve in the robot group for 56 patients181 but 
when extended to 96 patients this significance was not seen197 .  
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These findings again point to the benefit of robotic use, and contrast to the group’s findings 
in chronic subject which did not specifically find a beneficial advantage of the device when 
compared to “convention therapy”179. There may be a number of reasons for these 
differing results: a) the stage post stroke (acute/subacute stage may pragmatically be a 
better time to use this therapy); b) larger sample size; c) more intensive use of the robot 
(daily as opposed to three times a week); d) subjects were inpatients undergoing 
rehabilitation so potentially more motivated to use this device as a therapy adjunct.  These 
factors however, mean that direct comparison between the groups work in chronic 
compared to acute stroke population, cannot be made.  
It is unclear in the research discussed above, what inpatient rehabilitation the subjects 
were having, consisted of, and the therapy that both groups received were not defined in 
the literature. This is disappointing, as the findings of this body of work rather than being 
indicative of the benefits of robot therapy may instead be a reflection of convention therapy 
which may not have maximized movement practice 183.  Furthermore the study did not 
compare the use of the robotic device to equal amounts of conventional therapy, leaving 
the question whether it was the additional therapy that was beneficial or the use of the 
robotic device. 
Rabadi et al (2008)198 have also looked at using the MIT-Manus in a preliminary 
randomized control in acute stroke. Patients who had had single incident stroke within four 
weeks of admission to an inpatient rehabilitation facility were included in the study. Thirty 
subjects were enrolled and randomized into either a standardized therapy group, use of an 
arm ergometer or use of the MIT-Manus robotic device. All patients received standard, 
inpatient, post stroke rehabilitation training for three hours a day, plus additional 40 
minutes session of the activity-based therapy. In total subjects were seen for twelve 
sessions.  Primary outcome measures were the FMA, Motor Status Score, and FIM.   
The study found a similar degree of improvement in the discharge scores in all of the 
outcome measures. This suggested no difference between the three types of arm therapy 
with all three resulting in a decrease of impairment. The study had several limitations: It 
used a small sample size which may have precluded detecting important differences 
between groups; secondly the study used shorter, less intensive arm therapy sessions 
than other studies that have shown improvement in motor scores with robotic therapy181;193-
196
.  
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2.6.2 CLINICAL TRIALS USING THE MIME DEVICE. 
The MIME group192  have also looked at the device in subacute subjects, one to five 
months post stroke.  Thirty subjects were randomly assigned to either control or three 
different robot group (unilateral/bilateral/combined). All patients received fifteen one-hour 
treatment sessions over a four week period. The FMA , MSS, FIM and muscle power were 
used as outcome measures. Statically significant improvements in FMA were seen post 
robotic therapy than in the control group. However, as in their previous study in chronic 
subjects, gains were equivalent at the six month follow- up. When looking at improvements 
in individual subjects, robotic therapy was seen to be most effective in subjects in a middle 
range of motor impairments (falling between fifteen  and 23 inclusive on the proximal 
FMA). This result is very much in keeping with the groups work in chronic strokes and 
adds strength to support of the use of the device.  Caveats remain such as the small 
sample size and choice of outcome measures. 
Burger et al (2011)199 conducted a randomized control trial comparing the use of the MIME 
robotic device for two different dose intensities (low dose of fifteen  hours or high dose of 
30 hours) with an additional fifteen  hours of conventional therapy (in addition to usual 
care). Subjects (n=54) in this study were subacute strokes (seven to 21 days post stroke). 
As opposed to the groups previous studies in  chronic patients, gains in the primary 
outcome measure (FMA) was not significantly different between the groups. This may be 
explained by small number of subjects in each treatment group. Another possible 
explanation is that the study matched treatment intensity of use of the robot and 
conventional therapy. This leads to the question is it the robotic device or just additional 
therapy that results in achievement of reported gains? 
2.6.3 CLINICAL TRIALS USING THE BI-MANU-TRACK SYSTEM. 
 
Hesse et al185  using their Bi-Manu-Track, extended their previous work in chronic stroke 
patients to look at 44 patients, four to eight weeks after stoke. Subjects were randomly 
assigned to either using the robotic device or using electrical stimulation. All participants 
practiced 20 minutes every workday for six weeks. The robot group performed 800 wrist 
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movement repetitions per session with the robot, while the patients using electrical 
stimulation performed 60 to 80 wrist extensions per session. The FMA was used as the 
primary outcome measure, and was found to improve in both groups but significantly more 
in the robot group. This was also seen in muscle power. On three  month follow-up this 
improvement remained.  
This study also found that both proximal and distal arm control improved in the robot 
group.  Hesse et al185  recommend from this finding that emphasis of treatment should shift 
from the shoulder to the forearm, hand and fingers.  Although this is a notable 
recommendation, the evidence from their small, feasibility RCT is not strong enough to 
currently generalise. Furthermore, the findings of the study must be treated with caution as 
using electrical stimulation as a control treatment may be standard treatment in Germany; 
however this is not the case in the U.K, where guidelines by the Royal College of 
Physician (2012) 4 advice that FES should not be used as a stand alone treatment due to 
the lack of evidence currently supporting this modalities use.    
2.6.4 CLINICAL TRIALS USING THE REHAROB THERAPEUTIC SYSTEM 
 
The Robotic rehabilitation system for upper limb motion therapy for the disabled 
(REHAROB Therapeutic System) is a system that allows shoulder and elbow movements 
in a constant velocity. A trial of the system on thirty  subjects  has been performed using a 
mixed subject population consisting of stroke and head injury patients.200  Subjects in the 
study randomly assigned to either robotic therapy or control therapy. Every subject 
received 30 minutes of therapy on 20 consecutive work days; the robot group also 
received additional 30 minutes using the robot. A battery of outcome measures was used, 
including the FMA, Rivermead, FIM and MAS. The subjects improved in all measures post 
treatment. The MAS for shoulder adductors and elbow flexors showed a statistically 
significant change only in the robot group.  
The authors200 report that one of the stated aims of their study was to see the effect of tone 
of using the robot, and interesting this is the only measure that showed a significant 
change from the control group. (with a reduction in Ashworth scores in shoulder flexion 
and elbow flexion tone following use of the robotic device). This finding is difficult to 
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interpret and compare with other studies using different devices and the study uses 
subjects with different diagnosis and different stages in their recovery. 
2.6.5 CLINICAL TRIALS USING THE NE-RE-BOT DEVICE 
 
Masiero et al (2007)201have looked at robotic therapy in acute stroke patients using a novel 
robotic device the Neuro-Rehabilation Robot (NeReBot). This device performs flexion, 
extension, pronation and supination, adduction and abduction of shoulder and elbow. It 
can be used in supine as well as in sitting.  
In a study investigating the effectiveness of this robot, 35 single incident acute strokes, a 
week post stroke, were randomized to either robot group or control group 201.All subjects 
received daily therapy and the experimental group received additional robotic training 
consisting of two sessions a day, four hours a week for five weeks. The control group used 
the robot except that the exercises were performed with the unimpaired limb. Blinded 
outcome measures were taken at baseline, five weeks, three month and eight month 
follow-up. The study used the FMA, MRC scale, FIM, Trunk Control Test (TCT) and MAS. 
Compared with the control group, the robot group showed significant gains in muscle 
power, FMA for the proximal arm and the FIM. These gains were sustained at three and 
eight month follow-up. The authors do not clarify why the control group used the robot with 
their unaffected arm and this requires further explanation.  
The same study group updated this study in 2011202 performing a further trial in 21 
subjects (patients were within 20 days post stroke).  This study compared conventional 
therapy (40 minutes of treatment to the proximal arm in additional to patients normal 
inpatient therapy), with use of the NeReBot for two 20 minute training session (these 
patients also received their usual inpatient therapy). Both groups improved in outcomes 
(these included the FMA, muscle strength as measured by MRC and Motor-FIM), no 
statistical difference was found between the groups. This study does not discuss how 
subjects were randomized into the groups, used small sample size and used no specific 
upper limb functional outcome measures. 
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2.6.6 CLINICAL TRIALS USING THE HAND MENTOR DEVICE 
This device uses a pneumatic artificial muscle (actuator) and provides biofeedback 
regarding muscle activation and control .203 The device focuses on wrist movements 
.Activation of the air muscle rotates a bar about a pivot point positioned in line with the axis 
of rotation about the wrist. This action extends the wrist and fingers. The device has EMG 
biofeedback. It has been looked at in a RCT comparing use of the device and Repetitive 
Task Practice (RTP) against just RTP. 204 Seventeen subacute subjects participated, 
seven in the control group and ten in the active group.  Subjects completed three weeks of 
five days a week therapy, with the control group practicing four hrs of RTP. The other 
group performed two hours with the device and two hours RTP. The Stroke Impact Score 
was used as an outcome measure.  Both groups reported significant improvement in hand 
function with the intervention and this was also seen on follow-up. 
 
2.7 SUMMARY OF RESEARCH TRIALS THAT HAVE LOOKED AT ROBOTIC 
THERAPY IN ACUTE/SUBACUTE STROKES.  
This literature discussed above suggests that robotic therapy may be a useful adjunct to 
assist in upper limb recovery and that it may allow greater improvement in this as 
compared with “conventional therapy”  when used in acute or the sub acute stroke 
population ( with more studies suggesting this than seen in the chronic population). There 
has however been a paucity of research trials that have looked at robotic therapy in the 
acute stroke population. Theoretically, the acute phase post stroke is when potential for 
significant functional gain is greater. Therefore further research looking at robotic devices 
in the early stages post stroke is needed.  The studies in this theses aim to fill this 
research gap. 
Four systematic reviews of robotic therapy (including a recently updated Cochrane review) 
have been carried out to date163,205,206;207 .  These reviews have summarized that this 
therapy adjunct may improve impaired motor function and strength in the paretic arm but 
currently there is no evidence to suggest they improve functional abilities. They conclude 
that the results of studies looking into this therapy must be interpreted with caution 
because there were variations between the trials in the duration, amount of training and 
type of treatment and in the patient characteristics.   
76 
 
There has been little conclusive evidence from the findings of the literature as to whether 
improvements seen with the use of robotic devices are due to the device itself or via 
simply delivering more opportunity for UL practice. Recent work by Liao et al (2011) 186 
comparing dose-matched control and robotic therapy found significant improvements in 
the robotic group, suggesting a specific effect of the robot itself. However further clinical 
trials to investigate matched control and robotic therapyare needed. 
 
2.8 OTHER FACTORS  
There is a growing body of literature suggesting that stroke rehabilitation may improve 
functional performance for some patients89 .There is however, little information available 
about what constitutes optimum treatment, skill level and experience of therapists 
providing treatment189 .  Furthermore, progress in stroke rehabilitation is impeded by 
insufficient detail about components of treatment and description of convention therapy 
activities208.This  lack of detail and description of what consists therapy, limits replication of 
research studies and the incorporation of research findings into clinical practice117. Robotic 
therapy provides standardization of therapy and quantification of rehabilitation, which has 
been a problem dogging conventional therapy trials209. 
 
2.9. UNRESOLVED ISSUES WITH THE USE OF ROBOTIC DEVICES 
2.9.1 FACTORS AFFECTING THE TRANSLATION OF ROBOTICS INTO 
CLINICAL PRACTICE 
 
Despite the emergence of the myriad of robotic device listed above (with many more 
developed that have not yet, been clinical tested), there has been little translation of 
robotics currently into clinical practice. The current evidence does not illustrate that any 
particular robotic system is of any added benefit over another.  For robotic aids to be 
effective, their design and protocols for use must be driven by clinical need and developed 
as a result of engagement with all interested parties; engineers, therapists, patients and 
their careers 210.There are currently unanswered questions regarding the involvement of 
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robotic systems within the rehabilitation process. This is also the case regarding how 
practical it is to use robotic systems in clinical practice. The research in this thesis aims to 
address some of these issues and the remainder of this chapter will outline important 
unresolved issues and gaps in the current literature. These will be highlighted in each 
section. 
 
2.9.2 WHAT PLACE DO ROBOTIC SYSTEMS HAVE WITHIN THE 
REHABILITATION PROCESS?   
For robotics to be used as an adjunct to therapy, they need to be able to deliver increased 
intensity of practice, increased accuracy of performance and engage patients in the 
therapeutic process. Do we have any current evidence that suggests robotic systems are 
able to achieve these needs?  
 
2.9.3 WHO WOULD BENEFIT FROM USING A ROBOTIC DEVICE? 
In patients with severe upper limb paresis the ability to participate in repetitive task –
orientated activities is limited because they have insufficient underlying movement211. 
Barker et al 132 found that stroke survivors felt that “not enough movement to work with” 
was the greatest barrier to recovery. This may explain why stroke patients with severe 
paresis show limited improvement 212,125Robotic devices may be a means for these 
patients to perform repetitive, task-specific activity. The literature reviewed here has found 
improvements in subjects with “severe arm paresis” (defined as a FMA <15)192. Many of 
the robotic devices use an “active-assist” mode where the robot can assist movement. 
However some trials found that the greatest improvement seen with using robotics seems 
to occur in subjects with FMA greater than 20 on admission to trials 108. Furthermore there 
is discrepancy in the literature as to what FMA score is defined as “severe”. 108 An added 
complication to this is that current outcome scales may not be capturing changes in 
function which may be of relevance to patients. Hayward et al (2010)154 in a systematic 
review of interventions to promote arm recovery in stroke survivors with severe paresis 
found that robotics hold some promise, however the effectiveness will be dependent on 
whether they lead to  improvements in the ability to perform everyday tasks.  
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One of the aims of the studies detailed in this PhD is to evaluate if people with stroke with 
little arm movements can use the device. Furthermore does the level of arm paresis 
impact on functional recovery. 
 
2.9.3 INTENSITY OF PRACTICE 
In the acute setting, studies have found that stroke patients spend little time performing 
upper limb activities17.  Pilot studies suggest that an advantage of robotics devices is that 
they enable increased practice intensity and repetition of arm movements, compared with 
conventional therapy206.  As yet, clinical studies of conventional treatment regimes have 
not established optimum treatment intensity although a growing consensus is that it could 
be as much treatment as is tolerated.  For many patients after stroke, this may be as little 
as 20 – 40 minutes treatment a day. It is currently unknown the proportion of patients 
following stroke who would be able to use a robotic device, and would benefit from using 
such a device. This would be extremely useful clinical data, and would facilitate the 
integration of the use of these devices into routine clinical practice. The studies discussed 
in this thesis will perform exploratory work to look at this area. 
Clinical trials using robotic devices have varied the amount of treatment provided, ranging 
from 30 minutes,181;193;194 to 90 minutes each work day 176.  This amount of variation makes 
analysis of the benefits and outcomes of different devices difficult.   Studies that have tried 
to match the intensity of robotic therapy to the number of movements generated during 
conventional therapy did not find any significant benefit of one technique over the other183. 
In light of these equivocal results, future trials comparing the efficiency of robotics to 
standard therapeutic practice need to incorporate clear descriptions of the comparator 
treatment to establish that robotic training doses actually increase movement repetitions. 
Although recent publications 186;187have begun to explore this, further investigation in this is 
required and this will be explored in this thesis.  
 
 
2.9.4 INCREASED ACCURACY OF PERFORMANCE 
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The complexity of sensory and motor integration needed for dexterity and functional use of 
the arm complicates the rehabilitation process (as discussed in Chapter One).  Evidence 
from neuroimaging suggests that functional recovery from stroke is influenced by task-
specific training or everyday use of the arm and hand. 46;109;213 Most devices focus on 
shoulder and elbow movements, rather than wrist and hand movement.  In contrast, most 
functional tasks demand co-ordinated proximal and distal movements in order to reach, 
grasp and manipulate an object.   
Many of the robotic systems described previously are aimed primarily at training reaching 
movements, and have shown improvements proximally and at an impairment level.  Few 
studies showed functional change with use of a robotic device. 205. It is difficult to conclude 
the precise reasons for this. Has there been a lack of translation from improvements at an 
impairment level to activities of daily living due to patients practicing proximal movements 
with the robotic systems rather than distal movements? The Lieu et al (2012)186study is 
one of the few studies that has shown some functional improvements with the use of a 
robotic device (the Bi-manu-tract which trains wrist and hand function,) so this would 
concur with this premise. Or is it because many trials used impairment measures rather 
than measures looking at function? Again the Liau et al (2012)186 study is one of the few 
studies that have used activity and participation outcome measures to look at functional 
gains with the use of a robotic device.   There is however, currently no single reliable and 
valid tool that captures the complete range of arm function in stroke patients214 . (This area 
will be discussed in greater depth in Chapter Four.) Furthermore there is a debate in neuro 
rehabilitation about the role of impairment level interventions versus functional training 215. 
The studies in this thesis will use impairment and activities and participation measures to 
address this question. 
 
2.9.5 ENGAGING PATIENTS IN THERAPY 
Robotic aids are designed specifically to enhance the motivation and adherence of 
patients to treatments. In particular, having control over the difficulty level of the motor 
task, gaining feedback on performance, practising a meaningful movement, providing a 
suitable challenge and ensuring successful task-completion even with minimal active 
movement can influence patient motivation and produce different behaviours 216 
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.Furthermore, the competitive scoring system of feedback offered by robotics provides a 
gratifying incentive to enhance enjoyment and motivate patients to complete tasks and 
reach certain goals217. 
However, a potential problem with robotic aids is that reduced therapist-patient interaction 
may negatively affect motivation .216. The therapeutic relationship and rapport between the 
therapist and patient can influence patients’ intrinsic motivation and make exercising more 
effective 216,218;219.  If the interaction between the patient and the clinician is an important 
determinant of adherence then use of a robot may actually reduce adherence 220 . 
Empirical research is required to explore this range of factors impacting on the motivation 
of stroke patients to engage with use of robotic devices, to advance research in the field of 
rehabilitation robotics. This is again an area which will be examined in the studies detailed 
in this thesis. 
 
2.10 POTENTIAL DIFFICULTIES WITH THE USE OF ROBOTIC DEVICES IN 
CLINICAL PRACTICE 
In addition to these issues surrounding what a robotic system might do within the 
rehabilitation process, there are also practical implications of the use of robotic devices in 
clinical practice.  
 
2.10.1 IS THERE A RISK WITH THE USE OF ROBOTICS? 
Current robotics literature suggests that dropout rates from studies were very low and 
adverse reactions were rare205. In commercially available robotic devices, the machines 
have had to be extensively tested and pass  very tough certification processes.  Devices 
also have redundant safety measures.  However, for robotic machines to be of clinical use 
they must be reliable and safe for use by patients with or without therapists, with 
mechanisms in place to ensure that if breakdown occurs it is without risk. 
Few studies discuss shoulder pain with regard to use of robotics, and this has not been 
systematically explored in the literature.  This is interesting considering the high rate of 
reported shoulder pain post stroke72;221 70and observations that early-onset pain hinders 
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the motor recovery of the upper limb and may hamper daily activities222 ( Discussed in 
Chapter One Section 1.5.8). Systematic reporting of adverse events and a thorough 
review of the incidence of shoulder pain with the use of robotic devices would be helpful. 
This is included in the studies described in this thesis. 
 
2.10.2 HOW DO PATIENTS AND THERAPISTS RESPOND TO ROBOTIC 
THERAPY? 
Despite, the growing body of literature describing new robotic devices, there are 
surprisingly few papers that have addressed patients and therapists views of using robotic 
devices.  This is despite the growing recognition that, if medical devices are to be of real 
value, then the needs and capabilities of the users must be considered 223 .  Table 2.3 
summarises the literature that has investigated this. 
Krebs et al(1998)195 in their initial clinical trial of the Mit Manus system report the 
responses of 20 participants to five questions.  Burger (2000)182also described user 
involvement into the development of the MIME system.  Coote and Stokes (2003) 224 used 
a questionnaire survey to ascertain eight patients with stroke and six therapists’ 
perceptions of the Haptic Master Robotic system.  A questionnaire was used to gather 
information about patient’s satisfaction with the Reo Therapy System225 (a robotic device ).  
All of these found positive responses to the robotic systems. 
Five further studies identified that robotics are acceptable to patients 134;162;216;226;227and two 
have found that therapists had positive attitudes to robotic devices162.226 (Table 2.2 
describes these studies in more detail). Limitations with these studies are: a lack of clarity 
on question development; questionnaires were often administered by treating therapists, 
use small sample sizes, the psychometric properties of the questionnaires are not 
established, and questions or statements used are not always published. Further rigorous 
qualitative data on users’ perceptions on systems is needed to provide greater depth to the 
current work. This will be discussed further in Chapter Seven of this thesis. 
 
2.10.3 IS IT COST EFFECTIVE TO USE A ROBOTIC DEVICE? 
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The cost effectiveness of robotic devices has yet to be probably evaluated. Many of the 
devices are expensive and storage and placement of the device in ward based 
rehabilitation settings can be an issue .228 Lo et al 171;229 have looked at a cost analysis in 
their RCT which compared the Mit Manus system to matched intensive therapy and usual 
care. They found that the average cost of delivering both intensive comparison therapy 
and robotic therapy was more expensive than normal care. The cost of both intensive 
therapy and the use of the device were comparable, this questions previous opinion 
regarding using robotic systems as a means to deliver cheaper intensive upper limb 
therapy.  A  potential application of robotic systems is that they could be used as a means 
of independent repetitive practice for the patient, further work looking at cheap devices that 
can be used independently needs to be performed.228 . 
Two recent papers have tried to address this issue, by looking at the use of non actuated 
(no motor) arm orthoses212;230 These devices are smaller, more portable machines.  
Housman et al.(2009)230  describing the advantages of using cheaper non-assisted 
devices, commented that it has not yet been demonstrated that the expensive actuator 
components of the robot devices are necessary for the therapeutic effects associated with 
robotic therapy.  Clinical trials using these devices have also found improvements in 
impairments 212;2304.  They do not, however, provide clear evidence that non-assisted 
devices work as well as robotic devices with actuators, nor that they are more cost 
effective or practical to use at the bedside or in the patient’s home.  Furthermore, a non-
robotic device cannot provide active–assisted movement which limit the use of the device 
to mild to moderate impaired stroke survivors (although Barker et al (2008) 212 used the 
SMART Arm in severely impaired subjects), nor can it record or adjust programs as 
required with treatment progress.  
This area of cost effectiveness is a key area for future research in robotic and the 
comparison between robotic and non robotic aids needs to be established in larger 
studies. The level of supervision and assistance required to use robotic aids needs to be 
considered in the cost-benefit analysis. Preliminary work in this area will be examined in 
this thesis. 
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2.10.4 ROBOTIC THERAPY TO REPLACE THERAPIST IN UPPER LIMB 
REHABILITATION? 
Interestingly, the few studies that have looked at therapy perceptions of robotic  
devices134;162;231 have found that therapists do not report feeling threatened by the 
emergence of robotic technology .  The current generation of robotic devices support this 
assumption, as none have the capability to reproduce the hands-on facilitation of muscle 
activation provided by a therapist.  Engineers are now working towards programming 
robotic devices to specifically simulate therapeutic input with replicable visual, auditory 
and/ or sensory feedback232, to emulate as closely as possible the interaction between the 
patient and the human therapist232. 
Therapists have suggested that that a robotic device used for therapy should be versatile 
enough to be able to train many degrees of freedom and ranges of motion and to provide 
therapy from standing, sitting and lying positions 231.  This is not possible with any of the 
existing robotic systems 232 .  Technological advances have developed significantly in the 
last 10 years, but as yet small, cheap, versatile robots that can be used in the patients’ 
home environment or at the bedside have not yet been used in clinical trials. 
 
2.11 CONCLUSION  
The use of robotic device in upper limb rehabilitation is a new development to support 
recovery of arm function following stroke.  Robotic devices may be a means for stroke 
patients to perform repetitive, task-specific activity leading to improvements in function. 
89;233  . A variety of different robotic devices have been trialed in clinical studies, most of 
these assist with proximal arm movements, but devices which assist with distal activity 
have also been developed.  
This review has detailed the current evidence base for robotic devices as an adjunct to 
therapy for the upper limb. The clinical trials which have been described in this chapter 
have found modest benefits with the use of a robotic device when compared with normal 
therapy.  The studies carried out have been hampered by a small sample size, not all have 
used a control group, different durations of therapy, differing length of times using the 
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machine, uses of a variety of outcome measures, and use of the robotic device in a 
mixture of settings. The trials also look at a variety of different robotic aids. 
Current literature does not provide clear evidence of either increased intensity or better 
functional outcomes, but there is enough evidence to pursue this approach.  
Improvements in design both of the robots and the clinical trials used to evaluate them are 
needed.   
Unanswered questions remain from the literature, with further work needed to investigate: 
a) The use of robotic devices in the acute stage when potential recovery is the 
greatest 
b) The functional benefits of robotic devices 
c) Patients perceptions of the devices 
d) Risks with the devices 
e) What proportion of acute stroke patients could potentially benefit from using a 
robotic aid? No current work has looked into this area which has important clinical 
information 
f) Can patients with differing levels of arm paresis use the device? 
 
g) What resources are required in terms of trained and untrained staff?  
h) Does the use of different upper limb outcome measures that look at patient function 
better reveal any activity and participation benefit with robotic devices? 
The studies described in this thesis hope to address these questions through a mixed 
methodological approach. Chapter Three will now detail the aims and objectives of these 
studies. Particular emphasis will be given to conducting studies that explore the translation 
of robotics from experimental research into clinical practice. Five stages will be used to this 
achieve these aims (as detailed in Chapter Three) and will be discussed in the next 
chapters.
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Table 2.1: Summary of Clinical Trials that have looked at Robotic Therapy in Stroke Patients. 
Author Robot 
Type 
Movement
s  
performed 
by robot 
Stage 
post 
stroke 
Sample 
size 
Method 
used in 
trial 
Intervention Outcome 
measure 
Results 
 Duration Frequency Minutes/ 
session 
  
Aisen et 
al 
(1997)193 
MIT-Manus Planar 
reaching 
movements 
Acute , 
3 
weeks 
post 
stroke 
20 
 
RCT 
 
6-7 weeks  Daily 1 hour FMA, 
FIM, MSS 
Statistical 
significance in 
MSS in robotic 
group 
Volpe et 
al (2000) 
181 
MIT-Manus Planar 
reaching 
movements 
Acute , 
3 
weeks 
post 
stroke 
56 RCT 5 weeks Daily 1 hour FMA, MP, 
MSS,FIM 
Improvements 
seen in motor 
performance in 
shoulder and 
elbow in robotic 
group 
Fasoli et 
al 
(2004)234 
In- motion 2 Planar 
reaching 
movements 
Chronic 42 Pre-post 
test 
6 weeks 3 times a 
week 
1 hour FMA, MRC, 
MSS, MAS, 
pain 
shoulder. 
4 month f/u 
Sig FMA, MSS, 
MRC. And on 
f/u with the 
robot 
Daly et 
al 
(2005)170 
MIT-Manus Planar 
reaching 
movements 
Chronic 12 RCT, FES 
control 
group 
12 weeks 5 days a 
week 
1 hour ARAT, FMA Sig. in ARAT in 
robotic group 
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Author Robot 
Type 
Movement
s  
performed 
by robot 
Stage 
post 
stroke 
Sample 
size 
Method 
used in 
trial 
Intervention Outcome 
measure 
Results 
 Duration Frequency Minutes/ 
session 
  
Ferraro 
et al 
(2003)176  
MIT-Manus Planar 
reaching 
movements 
Chronic 34 pre-post 
test, 
18 
sessions,  
3 times a 
week 
1 hour FMA, MP, 
MSS,FIM.M
AS 
Stat sig FMA 
and MP and 
FIM UL in 
robotic gp 
Stein et 
al (2004) 
178
 
In-motion2 Planar 
reaching 
movements 
Chronic 47 Pre- post 
test 
6 weeks 3 times a 
week 
1 hour FMA, MAS, 
MSS, MRC 
Improvement in 
FMA, and force 
measurements 
MacClell
an et al 
(2005) 
177 
In motion 2 Planar 
reaching 
movements 
Chronic 27 Pre and 
post test 
3 weeks  2 sessions 
a day, 3 
days a 
week 
1 hour FMA, MSS, 
WMFT, 
motor 
power 
Significant 
improvements in 
all measures 
Finley et 
al (2005) 
173
 
In motion 2 Planar 
reaching 
movements 
Chronic 15 Pre and 
post test 
3 weeks 2 sessions 
a day, 3 
days a 
week 
1 hour FMA, MSS, 
WMFT, MP, 
SIS 
Improvements 
in FMA and MP 
Krebs et 
al (2008) 
174
 
In motion 2 Planar 
reaching 
movements, 
hand/arm 
component 
Chronic 47 Pre and 
post test 
6 weeks 3 days a 
week 
1  hour FMA Improvements 
in FMA 
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Author Robot 
Type 
Movement
s  
performed 
by robot 
Stage 
post 
stroke 
Sample 
size 
Method 
used in 
trial 
Intervention Outcome 
measure 
Results 
 Duration Frequency Minutes/ 
session 
  
Lo  et al 
(2010) 
171
 
Mit Manus 
“Whole Arm 
device” 
Able to 
perform 
both planar 
reaching 
and hand 
grasp 
movements 
Chronic 127  RCT 12 weeks 36 sessions 1  hour FMA, WMF, 
SIS 
Statistical  
significance in 
FMA when 
compared to 
usual care but 
not intensive 
therapy 
Lum et 
al (2002) 
165
 
MIME 4 modes of 
movement/ 
bilateral  
Chronic 27 RCT  
6 month 
f/u 
2 months 24 sessions 1 hour FMA, BI, 
FIM. 
Strength, 
reach 
Statistical  
significance in 
FMA 
Lum et 
al (2006) 
172
 
MIME 4 modes of 
movement-
and bilateral 
Subacu
te 
30 RCT 4 week  15 
sessions. 
1 hour FMS, MSS, 
FIM, MAS, 
motor 
power 
Stat Sig in 
proximal FM 
scores with 
robot, but gains 
equivalent 6 
month follow-up. 
Less benefit 
from bilateral 
mode. 
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Author Robot 
Type 
Movement
s  
performed 
by robot 
Stage 
post 
stroke 
Sample 
size 
Method 
used in 
trial 
Intervention Outcome 
measure 
Results 
 Duration Frequency Minutes/ 
session 
  
Burger 
et al 
(2011)199 
MIME 4 modes of 
movement-
and bilateral 
Acute 54 RCT 4 weeks 15 sessions Low 
dose- 15 
hours 
High 
dose- 30 
hours 
FMS, MSS, 
FIM, MAS, 
motor 
power 
No sig seen in 
the groups 
Amirabd
ollahian 
et al 
(2007) 
184
 
Haptic-
Master 
Shoulder 
movements 
Chronic 31 RCT, 
(Cross-
over). 
Robot V 
sling 
suspensio
n 
 9 weeks  Three times 
a week 
30 
minutes. 
FMA, MAS 
goniometry 
Multiple 
regression 
model, positive 
but modest 
trends favoring 
both 
interventions 
Coote et 
al (2008) 
108 
 
 
Haptic-
Master 
Shoulder 
movements 
Variety, 
sub-
acute, 
chronic 
 RCT, 
(Cross-
over). 
Robot V 
sling 
suspensio
n 
 9 weeks  Three times 
a week 
30 
minutes. 
FMA, MAS 
goniometry 
Multiple 
regression 
model, positive 
but modest 
trends favoring 
both 
interventions 
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Author Robot 
Type 
Movement
s  
performed 
by robot 
Stage 
post 
stroke 
Sample 
size 
Method 
used in 
trial 
Intervention Outcome 
measure 
Results 
 Duration Frequency Minutes/ 
session 
  
Liao et al 
(2011) 
186
 
Bi-manu-
Tract 
Mirror 
sup/wrist 
flexion 
Chronic 20 RCT 4 week 5 days a 
week 
90 
minutes 
FMA, 
accelometer
s, 
ABILHAND 
Stat sig in 
robotic group in 
all measures 
Hsieh et 
al 
(2011)187 
Bi-manu-
Tract 
Mirror 
sup/wrist 
flexion 
Cgronic 18 RCT 4 week 5 days a 
week 
90 
minutes 
FMA, MRC No stat sig seen 
Hesse  
et al 
(2005) 
185
 
Bi-Manu-
Tract 
Mirror 
sup/wrist 
flexion 
Sub 
acute 
44  RCT 6 weeks  20 
minutes 
FMA 
MRC 
MAS, 
FMA scored 
improved in 
both.  
Chang et 
al 
(2007)188 
BFIAMT 
 
Allows push 
and pull 
movements 
Chronic 20  pre and 
post test 
8 weeks  10 min of 
normal 
therapy, 
30 min of 
robot 
FMA, MAS, 
Frenchay 
arm test 
No stat sig in 
any measures. 
Grip and reach 
improved 
Fazekas 
et al 
(2007)200 
REHAROB 
 
Shoulder 
and elbow 
movements 
Range 
(1-87) 
months 
post 
lesion 
8 TBA/22 
stroke 
 
 RCT 20  days  30 
minutes 
FMA, MAS, 
ROM, 
RMA, FIM 
Stat sig FMA, 
range elbow, 
RMA, FIM self 
care 
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Author Robot 
Type 
Movement
s  
performed 
by robot 
Stage 
post 
stroke 
Sample 
size 
Method 
used in 
trial 
Intervention Outcome 
measure 
Results 
 Duration Frequency Minutes/ 
session 
  
Masiero 
et al 
(2007)201 
NeReBot 
(direct-drive 
wire 
actuation) 
Shoulder 
and elbow 
 
(3 degree of 
freedom) 
Acute 35  
 
RCT 
(8 month 
follow up) 
5 weeks Twice a day 4 hours a 
week 
MRC, FMA, 
FIM, TCT, 
MAS, VAS 
(tolerance) 
Stat Sig seen in 
MRC, FIM, FMA 
with robotics. 
Sustained on 
follow-up 3/8 
months 
Bovolent
a et al 
235(2009)
42
 
Reo 
Therapy 
System 
Forearm 
movement 
Chronic 14 Pre and 
post test 
4 weeks 5 days a 
week 
45 
minutes 
FMA, MAS, 
Ashworh, 
VAS (pain 
and tx 
statification)
,  FAT, 
B&B, FIM, 
ABILHAND, 
TUG, EQOL 
Significance 
seen in FMA, 
B&B, FAT and 
FIM 
Treger  
et al 
(2008)43 
Reo 
Therapy 
System 
Forearm 
movement 
Sub-
acute 
10, pre and 
post test 
3 weeks 5 days a 
week 
45 
minutes  
Questionnai
re, FMA, 
Manual 
Functional 
Test 
Stat Sig seen in 
FMA 
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Author Robot 
Type 
Movement
s  
performed 
by robot 
Stage 
post 
stroke 
Sample 
size 
Method 
used in 
trial 
Intervention Outcome 
measure 
Results 
 Duration Frequency Minutes/ 
session 
  
Casadio 
et al 
(2009)44 
Braccio di 
Ferro 
Planar 
device, 
shoulder 
and elbow 
movement  
Chronic 10 Pre and 
post test 
 10 weeks Once a 
week 
60 and 
75 
minutes 
FMA, MAS, 
Ashworth 
Significance 
seen in FMA, 
Takahas
hi et al 
(2008)41 
HWARD pneumatical
ly actuated 
hand device  
 grasp and 
release 
movements. 
Chronic  13 Pre and 
post test 
3 weeks 15 sessions 
over 
weekdays 
1.5 hours ARAT, box 
and Block, 
FMA, NIH, 
GDS, NSA, 
SIS, 
Ashworth, 
goniometry 
Stat Sig seen in 
FMA and ARAT. 
fMRI also used 
in study 
 
Reinken
smeyer 
et al 
(2012)190  
Pneu -
WREX 
Shoulder 
movements, 
release and 
grasp hand 
Chronic 27 RCT 9 weeks 3 times a 
week 
60 
minutes 
FMA,MAL, 
RLAFT 
Stat Sig seen in 
FMA 
Kahn et 
al 
(2006)183  
 
 
ARM Linear 
shoulder 
and elbow 
Chronic 19 RCT 8 weeks 24 sessions 45 
minutes 
RLAFT No significance 
seen 
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Author Robot 
Type 
Movement
s  
performed 
by robot 
Stage 
post 
stroke 
Sample 
size 
Method 
used in 
trial 
Intervention Outcome 
measure 
Results 
 Duration Frequency Minutes/ 
session 
  
Kutner et 
al 
(2010)204  
Hand 
Mentor 
Wrist and 
finger 
extensor/fle
xion.  
Sub 
acute 
17 RCT 3 weeks 5 days a 
week 
2 hours 
robot, 2 
RTP. 
Control 4 
hours 
RTP. 
SIS Stat significance 
seen in both 
groups. Single 
questions in SIS 
improved more 
in robot group/ 
NB:  * Finlay et al (2005) and Cootes et al (2008) describe preliminary data from larger studies which are reported in other studies. 
Abbreviations: Rx: Treatment, Stat Sig: Statistical significance, RCT: Randomized Control Trial, CV: Cardio vascular. 
SOMC: Short Orientation Memory Concentration assessment, RLAFT: Ranchos Los Amigos Functional Test, GDS-Geriatric 
Depression Scale , NSA-Nottingham Sensory Assessment, FMA: Fugl Meyer Assessment (UL section); FIM: Functional 
Independence Measure; TCT: Trunk Control Test; MAS: Modified Ashworth Assessment; VAS: Visual Analogue Scale, MAS: Motor 
Assessment Score; RMA: Rivermead Motor Assessment Score. MSS: Motor Status Score, WMFT: Wolf Motor Function Score, MRC: 
Medical Research Council Muscle Power Score, MAL: Motor Activity Log, SIS: Stroke Impact Scale, RTP: Repetitive task Practice 
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Table 2.2: Details of Studies reporting Patient and Therapists Opinions of Robotic Therapy. 
Study Name No. of 
patients 
No. of 
therapists 
Robotic 
Device 
Question 
Format 
Questionnaire 
Reproduced 
Results 
Dijkers  
et al (1991)65 
22 
 
11 OTs Unnamed Closed Yes/No Questions Yes 
Device to be safe, enjoyable and helpful 
Krebs  
et al (1998)64 
10 - MIT-Manus Likert Scale Statements Yes 
Device comfortable, and wanted to perform 
more therapy on it. Patients did not wish to 
replace therapist-led rehabilitation with just 
use of the robot. 
Coote & Stokes 
(2003)32 8 6PTs 
Haptic 
Master 
Likert Scale 
Statements 
and 
Closed Yes/No 
questions 
Yes 
Both patients and therapists showed a 
positive disposition to the device. Therapists 
were concerned about shoulder placement, 
patients were not. 
Holt  
et al (2007)63 
6 
4 OTs 
4PTs 
IPAM Likert Scale Statements No 
robot comfortable and safe 
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Study Name No. of 
patients 
No. of 
therapists 
Robotic 
Device 
Question 
Format 
Questionnaire 
Reproduced 
Results 
Doornebosch  
et al (2007)66 
10 10 ACRE 2 Unknown No 
Patients and therapist were satisfied with the 
device. Therapists were concerned about the 
arm support. 
Treger  
et al (2008)43 
10 - ReoTM Likert Scale Statements No 
Positive patient response 
Lee et al 
(2005)70 17 17 
Robotic 
devices in 
general 
Unknown No 
Therapists responded positively to the idea of 
a robotic device in a clinical setting. 
Hughes et al 
(2011) 67 5 - Unnamed 
Likert Scale 
Statements 
and open 
question 
Yes 
Device well accepted and tolerated by 
patients 
Lu et al 
(2011)236 - 233 
Robotic 
devices in 
general 
Online survey Yes 
Top attributes of a device included: facilitating 
a number of arm movements, can be used in 
sitting, having virtual activities specific to daily 
living, being useful in-home and having 
resistance adjustable to client needs. Also,  
the device should be low cost. 
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3.1 INTRODUCTION 
This PhD builds on the current literature (described in Chapter Two) on the use of robotic 
devices as an adjunct to upper limb rehabilitation, with the aim of addressing some of the 
unanswered questions regarding the use of this invention. Particular emphasis will be 
given in this thesis to conducting studies that explore the translation of robotics from 
experimental research into use in clinical practice.   
Unanswered questions that this thesis will explore are (also mentioned in Chapter Two): 
1. A systematic review of upper limb outcome measures 
2. What proportion of acute stroke patients could potentially benefit from using a 
robotic aid?  
3. Is there a difference in the potential benefit of the aid depending on the severity of 
arm paresis? 
4. Can patients with differing levels of arm ability use the robotic device?  
5. What intensity of practice can the device provide and is this beneficial? 
6. Do patient’s find the device acceptable and feasible to use? 
7. Are there any risks with the use of a robotic device 
8. What resources are required in terms of trained and untrained staff? Is the use of a 
device clinically feasible in a hospital setting?. 
9. Does the use of different upper limb outcome measures that look at patient function 
better reveal any activity and participation benefit with robotic devices?  
 
3.2 THE RELATIONSHIP BETWEEN THE INDIVIDUAL STUDIES AND THE 
OVERALL INVESTIGATION  
The overall investigation described in this thesis combines a number of methodological 
approaches and phases of investigation. The studies comply with the strategy set out in 
the MRC guidance for the development and evaluation of complex interventions237;238 . 
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Neurological rehabilitation may be conceptualised as a complex intervention. Complex 
interventions are built up from a number of components, which may act both independently 
and inter-dependently e.g. behaviours, parameters of behaviours (e.g. timing, frequency) 
and methods of organising those behaviours (e.g. type of practitioner, setting, location).  
Evaluating such interventions is challenging238. The MRC published ‘A framework for 
development and evaluation of RCTs for complex interventions to improve health’ in 
2000237 and revised this in 2008238.  The work described in this thesis followed the 
approach defined in the framework, uses a combination of both quantitative and qualitative 
methodology. This mixed methods research approach combines elements from both 
qualitative and quantitative paradigms to produce converging findings in the context of 
research questions239. 
3.3 THE MEDICAL RESEARCH COUNCIL FRAMEWORK 
The framework was designed to facilitate good research practice and to provide 
investigators with guidance in recognising the unique challenges which arise in the 
evaluation of complex interventions. The framework recognises the iterative approach 
needed for this type of research. The framework describes four separate stages237: The 
guidance recognises that a linear model of successive phases may not be appropriate to 
the development of complex interventions.  The framework identifies key elements in the 
development and implementation process and these are shown in Figure 3.1 below.   
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Figure 3.1 MRC Framework238 
 
 
Each stage of the framework with now be discussed and how these relate to the studies in 
this thesis: 
3.3.1 STAGE ONE: DEVELOPMENT 
The framework discusses that it is important to establish a theoretical basis that suggests 
the intervention may have an expected effect.  A number of approaches are used to 
develop the theory that underpins the subsequent development of a complex intervention.  
These include an analysis of individual experience, consensus views and a review of 
relevant literature.  The literature review is an important part of any study; completed at the 
start of a study to help with deciding a topic; reviewing the published and unpublished 
literature it is often returned to throughout the study with the original search being 
expanded on240. An iterative process is often used to develop the search terms241 and 
used in the Cochrane review processes; the aim being to develop a search that is as 
inclusive as possible and therefore yield the most papers. After each search the terms are 
revised and the searches re-run. It is also important to establish the outcomes that are 
aimed for237:. 
 
99 
 
With this in mind two comprehensive systematic reviews were carried out to firstly identify 
research which has looked at the clinical use of robotic devices in upper limb rehabilitation 
and the outcome measures used to evaluate the intervention. These reviews are found in 
Chapters Two and Four. 
3.3.2  STAGE TWO: FEASIBILITY AND PILOTING  
This stage includes testing procedures for their acceptability, estimating the likely rates of 
recruitment and retention of subjects, and the calculation of appropriate sample sizes238 
Exploratory trials allows the effects of an intervention to be seen and measured and 
uncover where weaknesses in the study design exist. The framework comments that a 
mixture of qualitative and quantitative methods may be needed, for example to understand 
barriers to participation and to estimate response. 
From the review carried out in Chapter Two, unanswered questions were identified in the 
robotic literature (which has been stated in section 3.1). These questions raised the need 
for further feasibility and piloting work to be carried out before definitive evaluations (Stage 
three of the framework could be carried out). This consisted of five components: 
1. A systematic literature review was carried out to establish the most reliable, 
valid and responsive available limb outcome scales to use in the following trials; 
(Chapter Four) 
2. An evaluation of consecutive acute stroke patients established the proportion of 
acute stroke patients that potentially benefited from rehabilitation using a robotic 
device (recruitment study, a phase II exploratory trial);  (Chapter Five) 
3. A exploratory randomized controlled trial determined how the use of a robotic 
device (ReachMAN) can be delivered in practice and provided estimates of the 
sample size needed for a definitive study (a phase II, exploratory trial); (Chapter 
Six) 
4. A qualitative study was completed to investigate patients perceptions of the 
robotic device. (Chapter Seven) 
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5. A psychometric analysis used new & traditional methods was carried out to 
evaluate and select the most appropriate outcome measures for future trials 
(Chapter Eight) 
Each chapter will discuss separately the reasons behind the methodology chosen to 
evaluate the different components of the questions.  
3.3.3  STAGE THREE EVALUATING A COMPLEX INTERVENTION 
The MRC framework discusses that there are many study designs to choose from, with 
different designs suiting different questions. The gold standard is a definitive RCT which in 
the earlier version of the MRC framework237  was described in phase iii as ‘to compare a 
fully defined intervention to an appropriate alternative using a protocol that is theoretically 
defensible, reproducible and adequately controlled, in a study with appropriate statistical 
power’237.  
Quantitative research describes the accurate assessment of the outcome or effects of an 
intervention that necessitates the careful manipulation of that intervention (experimental 
variable), in controlled conditions, and a comparison of the group receiving the intervention 
with an equivalent control group.  It is essential that systematic errors (bias) and random 
errors (chance) are minimized. This requirement necessitates carefully designed, 
rigorously carried out studies, using reliable and valid methods of measurement, and with 
sufficiently large samples of participants who are representative of the target population242. 
One of the aims of study performed in Chapter Six was to provide estimates of the sample 
size needed for a definitive study i.e. to be able to progress to this stage of the framework. 
 
3.3.4 STAGE FOUR IMPLEMENTATION  
This last stage of the framework discusses getting evidence into practice. This was one of 
the key drivers for the research studies described in this thesis. Chapter Two highlighted 
the gap between the current research and the clinical use of robotics in upper limb 
rehabilitation. These gaps formed the background to the work performed and this area will 
be further discussed throughout the thesis. 
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3.4 ReachMAN Robotic Device 
ReachMAN is a robotic device that was developed by a group of engineers at Imperial 
University in conjunction with the author of this PhD, Dr Diane Playford and Consultant 
physiotherapist Ann Holland. Burdett and colleagues aim to develop small, low cost and 
portable robotic aid designed for use at a patient’s bedside in a rehabilitation unit or at 
home 243. ReachMAN (Figure 3.2) facilitates shoulder flexion/extension, wrist 
pronation/supination and finger flexion/extension. These movements are fundamental 
components of many common everyday tasks such as opening a door, using a key or 
switching on an oven. ReachMAN is set up as a multilevel game with each level placing a 
greater demand on the patient.   
The device is capable of continuously assessing the patient’s motor performance 
recording speed, direction & strength of voluntary activity and duration of time & intensity 
of practice. The height of the ReachMAN is adjustable for standing or seating position. The 
subject's arm is rested on the arm support to prevent excessive use of the shoulder. 
Subjects train with ReachMAN while holding to the robot handle (secured with Velcro 
band) and looking at the computer monitor which provides visual feedback. The visual 
feedback displays the movement of the robot handle relative to the target position. 
All exercises are performed as a similar task where subject have to move the handle to a 
target position within 10 seconds and hold at the target for about 0.5 seconds. A new 
target appears when the subject has successfully completed a trial. If the time limit is 
breached, the trial is considered a fail, and the robot would help complete the movement to 
the target, after which a new target would appear.  
ReachMan was piloted on three subjects prior to the machine use in the studies. This pilot 
is described in Yeong et al (2010)244. 
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Figure 3.2. ReachMAN Robotic Device 
 
3.4 HYPOTHESIS 
The premise on which the use of the robotic device (ReachMAN) was based on was that 
recovery of movement and function of the hand and arm would be promoted by providing 
intensive, repetition of movement to the contralesional upper limb after acute/ subacute 
stroke. This had been tested via the null hypothesis that the use of a ReachMAN make no 
significant difference to the recovery of the hand and arm after stroke.  The alternative 
hypothesis that ReachMAN would significantly improve recovery of the upper limb in 
acute, sub-acute stroke was proposed. 
 
3.5 AIMS OF THE DIFFERENT STUDIES 
• The aims of the review of upper limb outcome measures: 
a)  Make recommendations about choice of outcome measure for RCT 
b) Assess feasibility and acceptability of range of measures 
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c) Evaluate psychometric properties 
• The aims of the recruitment study were to: 
a) Determine future recruitment criteria 
b) Determine the rate and timing of recruitment in practice  
c) Make recommendations about choice of outcome measure for RCT  
• The aim of the exploratory randomized control study was to determine how the 
intervention would be delivered in clinical practice to:  
a) Establish positioning and set-up needs of a range of patients so that they can 
interface with the device, and how long this takes 
b) Establish frequency and duration of device use in practice 
c) Define any training needs for physiotherapists and therapy assistants 
d) Evaluate the effects of the use of ReachMAN in an acute/ sub-acute stroke 
population 
e) Provide sample required for a definite RCT 
• The aims of the qualitative study was to:  
a) Explore patients’ and carers’ perceptions of using ReachMAN 
b) Inform future robotic design and treatment protocols. 
3.6 SUMMARY 
This Chapter has identified the research questions and aims for this thesis. The following 
chapters describe the original work that was carried out to explore these aims and 
unresolved issues in the robotic literature.  
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CHAPTER 4:A SYSTEMATIC REVIEW OF UPPER LIMB OUTCOME MEASURES 
Work described in this chapter has been previously published: 
Baker K, Cano SJ, Playford ED. Outcome measurement in stroke: a scale selection 
strategy. Stroke 2011; 42(6):1787-1794. 
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4.1 INTRODUCTION 
Chapter One and Two highlighted that upper limb recovery following stroke poses 
particular challenges. Recent innovations in treatment such as repetitive practice through 
the use of robotics hold promise for improving upper limb recovery.  Chapter Two identified 
that the current research looking at the use of robotics in upper limbs have found little 
improvement in function with the use of these devices. Is this due to the intervention or 
could a factor be the outcome measures that have been used to assess this? Evaluating 
the impact of a novel treatment such as the use of robotics in upper limb rehabilitation 
increasingly depends on the use of valid, reliable, and responsive outcome measures. The 
aim of this chapter is to describe a systematic review that was carried out to identify the 
most appropriate outcome measures for use in the trials described in Chapter Five and 
Six. 
 
4.2 BACKGROUND 
There has been an increasing awareness over recent years over the importance of the 
selection of rating scales used in studies. In fact, the conclusions made from neurologic 
studies are dependent on the rating scales used, and these conclusions in turn influence 
patient care, prescribing, policy making, and the expenditure of public funds245.The 
adequacy of these choices depends directly on the scientific quality of the rating scales.  In 
acknowledgment of this fact, there has been a rapid increase in the application of rating 
scale science (known as psychometrics) in health outcomes measurement in 
neuroscience.  
To assist with the growth of psychometrics and the increased use of rating scales, a 
number of guidelines have been published for the use of scales in clinical trials: In 2002 
the Scientific Advisory Committee of the Medical Outcome Trust (MOT) produced 
guidelines for the development and validation of patient reported outcome 
questionnaires246; The US Food and Drug Administration (FDA )247 have also recently 
published draft guidelines for rating scales in clinical trials which have been described in 
the Lancet248. The MOT and FDA documents are detailed and outline a wide range of 
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issues relating to the development and validation of Patient Reported Outcome Measures 
(PROM), based on current widely used psychometric methodology. Although these 
detailed guidelines refer to PROM they can be applied to all rating scales. 
 
4.2.1 PATIENT REPORTED OUTCOME MEASURES (PROM) 
To evaluate an intervention, data collection is required pre and post intervention.  
Historically outcomes were traditionally measured with clinician rated outcomes e.g. FMA 
which is a method of clinicians quantifying upper limb movement. However, this type of 
outcome misses a large aspect of change which the patient experiences. It is these 
experiences from the patient’s perspective, which bring a wider understanding of the 
impact of an intervention or treatment. Prompted by the need for evidence based health 
care there has been a transition from these clinician rated outcomes to a more holistic 
approach that encompasses a wider range of health variables249. Researchers have 
increasingly turned to developing measures that capture this broader concept of health 
including psychological well-being and satisfaction with treatment. These outcomes are 
generically called patient reported outcome measures (PROMS). 
PROMS are described as a measurement of any aspect of a patient’s health status that 
come directly from the patient (i.e. without the interpretation of the patient’s responses by a 
physician or anyone else)250.  A PROM can be used to measure the impact of an 
intervention on one or more aspects of a patients’ health status, ranging from purely 
symptomatic (e.g. response of a headache) to more complex concepts (e.g. ability to carry 
out activities of daily living) to extremely complex concepts such as quality of life. Data 
generated can provide evidence of a treatment benefit from the patient’s perspective.  For 
this data to be meaningful, however, there should be evidence that the PROM effectively 
measures the particular concept that is studied250. 
There are advantages with PROMS. These are: 
• Some treatment effects are only known to the patient; 
• There is a desire to know the patients perspective about the effectiveness of the 
treatment; and 
• Systematic assessment of the patient’s perspective may provide valuable 
information that can be lost when filtered through a clinician’s evaluation. 
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Disadvantages: PROM require the respondents to be literate and cognitively intact to a 
level where they can respond to closed questions with a choice of set responses. Pre-
coded response choices may not be sufficiently comprehensive, and not all answers may 
be easily accommodated. Some respondents therefore maybe ‘forced’ to choose 
inappropriate responses240. 
The use of patient reported outcome measures in stroke research is a relatively new 
development251  and is complicated in this population by cognition and communication 
difficulties which can occur in stroke survivors 252. Dorman et al (1999) 253 for example 
asked 2253 stroke patients to complete EuroQol and SF36 via mail and found that 50% of 
the stroke subjects were unable to complete the questionnaires by themselves. Absent 
data can cause biased estimates of stroke treatment effect, lessen the power of a study to 
detect responsiveness and reduce the generalisabilty of the results in. The inclusion of 
proxy data can assist in improving the above problems, although the use of proxy 
respondents should be approached with caution254;255 
Typically in upper limb measures PROM will look at functional activities that may involve 
the whole arm.  Clinician rated measures are more likely to examine impairment level 
movement or focus on a single task performed at varying degrees of difficulty. Both have 
their place but for interventions to be successful they must make a difference to patients' 
lives and this can only be successfully captured in a patient reported outcome. Therefore 
despite the problems described above with the use of PROM in the stroke population, it 
was felt to be important to use both clinician rated and PROM in the studies described in 
this thesis. 
4.2.2 CHOOSING UPPER LIMB OUTCOME MEASURES AND SCALES FOR 
THE STUDIES 
Various reviews have looked at upper limb outcome measures in both stroke and hand 
and arm function tests in other upper limb disorders 254;256;257.  The most recent review has 
been carried out by Ashford et al (2008) 214 who reviewed measures for the hemiparetic 
upper limb. This review identified six scales that met their selection criteria, but concluded 
that currently there was no single reliable and valid measure available to capture the full 
range of functional tasks in the hemiparetic upper limb. This type of systematic review 
provides invaluable information but also raises important questions. For example, how well 
targeted are different measures to the goals of specific interventions? How do we select 
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the best available measures for future clinical studies? What criteria should be used and 
why? 
A systematic review and scale selection strategy was therefore carried out to select the 
most scientifically sound and clinically relevant outcome measures to evaluate the studies 
performed in this thesis. This was carried out by the use of three stages: First, two  
psychometric guidance documents that define key scale assessment criteria were 
reviewed, Second, consideration was given, at a theoretical level, to clinical issues, 
concepts, and domains important to include in stroke outcome research. Thirdly a 
comprehensive literature review was performed and reviewed with input from healthcare 
professionals, psychometricians, and librarians.  
  
4.3 STEP I: PSYCHOMETRIC GUIDANCE DOCUMENTS 
 
The two most widely used guideline documents for psychometric standards for rating scale 
research were selected, to provide appropriate criteria against which to examine existing 
scales. First, the Scientific Advisory Committee of the Medical Outcome Trust 246(MOT) 
guidance for the development and validation of patient reported outcome (PRO) 
measures. Second, the US Food and Drug Administration (FDA )247 guidelines for PRO 
measures in clinical trials.  Both the MOT and FDA documents emphasize the importance 
of patients’ views in clinical research.248 Both documents identify key properties for 
psychometrically robust measures. Table 4.1 and. 4.2 summarizes the key issues 
identified by the documents (ie data quality, scaling assumptions, targeting, reliability, 
validity and responsiveness). Taken together these documents provide an essential basis 
in the process of selecting PROM because they provide rigorous standards that scales 
should meet. It is important to note that these properties of a PROM also have relevance 
to clinician-rated scales, which should be evaluated in the same rigorous manner.258  
  
109 
 
Table 4.1: 8 key “attributes” when designing outcome measures, as detailed 
in MOT259 
Attribute Properties 
Conceptual and measurement 
model 
 
Rationale for and depiction of the concept(s) the 
measure is intended to assess (e.g., scale and 
subscale structure) 
Reliability Degree to which the measure is free from random 
error, including internal consistency and test-retest 
reproducibility 
Validity  Degree to which instrument measures what is 
purports to measure, including content, construct, 
and criterion validity 
Responsiveness Instrument's ability to detect change in outcomes 
that matter to persons with a health condition, their 
significant others or their providers 
Interpretability Degree to which one can assign clinical or 
commonly understood meaning to quantitative 
scores 
Respondent and administrative 
burden 
Time, energy, and other difficulty placed on 
respondents and on those who administer the 
instrument 
Alternative forms Equivalent information on versions of measures 
other than original source 
Cultural and language adaptations 
(translations). 
Conceptual and linguistic equivalence and 
psychometric properties of cross-cultural adaptation 
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Table 4.2: Summary key issues in FDA guidelines (adapted from Cano& 
Hobart (2008)260) 
Psychometric property  Definition 
Data quality  
 
Assessed by completeness of data and score 
distributions 
 
Scaling assumptions  
 
• Items in a scale should measure a common 
underlying construct 
• Items in a scale should contain a similar 
proportion of information concerning the construct 
being measured 
• Items should be correctly grouped into scales 
 
Targeting  
 
• Indicates whether a scale is acceptable as a 
measure for the sample 
Reliability 
Internal consistency  
 
Test–retest reproducibility 
 
• The extent to which items in a scale measure the 
same construct 
• The stability of a scale between repeat 
administrations of the scale on two occasions 
111 
 
 
4.4 STEP II: STROKE-SPECIFIC ISSUES IN THE SELECTION OF 
APPROPRIATE OUTCOME MEASURES 
There is no consensus on the battery of outcome measure to use when assessing physical 
recovery post-stroke. Selecting the appropriate scales to assess recovery in stroke is a 
difficult task given the heterogeneity of stroke aetiology, symptoms, severity, and even 
recovery itself. However, despite these complexities, several clinically anchored strategies 
can assist in selecting the right measure for this population in clinical research. Thus, in 
addition to the psychometric guidelines described above, the International Classification of 
Functioning, Disability and Health (ICF)261 framework was also included to help identify 
scales with relevant domains for the studies.  
Figure 4.1: ICF Model 261 
 
 
 
The ICF framework provides a conceptual framework for the selection and classification of 
outcome measures. The domains contained in the ICF include Body Functions and 
Structures (impairments) and Activities and Participation (disabilities): 
112 
 
• Body functions and structures: This refers to physiological functions of body 
systems including psychological. Structures are anatomical parts or regions of 
body and their components. Impairments are problems in body function or 
structure.   
• Activity: activity refers to execution of a task by an individual .Limitations of a task 
are defined as difficulties an individual might experience in completing a given 
activity. 
• Participation: involvement of an individual in a life situation. Restrictions to 
participation describe difficulties experienced by the individual in a life situation or 
role. 
• Contextual factors: these include personal and environmental factors that influence 
the relationship between the different components  
The impacts of stroke on the domains of the ICF are not always directly related to each 
other. The severity of impairment does not necessarily determine the limitation in activities 
and participation due to the varied interplay between these domains and the influence of 
contextual factors.262 Such differences may also be seen in relation to the effects of any 
intervention (e.g. changes at the impairment level do not necessarily translate into the 
other domains, e.g. participation) 
Measures of impairment have been postulated to be the best markers of prognosis  254  
Impairment scales may be the most sensitive to change and have the greatest capacity to 
differentiate between treatment groups. However, for clinical significance and health policy 
it is important to relate changes in impairments to changes in activity and participation. 
Activity measures are the most frequently used primary outcome measures in stroke. The 
most common domain of activity measurement is basic activities of daily living 
(ADLs)263.However, it has been found in studies of unselected stroke population, that  
approximately 60% of the patients will make a “complete recovery” in basic ADL 263.This 
means that ADL measures are subject to ceiling effects and may therefore not show a 
difference between groups in outcome, significantly reducing the power of any study254.   
A challenge in all activity and mobility measures is that the link between the extent of loss 
at the level of pathology and impairment is not perfectly correlated and other factors may 
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influence the outcome262. For example, an individual may improve in motor function, but 
without good social support to encourage independence, he or she may not resume social 
roles, such as being a grandparent or going out with friends..  Although there is a growing 
call to include participation measures as an important component of disability. Few 
measures look at this aspect.  
In the context of upper limb rehabilitation post stroke research, it may be important for 
researchers to know what impact an intervention has had at an impairment level, but it is 
equally important to identify what impact these changes have for individuals at an activity 
or participation level and how this affects more complex multidimensional concepts such 
as quality of life264.  
Novel treatments need refining until their impact at the level of body structure and function 
translates into something meaningful for the patient. The studies outlined in this thesis 
used stroke survivors ranging from those with only a few proximal shoulder flickers to 
those with near normal arm strength. To appropriately assess ReachMAN, scales were 
required that captured clinically important improvements in arm movements at all levels of 
the ICF. This is endorsed by Sivan et al (2010)262 who concluded in their review of the 
outcome measurement used in clinical literature investigating robotic devices that a basket 
of outcome measures covering all domains of ICF is crucial, as it is important to measure 
change in each domain. 
 
4.4 STEP III: LITERATURE REVIEW 
A comprehensive literature search strategy and review were developed in conjunction with 
healthcare professionals (the author of this thesis (KB) and Dr Diane Playford), 
psychometricians (Stefan Cano), and a librarian (Kate Brunskill). An electronic 
bibliographicsearch was conducted in the following databases: Medline, Embase 
(Excerpta Medica), CINAHL, and PsycINFO. The databases were searched from 1966 to 
2011. Limits were placed on each search to exclude non-English citations and nonhuman 
subjects using a variety of key terms, including upper limb, upper extremity, arm function, 
outcome measure, stroke, cerebral vascular accident, assessment, scale, score, quality of 
life, and questionnaire. All instruments included in the review were identified as an upper 
limb outcome measure. A follow-up review of references was performed to find relevant 
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articles not detected in the electronic searches. From this search, scales that measure 
global motor function but also included a specific upper limb subsection were included (eg, 
the Rivermead Motor Assessment). However, scales in which upper limb function was not 
separate from other functions were excluded (eg, the Stroke Impact Scale). Scales that 
had not been psychometrically evaluated in patients with stroke were also excluded. 
Figure 4.2 illustrates this search.  
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Figure 4.2:  Flow diagram of systematic literature review carried out to 
identify upper limb outcome measures 
 
230 abstracts 
identified 
45 measures 
identified 
20 instruments failed 
criteria and rejected 
25 instruments Reviewed 
Apply Inclusion/Exclusion Criteria 
Inclusion: Upper limb measure 
Exclusion: Non-English language instrument 
Not specific to upper limb or not reviewed in stroke 
patients. 
Mapping of Topic: 
Search Terms: upper limb, upper extremity, arm 
function, outcome measure, stroke, cerebral vascular 
accident, assessment, scale, score, quality of life and 
questionnaire 
Electronic Bibliographic Searches: 
Medline; EMBASE (Excerpta Medica): CINAL 
(nursing and therapy database); PsychInfo 
(Psychological Abstracts) 
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4.4.1 RESULTS OF THE LITERATURE REVIEW 
 
The findings from the literature review were cross-referenced against the guideline 
documents criteria and clinical considerations underpinned by the ICF framework. The 
review itself identified 25 outcome measures used to evaluate upper limb recovery post 
stroke. These measures were separated into stroke-specific clinician-rated and PROM. 
The properties and initial evaluation of these 25 measures against the specific criteria 
identified on the MOT/FDA guidance are shown in Table 4.3 and 4.4. Three measures 
were identified that best met the criteria of the MOT and FDA guidelines: Chedoke Arm 
and Hand Inventory, Stroke Rehabilitation Assessment of Movement upper limb section, 
and ABILHAND. Details regarding the development and psychometric properties of these 
measures are described below. A fourth measure, the Upper Limb– Motor Assessment 
Scale, also fit many of the MOT criteria, but a closer inspection of psychometric properties 
of the measure found that the upper limb items should be used with caution. This scale 
was therefore not felt to be suitable for use in our study. A summary of the three identified 
measures is presented below. (Appendix 111 describes psychometric criteria used for 
evaluation of the measures). 
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Table 4.3: Stroke clinician rated scales: Development and validation criteria 
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Patient Interviews  
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Literature  
♦ 
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Expert opinion  
♦ 
     
♦ 
  
♦ 
          
Develop conceptual 
model 
                     
Item Reduction 
                     
Expert opinion  
♦ 
        
♦ 
          
Item redundancy  
♦ 
        
♦ 
          
Endorsement  
♦ 
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♦ 
                  
Factor analysis                      
Tests of scaling 
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Psychometric 
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Acceptability                     
Internal consistency 
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♦ ♦  
        
Item total 
correlations 
          
 
         
119 
 
 
A
R
A
T
 
C
A
H
A
I
 
1
0
-
s
 
t
e
s
t
 
A
M
A
T
 
W
M
F
T
 
F
M
A
 
M
S
S
 
U
L
-
M
A
S
 
D
e
S
o
u
z
a
 
R
M
A
 
S
T
R
E
A
M
 
M
E
S
U
P
E
 
M
o
t
r
i
c
i
t
y
 
I
n
d
e
x
 
N
H
P
T
 
F
A
T
 
S
o
d
r
i
n
g
 
S
o
l
l
e
r
m
a
n
 
M
C
A
 
M
M
A
C
 
B
o
x
 
a
n
d
 
B
l
o
c
k
 
F
u
n
c
t
i
o
n
a
l
 
Inter -rater reliability 
♦  ♦ 
 
♦ ♦ ♦ ♦ ♦ 
 
♦ ♦ 
        
♦  ♦  
Test-retest reliability 
♦  ♦ 
 
♦ ♦ ♦ ♦ ♦ 
 
♦ ♦ 
 
♦  ♦ ♦ 
 
♦  
  
♦  
 
Validity: within scale 
♦  ♦ 
   
♦ 
 
♦ 
 
♦ ♦  
 
♦ ♦ 
 
♦  
    
Validity: comparison 
with 
other measures 
♦  ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ ♦ 
 
♦  ♦ ♦ ♦ ♦  
 
♦ ♦  
 
Validity: hypothesis 
Testing 
                     
Responsiveness 
♦  
      
♦ 
  
♦ 
        
♦  
 
Key:ARAT, Action Research Arm Test; CAHAI, Chedoke Arm and Hand Inventory;10-s Test, 10 second Tests; AMAT, The Arm 
Motor Ability Test; WMFT, Wolf Motor Function Test;FMA,Fugl-Meyer Assessment; MSS, Motor Status Score; UL-MAS, upper limb 
of Motor Assessment Scale; Dezouza, Dezouza arm Test; RMA, Rivermead Motor Assessment: STREAM, stroke rehabilitation 
assessment of movement, MESUPE. Motor Evaluation Scale for the Upper Extremity in Stroke Patients; NHPT, Nine Hole Peg 
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Test, FAT; Frenchay Arm Test; Sodring, Sodring Motor Evaluation Test, Sollerman, Sollerman Hand Function Test; MCA, Motor 
Club Assessment, MMAC, Modified Motor Assessment Chart 
 
 - As defined by Rasch analysis using RUMM 2010 software. 
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Table 4.4: Stroke Patient Reported Outcome Measures: Development and 
validation criteria 
 DHI MAL ABILHAND UMAQS 
Item Generation 
    
Patient Interviews   ♦   
Literature   ♦   
Expert opinion   ♦   
Develop conceptual model   ♦   
Item Reduction 
    
Expert opinion   ♦   
Item redundancy   ♦   
Endorsement frequencies   ♦   
Missing data   ♦   
Factor analysis   ♦   
Tests of scaling assumptions   ♦   
Psychometric Analyses 
    
Acceptability   ♦   
Internal consistency reliability ♦  ♦  ♦   
Item total correlations  ♦  ♦   
Inter -rater reliability   ♦   
Test-retest reliability ♦   ♦  ♦  
Validity: within scale  ♦  ♦   
Validity: comparison with other measures ♦  ♦  ♦   
Validity: hypothesis testing   ♦   
Responsiveness ♦   ♦   
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Key: DHI-Duruoz Hand Index, MAL-Motor Activity Log. ABILHAND-ABILHAND 
Questionnaire, UMAQS- University of Maryland Arm Questionnaire for Stroke 
4.4.2 IDENTIFIED SCALES FROM THE INITIAL LITERATURE REVIEW 
 
CHEDOKE ARM AND HAND INVENTORY265 
Purpose: This measure was developed methodically to look at functional tasks post stroke. 
Initially 109 stroke patients and their carers were interviewed and from this literature 
review and expert opinion 751 items were generated. Item reduction was then carried out 
by statistical analysis and expert opinion as well as piloting the measure. 
Content: The test consists of thirteen real-life functional tasks that reflect domains deemed 
important by survivors of stoke. This included (1) bilateral activities (2) non-gender specific 
tasks, (3) the full range of movements, pinches and grasps and (4) covering all stages of 
motor recovery post stroke266  
Psychometric data: The development ensured face, content and factorial validity. 
Convergent validity with the ARAT (r= .93) and the CMSA (r= .87) were high.  Internal 
consistency (r= .98) and single item factor loading are high (range .76-.96). Interrater 
reliability was high (ICC .98) 265 . 
STREAM267 
Purpose: 
 Provides a comprehensive, objective and quantitative evaluation of motor functioning of 
individuals with stroke. 
Content: Consists of 30 items that are distributed among three subscales, Upper Limb 
movements, Lower limb movements and basic mobility items. Limb movements are scored 
on a 3 point scale, while mobility items are scored on 4 point scale. There is a maximum 
score of 70 with each limb subscale scored out of 20. 
Psychometric Properties: Reliability and Validity has been established. Inter and intrarater 
reliability correlation coefficients of .99 (total score), .96 to.99 for subscores. Internal 
consistency in 26 patients was found Cronbach alpha >.98 268. Wang et al (2002)267 on 54 
patient’s found inter rater reliability weighted kappa of individual items ranged 0.55-0.94, 
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intraclass correlation co-efficient total score was 0.96 and was also high in the subscales 
(UL scale 0.95). Concurrent validity against Barthel Index and FMA has found a spearman 
rho 0.67 and 0.95, and against FMA-UL subscale r= 0.87. Ahmed et al (2003)269 looked at 
validity against various measures including Box and Block and found Pearson coeffiencent 
0.57 to 0.80. Predictive validity was comparable to BI and gait speed. The authors269 found 
responsiveness mean estimate supported the ability of the STREAM to reflect change over 
time.  
 Rasch analysis has also been performed on this measure, using WINSTEPS software.270 
After deleting items from scale to fit the model, the shortened measure was found to 
demonstrate high Rasch reliability, unidimensionality, and concurrent validity in patients 
with stroke. 
4.4.3 PATIENT REPORTED MEASURES 
 
ABILHAND271 
Purpose: This was initially devised to measure “manual (dis) ability in patients with 
Rheumatoid arthritis who had undergone arthrodesis. The test was then looked at in 
chronic stroke patients. The measure was devised using Rasch. 
Content: “ABILHAND” is an inventory of 56 manual activities that patients were originally 
asked to judge on a 4 level scale: 0 (impossible), 1 very difficult, 2 difficult, and 3 easy. 
The test explores both unilateral and bimanual activities done without other human help. 
For each question the patient provided his/her feeling of difficulty irrespective of the limb 
actually used to do the activity. 
Psychometric data: The ABILHAND was initially analysis with use BIGSTEPS Rasch 
analysis computer software, in a group of patients with rheumatoid arthritis. The scale was 
then adapted for chronic stroke using the Winsteps Rasch analysis computer program. 
The measure was found to have a Rasch reliability of 0.90, and item-difficulty hierarchy 
was stable. 271 
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Table 4.5: Classification of UL outcome measures in the ICF framework  
Impairments Activity Participation 
STREAM CAHAI ABILHAND 
 
4.5 ADDITIONAL SCALES 
 
There were immediate drawbacks to using the three identified scales in isolation. All are 
relatively new scales that have not been widely used in the upper limb intervention trial 
literature. Using these scales alone would have made it difficult to compare the results of 
the studies with others in the stroke literature. Therefore, it was felt to be appropriate to 
add further scales that would address this key point but would still be psychometrically 
valid and cover impairment and activity. From the initial electronic bibliographic search, 
two further measures of impairment were selected. The FMA upper limb section and ARAT 
were chosen because they have been widely used in the robotic stroke literature and have 
been used as “gold standard” for comparison with other measures. A summary of these 
measures follows. 
FUGL-MEYER ASSESSMENT (FMA)272 
Purpose: This impairment based measure was developed to assess motor recovery 
following stroke and was based on early works of Twitchell273 and Brunnstrom274. It is 
widely used in stroke research and has been used as a gold standard to compare the 
reliability and validity of other outcome measures. 
Content: Scoring ranges from 0 to a maximum of 66 for upper limb movement. The upper 
limb section has 33 items, which include reflex testing, movement observation, grasp 
testing and assessment of co-ordination. 
Psychometric data: The validity, reliability and responsiveness of the FMA have been 
extensively reported.  Concurrent validity has been demonstrated with the MAS (r.= 64-.92 
275
, each subscale of the ARAT(functional ability, r=.94, quality of movement=.94) 276, and 
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the Barthel Index (r=.75)  Intra-rater reliability (r=.995)and inter-rater reliability (r=.992)277 
test-retest reliability (intraclass correlation coeffiecient, .94-.99) 278, along with internal 
consistency (r=.97)279 have been found to be excellent.  
Rasch analysis has been performed on the FMA upper limb section280. Woodbury et al 
(2007) 280who conducted this analysis concluded that based on Rasch model criteria as 
operational by Winsteps software the items testing reflexes may threaten the assessments 
dimensionality. The Rasch –item difficulty order was not consistent with the hierarchical 
structure and item order of the measure. A modified FMA was found to show a 
longitudinally stable item difficulty order. 
ACTION RESEARCH ARM TEST (ARAT): -  
Purpose: This measure was devised in 1965 as the upper extremity function test 
(U.E.F.T), it was developed by testing on 200 people with UL difficulties with the objective 
of developing a testing procedure that was representative of the major activities of the 
upper limb in everyday activities of daily living 281. The test was reorganised by Lyle (1981) 
282to look specifically at UL dysfunction post cerebral cortical injury, using a Guttman scale 
and renamed “ARAT”. The test has been widely used in rehabilitation and treatment trials.  
Content: The ARAT is a performance test that consists of 4 domains: grasping (lifting up 
different size objects), gripping (holding and moving objects), pinching (picking up small 
objects) and gross movement (e.g. hand to mouth) involving 19 movements. 
Psychometric data: Just as the FMA, this measure has been extensively examined against 
other measures, and is used as a ‘gold standard’ for the comparison of other upper limb 
measures (64-69). The measures reliability, validity and responsiveness have been 
extensively examined and established. Interater reliability (.98) and test-retest reliability 
(.99) have been established 283 284. Concurrent validity of the ARAT with the Fugl-Meyer 
Assessment (r range .91-.94) 276  285, the ARAT and the Motor Assessment Scale, upper 
extremity part (r=.96) 283 and the ARAT and the Motricity Index has been demonstrated 
(r=.87) 283.Various authors have found that the ARAT is responsive to change (effect size 
greater than 1.0) 284 285 ,  
The scale unidimensionality has been validated by Mokken analysis (a non-parametric 
item response theory model).286 Koh et al (2006) 286 also  examined  the parametric 
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function of ARAT by Rasch analysis using WINSTEPS program. This analysis produced 
poor Rasch model–data fit, suggesting that the raw scores of the ARAT cannot be 
transformed into interval scores and do not represent patients exact functioning. From this 
analysis Koh et al (2006)286 advise that interpreting the difference in scores should be 
interpreted with great care. 
 
4.6 SCALE EVALUATION - CLINICAL CONSIDERATIONS 
At this stage measures had been identified that were:  1. Psychometrically robust, 2. In 
common usage and 3. Evaluated a range of impairments. A measure of activity had been 
identified and one of participation that although psychometrically robust were used rarely. 
However scales had not been identified that quantified the severity of the stroke, the 
impact of stroke on daily life or measured quality of life. Therefore a consideration was 
given to a number of measures that were more generic, and thus not identified in the 
original literature review, but are familiar because they are in common usage. These 
included the National Institutes of Health Stroke Scale the SF 36, Barthel index and EQ-
5D. The EQ-5D was also included to allow assessment for health economics. (as 
recommended by Sivan et al (2010)262).  A further PROM specific upper limb measure the 
Disabilities of the Arm Shoulder and Hand (DASH) was also included. This was included 
as although this measure has not been widely used in stroke or robotic research the 
measure has undergone extensive psychometric testing and is a measure of everyday 
active arm function. 
Further specific search targeting the psychometric properties of these scales was 
conducted and detailed below: The levels under ICF framework that the added scales fall 
under is seen in Table 4.6. 
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NATIONAL INSTITUTES OF HEALTH STROKE SCALE (NIHSS)287  
Purpose: The NIHSS was initially designed to assess differences in interventions in clinical 
trials, although it has also been used is an initial assessment tool. .The scale was 
designed to evaluate neurologic outcome and degree of recovery for patients with stroke. 
It was based on three previously used scales, the Toronto Stroke Scale, the Oxbury Initial 
Severity Scale and the Cincinnati Stroke Scale287  
Content: The NIHSS is a 15-item scale, which assesses level of consciousness, 
extraocular movements, visual fields, facial muscle function, extremity strength, sensory 
function, coordination (ataxia), language (aphasia), speech (dysarthria), and hemi-
inattention (neglect).  
Psychometric Properties: Reliability, validity and responsiveness have been investigated in 
the scale and match recommended criteria. Test-retest reliability of the original NIHSS was  
reported as  adequate to excellent287.The inter-rater reliability and intra-rater reliability has 
been established.288.The validity of the scale has been looked at with the Modified Rankin 
Scale and Barthel Index and Glasgow Outcome Scale 288... The NIHSS was found to 
predict against these other measures at 3-month outcome. No studies have examined the 
internal consistency of the NIHSS. A significant ceiling effect has been detected with the 
NIHSS.289;290 
SF-36291 
Purpose: The Medical Outcomes Study 36-item Short-Form Health Survey was developed 
as part of the Medical Outcomes Study (a two-year study of patients with chronic 
conditions) 291 
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Content: The SF-36 consists of 11 questions, with 36 items in total. With the exception of 
the general change in health status questions, subjects are asked to respond with 
reference to the past 4 weeks. An acute version of the SF-36 refers to problems in the past 
week only . Items of the SF-36 are divided into eight different domains: Physical 
component which consists of Physical functioning , role limitations due to physical 
problems,bodily pain, and general health perception; Mental component which is broken 
down to items of social functioning, general mental health, role limitations due to emotion 
problems and vitality. Respondents are also asked to rate their current health status 
compared to their health status one year ago. 
Psychometric Properties: The reliability of the measure match recommended criteria, 
although no studies have examined the inter-rater reliability of the measure. The validity of 
the measure has been questioned in stroke with five of the eight SF-36 subscales were 
found to have limited validity as outcome measures, and that the reporting of physical and 
mental summary scores were not supported.292 These findings have been disputed by De 
Haan.(2002) 293 Rasch analysis has been performed on the measure examining the 
unidimensionality and differential item functioning of the physical functioning subscale of 
scale.294 For some items differential item functioning was seen for the stroke sample 
compared with other neurological conditions.  
EQ-5D295 
Purpose: The EQ-5D was developed by an international and interdisciplinary group of 
researchers (EuroQol Group) in 1987. The scale was devised to produce developing a 
standardized non-disease-specific instrument for describing and valuing health-related 
quality of life. The score can be used as weights for calculating quality-adjusted life years.  
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Content: The EQ-5D questionnaire is a simple generic instrument which consists of 5 
dimensions mobility, self-care, usual activities, pain/ discomfort and anxiety/depression 
Subjects have to choose the level that best describes their health status on each 
dimension. Each subject's health status is described as a combination of five digits (one 
for each dimension rated), and the EQ-5D descriptive system generates 243 different 
health states.  
Psychometric Properties: The reliability, validity and responsiveness have been examined 
and match criteria. The measure has been assessed against many other measures 
including SF-36. Ceiling effects have been found with the measure. 
BARTHEL INDEX296 
Purpose: The BartheI Index was first developed by Mahoney and Barthel 297in 1965 and 
later modified by Collin et al in 1988296. The index was developed for use in rehabilitation 
patients with stroke and other neuromuscular or musculoskeletal disorders. A number of 
version of the index exist, with no consensus over which should be considered the 
definitive version of the Barthel Index , but the original and the 10-item and 15-item 
modifications are the most commonly used.  
Content: The index measures the extent to which somebody can function independently 
and mobility in their activities of daily living (ADL) i.e., feeding, bathing, grooming, 
dressing, bowel control, bladder control, toileting, chair transfer, ambulation and stair 
climbing. The index also indicates the need for assistance in care. 
Psychometric Properties: Reliability, validity and responsiveness have been found to match 
evaluation criteria . Inter rater reliability has also been established.298 Concurrent validity of 
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the index with the SF-36, Berg balance scale, FMA and Frenchay Activities Index has 
been demonstrated. 298The measure has been found to have significant ceiling effects299 
DISABILITIES OF THE ARM SHOULDER AND HAND (DASH)300 
Purpose: A region specific measuring tool to measure outcome of musculosketal 
conditions affecting the upper limb 300 The measure was methodically developed using a 
group of methodologists and clinical experts. Item reduction was then carried out via 
extensive field-testing in patients. It has been used widely as a measure for conditions of 
the hand, wrist, elbow and shoulder. 
Content: It is a 30-item questionnaire, which measures physical, and social functions 
together with symptom impact. There are optional sport/music and work specific sections. 
Each question is scored is by a five point Likert scale and scores are summed with a lower 
score indicating less disability. An 11 item Quick DASH has also been developed, using 
the most sensitive and responsive questions 301This measure is being increasingly used in 
research regarding neurological impairment. 
Psychometric Properties: Atroshi et al (2000) 302looked reliability and validity in patients 
with surgical and non-surgical muculosketal disorders. Internal consistency was high 
(alpha:0.96), as was test-retest reliability (ICC:0.96). 302Validity has also established, with 
Beaton et al (2001) 301 finding good correlation with DASH, the Brigham (carpal tunnel) 
questionnaire, the SPADI (Shoulder Pain and Disability Index), and other markers of pain 
and function (r > 0.69.) 
 
4.6.1 LIMITATIONS OF THE ADDITIONAL SCALES SELECTED. 
When looking at the psychometric properties of the above measures it was clear that there 
are weaknesses in the measures. In an ideal situation more robust psychometric 
measures would be used. However on a pragmatic level the use of these measures 
allowed comparability, meta analysis and cost effectiveness analysis. 
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Table 4.6: Classification of measures in the ICF framework 
Impairments Activity Participation 
NIHSS Barthel Index SF 36 
FMA ARAT EQ-5D 
  DASH 
 
4.7 CONCLUSION 
To identify the most appropriate outcome scales for the studies in this thesis a three stage 
approach was used: firstly best practice psychometric guidelines were used to evaluate 
measures, these were then compared against a theoretical framework and clinically 
important criteria. The scales were then categorized into the ICF framework to ensure 
clinical relevance. ‘Gold standard’ measures and measures of wide spread use were also 
included to ensure the results were understood by the wider research community and were 
reproducible. Using this method, the above scales were chosen to be used in this research 
trial: STREAM, CAHAI, ABILHAND, FMA, ARAT, EQ5D, SF36, Barthel Index, NIHSS and 
DASH. These scales represent not only all domains of the ICF framework but also 
incorporate a mixture of clinical rated and patient reported outcome measures. 
The scale selection strategy described in this chapter highlighted that current rating scales 
have their limitations. With the example of scales for the hemiparetic upper limb, there is 
currently no single valid and reliable scale available to portray the complete range of 
function in the arm214.  Scales that look at the participation component of the ICF are 
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extremely limited. Furthermore, studies have used scales that have been found to be 
psychometrically restricted. However, it was felt that the studies described in this thesis 
needed to use scales that covered a wide range of activities, and ICF domains, even if the 
scales had weakness. This was also to allow the studies to be compared and 
amalgamated using meta-analysis with other robotic studies. 
 
4.8 SUMMARY 
This chapter has discussed the scale selection strategy used in the identification of 
outcomes for the studies in the thesis.  The following chapters will describe fully the 
methodologies used in each of the stages of the study and the results that they generated 
as well as implications for practice.
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CHAPTER 5- A RECRUITMENT STUDY (PHASE 1). 
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5.0 INTRODUCTION 
Motor deficit of the upper limb is common after stroke and severe impairment is prognostic 
of poor recovery  74.  Although a range of therapeutic techniques is used, most of these 
interventions (e.g. CIMT, task specific training) rely on the presence of at least some active 
movement.  A number of experimental techniques are currently being investigated such as 
the use of robotic devices, however, these are not yet integrated into routine clinical 
practice. At present there is little therapy specifically to promote recovery of the severely 
paretic or paralysed upper limb after stroke. 
The clinical trials that have looked at the use of robotic devices in the acute and subacute 
population suggest that this adjunct may improve motor performance post stroke (as 
discussed in greater depth in Chapter Two).  In order to evaluate this further and in 
particular assist in the integration into clinical practice, the present study was designed to 
establish the proportion of acute stroke patients who could potentially benefit from 
rehabilitation using a robotic device.  The study was designed to comply with the MRC 
(2008) guidance   It may be defined as Phase II (modeling) study. 
The aims of this first phase of the study were: 
5.1 AIMS:  
5.1.1  Determine future recruitment criteria 
5.1.2  Determine the rate and timing of recruitment in practice  
5.1.3  Make recommendations about choice of outcome measure for the second phase 
of the study-the exploratory RCT.  
5.2  RESEARCH QUESTIONS 
5.2.1 What are the inclusion and exclusion criteria for an exploratory RCT?  
5.2.2 How many people would be able to use a mock up of the device and how long does 
this take to recruit in practice? 
5.2.3 Are the outcome measures feasible and practical to use? 
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5.3  METHODOLOGY 
5.3.1 PATIENT SELECTION 
The initial plan was to recruit one hundred consecutive single incident stroke patients 
admitted to UCLH NHS Trust, provided they were capable of giving informed consent.  
The criteria for inclusion and the actual number of patients recruited is discussed in more 
detail in section 5.4 
 
5.3.2  SETTING 
Recruitment into this study commenced in July 2009. At that time people with suspected 
strokes were admitted to UCLH Accident and Emergency department and then transferred 
to a designated ward in the hospital. In 2010 UCLH, was designated as one of eight hyper-
acute stroke units (HASUs) in London and the only one in the North Central London. This 
formed part of Healthcare for London’s plan for the improvement in the quality of stroke 
care. HASU admits acute stroke patients from across North Central London .This HASU 
see about 160 patients each month, about 80 of these are strokes. HASU provides rapid 
assessment, thrombolytic and interventional treatment to patients in the hyperacute phase 
following stroke. Most patients who have been diagnosised with a stroke stay for 72 hours 
on HASU before being transferred to their local stroke unit or discharged home. 
 
5.3.3 PATIENT RECRUITMENT 
All patients who were admitted to UCLH NHS Foundation trust who were confirmed to 
have had a stroke (confirmation of stroke either seen on CT/ MRI scan or by clinical 
symptoms, the diagnosis being made by specialist stroke consultants) were notified to the 
research physiotherapist (KB) by a research nurse. The responsible clinician was then 
asked for permission to approach the patient. 
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Initial inclusion criteria for the study were: 
1. Able to give informed consent 
2. Single incident stroke, within the last seven days. 
Recruitment of this phase of the study began in July 2009. It became clear from the onset 
that excluding people from the study who had had subsequent strokes was an oversight as 
this may have missed the large number of patients with second strokes who could also 
benefit from using the robotic aid. In retrospect, the decision to exclude second strokes 
seemed somewhat arbitrary. Therefore an amendment to the ethical approval protocol for 
the study was applied for and obtained in December 2009. This amendment therefore 
meant that anyone within seven days of having a new stroke would be eligible to be 
recruited. Recruitment was to continue until 100 single incident strokes were recruited.  
 
5.3.4 STUDY INFORMATION 
The information sheet for participants was written using UCLH guidelines; this sheet gave 
them further information about the study, possible interventions and how the data collected 
would be used (see Appendix IV).  Each participant read the information sheet prior to 
agreeing to participate in the study. Once verbal agreement was reached a consent form 
was then signed.  The consent form was developed using UCLH guidelines  and National 
Research Ethics Service guidelines (see Appendix IV). 
 
5.3.5 ETHICAL APPROVAL 
Ethical approval for the study was obtained from the joint research ethics committee of the 
NHNN and the ION (see Appendix V) (Approval number 08/H0716/13). All participants 
gave their informed written consent.  
 
5.3.6 PROCEDURE 
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Screening was undertaken by the Research Therapist, following notification of new strokes 
admitted into HASU by the stroke research nurse.  Ward lists were reviewed on a regular 
basis, the MDTs were consulted regarding the suitability of people for the trial, and medical 
notes were screened for all those diagnosised with a confirmed stroke. The Research 
Therapist also attended ward rounds if able.  Wherever possible, the Research Therapist 
was introduced to potential participants by a member of the MDT.  A verbal explanation of 
the trial was given to the individual (and also to their relatives and friends, when they were 
present).  This was supported by the provision of the Patient Information leaflet. Individuals 
were encouraged to discuss their participation with family/friends/members of the MDT, 
and to ask questions about the trial.  It was stressed that the individual could withdraw 
from the trial at any stage and that participating would not affect their usual care.  The 
Research Therapists, family and friends of the individual, and the Speech and Language 
Therapists supported people with aphasia in the consent process.    Informed consent was 
taken by the Research Therapists, a copy of the consent was given to the individual and a 
copy was placed in their medical records. 
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Figure 5.1: Flow Diagram to Show the Recruitment Process 
1920 patients were admitted to UCLH trust July 
2009- Dec 2010 
260 TIA 700  non 
strokes 
960 confirmed strokes 
(confirmed via scan results and 
or clinical presentation) 
460 out of area ( this 
number mainly after 
jan 2010 when 
hyperacute unit 
opened at UCLH 
180 unable 
to consent 
150 others 
(includes patients 
not eligible, lost due 
to researcher 
absence)  
43 previous infarct 
(excluded from study 
initially July 2009-Jan 
2010 when 
amendments to  the 
research protocol 
included previous 
infarcts.) 
125 patients recruited 
2 patients not consent (not 
wish to be involved in 
research)  
100 Single 
incident strokes 
25 subsequent 
strokes 
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5.3.7 INTERVENTION 
Patients were assessed by the Research Therapist within seven days of admission. This 
assessment consisted of a series of Patient Reported outcome measures and Clinician 
Rated outcome measures. These measures have been described in detail in Chapter 
Four. 
If the patient had any difficulties with using their arm they were seen weekly for six weeks 
or until they were discharged. All patients with upper limb problems were re assessed at 
six weeks. This assessment either occurred at UCLH, the Acute Brain Injury Unit at NHNN 
or the patient was seen at home. 
The patients who were seen to have upper limb problems were seen weekly until 
discharge. During this weekly visit, their ability to interface with a ‘mock up’ of the robotic 
aid was assessed. This device is shown in Figure 5.2 (this mock up device was named 
pReachMan). 
 
Figure 5.2: Illustration of the mock up robotic device (pReach MAN): a) 
Photograph of the device b) A subject using the device. 
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The pReachMan device has no actuated motors. The device is equipped with sensors that 
allow kinematic and dynamic data to be saved and monitored with a standard PC or a 
laptop. Patients can see visual graphs when they perform movements with the device. 
pReachMan was set up to  record impairment level information including the range (i.e. 
position) and strength (i.e. force/torque) of the following movements: supination, pronation 
of the forearm and extension and flexion through the  elbow and shoulder.  
Subjects were set up and trialed to use the device on a weekly basis if possible.   
(pReachMan was designed by Dr Alejandro Medendez in 2009 who  designed the 
machine as a part of his Phd thesis from Imperial College. He describes the design of the 
device in his thesis 303 ) 
 
5.3.8 ANALYSIS 
Descriptive analysis of the numbers of people admitted to UCLH  trust over the time period 
of the study was undertaken and the numbers of strokes who matched the recruitment 
criteria. A further descriptive analysis was undertaken of the number of stroke participants 
who had upper limb deficits and who were able to interface with the robotic device. 
Outcome measures were recorded for all participants. This was to evaluate the feasibility 
and acceptability of the measures for the next stage of the study (the exploratory RCT). 
Furthermore this was also to allow psychometric analysis of the measures. This analysis 
will be discussed in detail in Chapter Eight. 
 
5.4 RESULTS    
Recruitment into this stage of the study occurred from July 2009 until December 2010. 
Figure 5.2 illustrates the recruitment process into the study. During the time period 1920 
patients were admitted into trust. 260 of these patients were diagnosised with TIA and 
therefore did not meet the study criteria, while a further 700 were found to have not had a 
stroke. These again were excluded from the study. Of the remaining 960 patients who 
were confirmed as stroke, 460 of these were out of area. This meant that following their 
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initial presentation and admission to HASU they were then transferred to a hospital outside 
of UCLH trust within seven days of surviving a stroke. These patients were not able to be 
followed in their new destination as the study was for single site ethics approval only. The 
majority of these patients were lost to the study after January 2010, when the HASU was 
opened, as this new unit covered people from the entire North London sector. Previous to 
HASU opening the stroke unit mainly admitted more local patients. 
180 subjects were unable to consent to inclusion in the study within the allocated seven 
days post stroke diagnosis. A further 150 patients were excluded from the study, for a 
variety of reasons- including being longer than seven days post stroke, or the researcher 
not being able to see them in time due to absence.  Between July 2009-January 2010 
when the study only included first time strokes, 43 stroke patients who had  previous 
stroke were also excluded from the study.  
The average age of the excluded subjects was 73 years in age, and the average NIHSS 
score was 10. These are in line with average nominal data for stroke age and mild 
impairment following stoke 9 
Two patients who match the study criteria did not consent to be involved in the study. 125 
patients were recruited into the study (100 single incident strokes and 25 subsequent 
strokes).  A breakdown of the problems seen in these patients is summated in Figure 5.3. 
142 
 
 
Figure 5.3a: Breakdown of Impairments seen in the consented subjects 
 
 
 
 
 
 
 
 
 
 
 
 
125 subjects 
recruited 
24 “Other impairments” 
includes facial 
weakness, visual 
disturbance, speech 
difficulties, neglect, 
cognitive impairment) 
35 fully resolved 10 balance and 
gait 
56 UL deficits 
7 no upper limb 
movement 
6 ataxic 26 interface 
with the device 
10 fine distal 
movements  
7 sensory (full 
motor power) 
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 Figure 5.3b: Breakdown of Impairments seen in the consented subjects 
 
 
 
 
 
56 UL deficits 
49 Able to interface with 
device 
7 Unable to interface  
26 found device useful 
23 Device not useful 
6 ataxic 7 sensory (full motor power) 
10 fine distal movements  
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Of the 125 participants recruited, 35 subjects on assessment were seen to have fully 
resolved from the initial symptoms that they presented to hospital with (these participants 
had been diagnosised with an acute new incident stroke from scan results and clinical 
diagnosis). Ten of these subjects were found to have no upper limb deficits but difficulties 
with their balance and gait.  Twenty four of the subjects recruited were also seen to have 
no upper limb deficits but were seen to have other impairments as a result of their stroke, 
which included facial weakness, visual disturbance, speech difficulties and cognitive 
difficulties.  
Fifty six subjects (45%) did however present with some degree of difficulty using their arm 
following their stroke. Of the patients with upper limb difficulties, patients with no upper 
limb movement were unable to interface with the device. Patients with fine distal problems/ 
ataxic/main problem reduced sensation were able to use the device but it was not 
sensitive enough to be used as a training aid.( This is shown in figure 5.3 b)  
Twenty six of the 56 participants with upper limb deficits were able to interface with 
pReachMAN (46%). This means that subjects were able to (either independently or with 
assistance) place their arm on the arm support,  rest hand on the hand handle (as shown 
in figure 5.2) and move the arm support. 
 Participants with severe arm paresis were able to use this device. Severe paresis in the 
context of this phase of study was defined as the some flickers of activity in the arm (in the 
majority of cases, this presented in practice as an ability to shoulder shrug and protract 
and retract at the shoulder but no other arm movement). Lack of hand movement did not 
seem to prevent people from resting their arm on the hand handle, because the handle 
can rest in pronation. People with flickers of shoulder movements were able to use the 
support to reach with. The most likely mechanism for this is was combination of trunk 
movement facilitating shoulder extension.  
Participants needed to be able to sit out in a chair (which could have supportive back to 
allow them to sit) for periods longer than ten minutes to be able to use the device. They 
also needed to be have some level of vision to be able to see the screen. Furthermore 
participants were required to be able to attend and focus on the task for at least 10 
minutes.  
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It was initially envisaged that weekly data using pReachman could be collected from the 
subjects who were able to interface with the device. Unfortunately due to the sensors 
breaking and delays in fixing these this information was not available for all 26 subjects 
who were able to use the device. 
Alejandro Melendez Calderon who designed pReachMAN reports in his PhD thesis on 
data from three subjects that was able to be processed from the device. He compared this 
data to three right-handed, healthy subjects (aged between 24 to 29 years old), in order to 
have a baseline for qualitative evaluation of the order of magnitude of deviations from the 
patients. He has given permission for this data to be reproduced in this chapter. Further 
information and analysis from this is available in his Phd thesis.304 
Figure 5.4 shows the lateral force applied against the walls of the device versus the hand 
position along the straight line. Stroke subjects exhibited greater amount of lateral forces 
and changes in direction than healthy subjects.  
 
Figure 5.4 – Lateral force vs. position along the straight line.  
 
Post-stroke patients performed movements with the paretic arm, while 
subjects with their non-dominant hand. On the right-lower corner of each 
figure the mean and standard deviation of the time taken to perform the 
movements is shown. 
146 
 
All subjects seen at 6 weeks demonstrated improvements in their outcome measures (this 
was to be expected). This data was used to look at the responsiveness of the outcome 
measures (and is discussed below in section 5.4.1) 
 
5.4.1 OUTCOME MEASUREMENT SELECTION 
The outcome measures that were used in this phase of the study, were analysed to look at 
the acceptability, targeting and responsiveness of the measures. 
Of particular interest was the upper limb scales. Table 5.1.  shows the scale range, mean 
score, skewnwss and floor/ceiling effects seen in each of the upper limb measure: 
 
Table 5.1.: Data quality, scaling assumptions, acceptability and reliability of 
the uppe limb measures used in the study (N=125) 
 
FMA DASH  STREA
M 
ARAT ABILHAN
D 
Chedoke 
Data quality 
      
Item missing data 
% 
0 0 0 0 0 0 
Computable 
scale scores % 
100 100 100 100 100 100 
Acceptability 
      
Score range 6-100 0-88.3 0-20 57-114 0-100 13-91 
Mean score (sd) 80.8 
(27) 
 
28.1(28.8
9.95 
(3.11) 
93(23) 70.7(33.1) 69.31(26.8
) 
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) 
Floor/ceiling, %  0/47.2 0/27.2 0.8/0.8 20.8/32
.5 
8.9/44.4 8.8/44.8 
Responsivenes
s 
      
Mean score (sd) 
at 6 weeks 
90.3 
(30) 
20.2 (20) 10.1 (3) 94(25) 79(34) 71(29) 
 
DATA QUALITY 
There were no missing data for all the scales and all scales were successfully completed 
by patients. 
ACCEPTABILITY (TARGETING) 
This is the targeting of a scale to a sample so that score distributions adequately represent 
the true distribution of health status in the sample.305 This was achieved by  the scores 
being examined to determine that observed scores were well distributed, mean scores 
were near the scale mid-point,floor and ceiling effects were low, and skewness statistics 
ranged from -1 to +1. 
This analysis (as shown in Table 5.1.) showed that all the measures observed scores were 
well distributed. However mean scores for many of the measures (FMA, ARAT, 
ABILHAND, Chedoke) were not near the mid point of the scale (mostly much nearer to the 
higher end of the scales). This is also seen in floor and ceiling effects. Ceiling effects were 
seen in the FMA, ARAT, ABILHAND, and Chedoke measures.  Floor effects were also 
seen with the ARAT. Skewness in the FMA was found to be over the accepted range of -
1to +1. 
A possible explanation for the problems seen in targeting of the measures was the high 
proportion of participants recruited into the study that had no upper limb deficit (55%). 
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Chapter Four discussed the rationale for scales selected in the studies. Unfortunately 
upper limb scales have been found to be psychometrically restricted258 306 and this was 
found to be the case in this analysis. Due to the lack of psychometric robust scales in 
routine use214 (as further discussed in Chapter Four) it was decided to continue to use this 
battery of upper limb measures for the exploratory RCT (which will be described in 
Chapter 6). 
RESPONSIVENESS 
Responsiveness is the ability of a tool to accurately detect important changes over time.307 
This was evaluated by comparing the mean and standard deviations of the upper limb 
measures from baseline and at six weeks. This is illustrated in Figure 5.5.  All subjects 
showed improvement at six weeks (which would be expected when looking at subjects 
early post stroke). However the FMA and Abilhand appeared to show greatness difference 
in pre and post scores. 
The analysis of data quality of the measures suggested that the Abilhand demonstrated 
the most acceptability, targeting and responsiveness. A further discussion of this is 
detailed in Chapter Nine. 
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Figure 5.5: Graph illustrating mean scores at baseline and at six weeks for 
the upper limb outcome measures. 
 
The time taken to complete the battery of outcome measures varied depending on the 
severity of participant’s upper limb deficit but the maximum it took to complete was thirty 
minutes and all participants complied with this.   
One of the measures, the SF36, was greatly disliked by the majority of participants- with 
most finding the questions intrusive and many requested not to answer the questions. In 
particular the first two questions of the measure which ask participants to describe their 
current health status and how this compared to one year ago were generally disliked. One 
participant remarked, which describes many of the subject’s comments on the measure:  
“ I find that an insulting question, how do you think I would describe my health, they 
have just told me I have had a stroke”. 
It was therefore decided to leave out this measure from the RCT.  
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5.4.2 RECRUITMENT CRITERIA 
A number of practical factors presented themselves during the course of this phase of the 
study which significantly shaped the criteria for the next phase of the study: 
Firstly, to be able to interface with the device, patients needed to be able to sit out for a 
significant length of time (ten minutes or so was found to be a lengthily period for some of 
the subjects in the very acute phase post stroke), focus and attend to the device to be able 
to use it. In many cases patients sitting tolerance and attention improved with time. 
Therefore, although the study wished to capture acute patients, it was felt to beneficial to 
include subjects up to eight weeks post stroke to maximise recruitment numbers.  
For the RCT it was envisaged that patients would be able to use the robotic device for 30 
minutes or more and therefore a criteria of the RCT was to be able to sit out and attend to 
the task for 30 minute periods. 
The study demonstrated that patients with very little arm movement could use the device 
(although some arm movement was required). This allowed patients with severely 
impaired arms to be included in the second phase of the study. This not only allowed a 
broad recruitment criteria for the second phase of the study but was seen as very 
encouraging as at present there is little therapy specifically to promote recovery of the 
severely paretic or paralysed upper limb after stroke.  
From the 125 patients that were recruited it was possible to determine recruitment criteria 
for the next phase of the study (an exploratory RCT using ReachMan robotic device). This 
was: 
1. Acute stroke patients 0-8 weeks since having a stroke 
2. Able to consent to treatment 
3. Able to understand basic information 
4. Able to sit out in a supportive chair if required for at least 30 minutes 
5. Able to see the graphics and visual display on the machine 
6. Able to attend and focus on the games for at least 30 minutes.  
7. Severe to moderate UL impairment. However must demonstrate some degree of 
arm movement (i.e an ability to shoulder shrug).  
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5.4.3 RATE AND TIMING OF RECRUITMENT IN PRACTICE 
This phase of the study also helped provide a guideline to the rate and timing of 
recruitment into the next phase of the study.  It was felt taking into account the through put 
of patients from the HASU into local stroke unit (ABIU) to the rehabilitation ward, 
recruitment numbers were likely to be one to two patients a month into the RCT. Further 
details of the actual recruitment rates are given in chapter six. 
The study also highlighted some important information about recruiting acute strokes into a 
clinical trial.  ULCH trust sees a large number of patients admitted into its stroke unit. 
However due to the fast turnover of patients (patients only stay in HASU for 72 hours and 
are then repatriated to their local stroke unit), a large number of patients potentially with 
upper limb deficits (460) and who may have been able to interface with the device were 
unable to be assessed or recruited into the study. This was because they were transferred 
to their local stroke unit (the study had ethics approval for single site recruitment only- 
UCLH hospitals).   
Furthermore, a number of patients were ineligible for inclusion to this phase of the study 
because they were unable to consent to participation within the seven day time period post 
stroke (i.e. very early days post stroke). However some of these patients at a later period 
were notified to the research therapist by the MDT team but were then ineligible for 
recruitment into the study.  
 
5.5 CRITIQUE OF THE METHODOLOGY USED IN THIS RECRUITMENT 
STUDY  
The aim of this study was to define the number of people who would be able to use the 
device in practice, and define recruitment criteria. These aims were met, however there 
were limitations with this phase of the study.   
The people recruited to the trial represented a heterogeneous population, including those 
with both haemorrhagic strokes and infarcts, single incident strokes as well as people who 
had had multiple strokes. Although this mirrors the population treated in clinical practice, 
the research design could be criticised for including people with haemorrhage as this type 
of stroke has a different aetiology and, sometimes prognosis, from infarcts that comprise 
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the majority of strokes. Furthermore prognosis and rate of recovery can also differ with 
subsequent stroke.16  
The study was not blinded and the Research Therapist completed the measures with the 
participants and this could have introduced bias.  
There were various absences of the Research Therapist during the trial period. 
Furthermore, the Research Therapist did not work over the weekend. Stroke patients 
admitted to the Trust during these time periods who may have been eligible for inclusion to 
the study, were unable to be seen or known to the researcher. Therefore the data 
presented here cannot be verified as being an accurate representation of the number of 
strokes admitted to UCLH during the time period or necessary reflects completely 
consecutive patients that were admitted into the Trust.  
This phase of the study aimed to look at the proportion of acute participants who could 
potential use a robotic device. For this reason every person who had had a stroke in UCLH 
over the time period were invited to participate in the study. This did however mean that a 
proportion of participants were recruited that did not have upper limb deficits. This resulted 
in some problems when analysising the targeting of the outcome measures. 
 
5.6 SUMMARY 
This chapter has reported the findings of a recruitment study that was performed to 
establish the proportion of acute stroke patients that could potentially benefit from 
rehabilitation using a robotic device.  Clinical trials that have investigated the use of robotic 
as an adjunct to upper limb rehabilitation, have used a variety of impairment levels and 
little work has looked at the use of these devices in the early, acute phase following stroke 
(this has been discussed in Chapter Two ). However in clinical practice it is important to 
know the amount and impairment level of patients who could potentially use these devices. 
This phase of the study provided useful information about the rate and timing of 
recruitment in practice, the recruitment criteria for an exploratory RCT and analysis 
whether the battery of outcome measures selected were practical, feasible and 
appropriate.  
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The next chapter will describe the exploratory RCT that was performed which build on the 
information established in this study. 
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CHAPTER 6- AN EXPLORATORY RANDOMISED CONTROL TRIAL TO EXPLORE 
THE EFFECT OF THE USE OF A ROBOTIC DEVICE ON UPPER LIMB ACTIVITY 
IN SUB ACUTE STROKE PATIENTS. 
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6.0 INTRODUCTION 
Chapter Five described the process of defining a recruitment criteria & the identification of 
the proportion of patients who could participate in robotic training using the Reachman 
robotic device. Using this information an exploratory Randomised Control Trial was carried 
out. This chapter will discuss this exploratory trial. This feasibility study allowed variations 
of the intervention to be tested and formed a Phase II study using the MRC framework. 
Phase II of the framework facilitates both quantitative and qualitative designs being used.  
This chapter will report how all the quantitative data was collected and will discuss the 
results. The following chapter will discuss the qualitative data collected through semi-
structured interviews at the end of the period of intervention.  
This Chapter will describe an exploratory RCT that was carried out to investigate the 
effects of using ReachMAN robotic device on arm movement and function in the sub-acute 
phase after stroke. 
Chapter 2 has discussed the literature that suggests robotic therapy may be a useful 
adjunct to assist in upper limb recovery and that it may allow greater improvement with this 
when compared with “conventional therapy”. This has been particularly seen when used in 
acute or the subacute stroke population. There has however been a paucity of research 
trials that have looked at robotic therapy in the acute stroke population. Theoretically, the 
acute phase post stroke is when potential for significant functional gain is greater. 
Therefore further research looking at robotic devices in the early stages post stroke is 
needed.  The study detailed below aimed to fill this research gap. 
 
6.1 OBJECTIVES 
6.1.1  HYPOTHESIS 
In this study the hypothesis tested was that an early use of a robotic aid (Reachman) in 
addition to conventional therapy following stroke would improve arm movement more than 
therapy alone. 
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6.1.2 NULL HYPOTHESIS 
The null hypothesis was that there would be no difference between the groups as 
measured by the Fugl Meyer Upper limb Score and other secondary outcome measures 
as a result of the intervention- using a robotic device. 
 
6.2  AIMS 
The aims were to investigate: 
i. The resource needs in terms of engineering, trained and untrained 
rehabilitation staff to bring robotic training into routine practice 
ii. The frequency, duration and intensity of robotic training tolerated by patients 
iii. The increase in practice time that this represents 
iv. The size of a definitive randomized control trial.  
6.2.1 RESEARCH QUESTIONS 
1. What are the effects of using a robot on the motor performance of the hemiplegic 
upper limb in the sub-acute phase after stroke? 
2. What severity of arm impairments could use the device and is there a difference in 
the potential benefit of the aid depending on the severity of arm paresis? 
 
6.3 METHODOLOGY   
An RCT involves the random allocation of participants between an experimental group 
whose members receive the treatment or intervention and control group who receive 
standard treatment. The outcome of the groups is then compared. 
This methodology was chosen for this part of study because as the literature reviewed in 
Chapter Two demonstrated the use of robotic devices has been extensively examined in 
studies with no comparator group. Therefore, further work using this methodological 
design was not felt to be warranted. However, there has been limited work comparing 
upper limb recovery in the subacute phase with rehabilitation alone with additional use of a 
robotic aid. Therefore an RCT design was felt to be appropriate. 
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There are different types of Randomized control trials:  Cluster RCT and cross over RCT. 
For most trials the unit of randomization is the individual person being allocated to a 
specific intervention or to a control or placebo. There is a growing interest in the use of 
cluster randomization in community trials. Cluster randomized trials are trials that 
individuals are not randomized but units (clusters) such as clinics, hospitals, physicians or 
families. Advantages of cluster randomization trials are that they reduce “contamination” of 
the interventions between groups, they can increase participation, and they allow for better 
administrative and logistic organisation in implementing the intervention. The MRC 
guidelines discuss using cluster randomization in complex interventions238 .  However for 
this study a cluster randomized trial was not chosen as the study design. This was due to 
the small nature of the trial (it being a feasibility study) which was based in one trial center. 
A crossover design was considered for the study. This is using within patient comparison 
(i.e. participant acts as own control). For example both the intervention and the control 
group would use the robotic device, this would just be randomized to different time 
periods. This design was trialed in a pilot study performed on three subjects subsequent to 
the RCT (This is reported in Yeong et al (2010)244. Unfortunately however this was not 
found to be practical to implement in practice. The intervention period for the groups was 
six weeks, and not all subjects stayed as inpatients for the whole 12 week period needed 
for a cross over design (i.e. 6 weeks control group/ usual rehabilitation, Six weeks use of 
the robot).  Therefore a conventional RCT design was used. 
Poorly designed and reported RCT trials are common in the literature and to combat this 
problem the Consolidated Standards of Reporting Trials (CONSORT) statement308 was 
written and first published in 1996 and updated in 2001 and 2010309. These guidelines are 
used to structure this chapter. Within these guidelines the following need to be considered: 
SAMPLE SIZE 
The sample size for a trial needs to be considered carefully as ideally it needs to be large 
enough to have a high probability (power) of detecting a statistically and clinically 
difference if such a difference exists309. An aim of this study was to provide details for a 
power calculation of sample size for a definitive RCT. 
158 
 
RANDOMISATION 
Participants should be assigned to comparison groups in a trial on the basis of a chance 
(random) process characterised by unpredictability309.  Random allocation between 
experimental and control groups means that study participants were allocated to the 
groups in such a way that each has an equal chance of being allocated to either group. 
The purpose of random allocation is to achieve similarity of baseline characteristics in the 
treatment groups. If the treatment groups differ in baseline characteristics, confounding 
may result. Confounding factors are those that influence treatment and outcome measures 
and include demographic characteristics, prognostic factors, and other characteristics that 
may influence someone’s likelihood of participating in or withdrawing from a trial. 
Therefore, any differences between treatment groups in outcomes may not be due to 
differences in the treatment received but to differences in baseline characteristics. Pure 
randomisation is based on a single allocation ratio is known as simple randomisation (a 
1:1 allocation ratio analogous to a coin toss). 
 Block randomisation is randomising participants within blocks such that an equal number 
are assigned to each treatment .This type of randomisation can be used in trials with small 
numbers to assist with an even distribution among groups. 
Block randomisation with blocks of size four was used in this trial (further details of this are 
given in section 6.5) to allocate patients to treatment group. This involved selecting groups 
of four consecutive patients recruited into the study. Within each group of four patients, 
two were allocated to the control group and two to the treatment group However, the order 
in which treatments were allocated in each block was random. This type of randomisation 
was used to ensure that consecutive patients were distributed equally between treatment 
groups.   
ALLOCATION CONCEALMENT 
The method used to implement random allocation is called allocation concealment which 
seeks to prevent selection bias, protects the assignment sequence until allocation, and 
can always be implemented309. 
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BLINDING 
Blinding refers to withholding information about the assigned intervention from people 
involved in the trial who may potentially be influenced by this knowledge. It seeks to 
prevent performance and ascertainment bias, protects the assignment sequence after 
allocation, and cannot always be implemented309. Unfortunately this feasibility study did 
not use blinding. This will be further discussed in Chapter Nine. 
LIMITATIONS WITH RCT DESIGN  
There are problems with using RCTs in therapy intervention trials. RCTs predominately 
identify changes that are statistically significant, this may miss however the clinical 
importance of change, , 310. Furthermore considering a treatment technique in relation to a 
heterogeneous population (e.g. stroke) is challenging as people may respond differently to 
the intervention, and an RCT design does not always reflect individual change.  
It is also difficult to perform “gold standard”, high quality randomised control trials when 
researching neuro rehabilitation 311. It is extremely hard to perform double blinded research 
, a placebo treatment unknown for both the therapist and the patient, unless there is a drug 
or injection treatment, as both will usually be aware of the treatment Kersten et al ( 2010) 
311
 further discuss the difficulties in performing RCT in neurological rehabilitation research,  
especially due to the complexity of rehabilitation interventions, selective research samples 
and multiple understandings of perspectives of benefits.  
The MRC framework acknowledges the difficulties with complex interventions and the 
framework process provide a guide to assist with performing RCT having considered these 
issues. The feasibility RCT study described in this study and the qualitative study 
described in Chapter Seven follow these guidelines, aiming to address some of the 
unanswered questions in the robotic literature and assist with the development of a 
definitive RCT, acknowledging the difficulties in performing gold standard RCT research in 
this area.   
6.3.1 TRIAL DESIGN 
The trial was randomised and controlled with two comparator groups. The trial was a 
single centre study. Measurements were taken pre- and post intervention.  
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6.3.2 PARTICIPANTS 
Patients within 0-8 weeks of stroke with upper limb impairment who matched the inclusion 
criteria were approached for recruitment into the study. Inclusion and exclusion criteria 
have been discussed in Chapter 5. The eligibility criteria for the trial were: 
1.  Acute stroke patients 0-8 weeks since having a stroke 
2. Able to consent to treatment 
3. Able to understand basic information 
4. Able to sit out in a supportive chair if required for at least 30 minutes 
5. Able to see the graphics and visual display on the machine 
6. Able to attend and focus on the games for at least 30 minutes.  
7. Severe to moderate UL impairment. However must demonstrate some degree of 
arm movement (i,e an ability to shoulder shrug).  
6.3.3 STUDY SETTING 
 
The study took place at the National Hospital for Neurology and Neurosurgery (NHNN) 
from January 2010 through to March 2011.The trial recruited patients from University 
College London Hospitals (UCLH) stroke services   
UCLH is one of the leading centres for stroke research. Stroke patients are first admitted 
into a hyper acute stroke unit (1643 approximately per annum). Within 72 hours patients 
are transferred to their local stoke unit. More than 400 patients with stroke are admitted to 
the NHNN each year. The NHNN houses the Acute Brian Injury Unit where local Camden 
and Islington patients following stroke are admitted. From this unit, patients who require 
rehabilitation are assessed and admitted to National Rehabilitation Unit (NRU) where they 
on average receive three months rehabilitation. The NRU is an 18 bedded specialist 
rehabilitation unit, in 2010 23.2 % of people admitted to the unit had had strokes. The 
NHNN also includes the Albany Rehabilitation Unit which provides rehabilitation for stroke 
patients who live in Kensington & Chelsea or Westminster PCT. This is a 10 bedded unit. 
In 2010 74.2% of patients admitted to this unit had a diagnosis of stroke. 
6.3.4 ETHICS 
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Ethical approval for this stage of the study was obtained from the joint research ethics 
committee of the NHNN and the ION (see Appendix V).The trial was sponsored by 
University College London Hospital Trust, and funded by a project grant from The Stroke 
Association. (Approval number: 08/H0716/13. Project Grant:TSA 2007/14). All participants 
gave their informed written consent. 
6.3.5 STUDY INFORMATION 
The information sheet for participants was written using UCLH guidelines; this sheet gave 
them further information about the study, possible interventions and how the data collected 
would be used (see Appendix VI).  Each participant read the information sheet prior to 
agreeing to participate in the service. Once verbal agreement was reached a consent form 
was then signed.  (see Appendix VI). 
 
6.3.6 PROCEDURE  
Screening was undertaken by the Research Therapist.  Ward lists were reviewed on a 
regular basis, the MDTs were consulted regarding the suitability of people for the trial, and 
medical notes were screened for all those the MDT considered suitable for the trial. On a 
weekly base the Research Therapist would contact the relevant wards (Acute Brain Injury 
Unit, NRU and ARU) to discuss if they had been any new admissions that may be suitable 
for the trial.   Wherever possible, the Research Therapist was introduced to potential 
participants by a member of the MDT.  A verbal explanation of the trial was given to the 
individual (and also to their relatives and friends, when they were present).  This was 
supported by the provision of the Patient Information leaflet.  Individuals were encouraged 
to discuss their participation with family/friends/members of the MDT, and to ask questions 
about the trial.  It was stressed that the individual could withdraw from the trial at any stage 
and that participating would not affect their usual care.  If there was any doubt the 
participant was excluded from the trial.  The Research Therapists, family and friends of the 
individual, and the Speech and Language Therapists supported people with aphasia in the 
consent process.  All prospective participants were given at least 24 hours to consider 
taking part in the trial before written informed consent was sought.  Informed consent was 
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taken by the Research Therapist, a copy of the consent was given to the individual and a 
copy was placed in their medical records. 
Baseline measures (detailed in section 6.5) were made on Day One by the Research 
Therapist.  A standardised position was used (i.e. sitting upright at a table) for the clinical 
scales; however, when this was not possible (e.g. due to lack of assistance with transfers 
or the severity of impairment), the best possible position was adopted and noted in the trial 
records. All participants were given the opportunity to complete the patient reported 
measures in their own time (but within 48hours of recruitment into the trial). If subjects and 
their family requested assistance with the PROM, it was administered face-to-face by the 
Research Therapist. 
On the following day (Day Two) the participant was randomised into one of the two groups. 
Each day the participants were checked for adverse events..  If adverse effects, which 
could not be explained by a clinical reason other than participation in the trial, were 
experienced on three consecutive days during the treatment period then treatment was to 
have been discontinued, however, the outcome measurement battery was completed.  
Outcome measures were collected at six weeks. 
 
6.4 INTERVENTION   
6.4.1 CONTROL GROUP 
Participants in the control group received their usual practice rehabilitation which consisted 
of a minimum of two 45 minute treatment session each day from physiotherapy and 
occupational therapy. Therapy sessions were conducted in either the rehabilitation gym, 
by the patient bedside or in other therapy areas in the rehabilitation units.  In addition 
patients had input from speech and language therapy, psychology, and social work as 
required and practice/exercise sessions supervised by nurses and rehabilitation 
assistants.  The input all patients receive were recorded through integrated care pathways 
and the Northwick Park Therapy Dependency Scale and the Northwick Park Nursing 
Dependency Scale This constituted usual practice at the NHNN and enabled recording of 
the amount of therapy patients were receiving. As well as these scales, the amount and 
content of therapy given to participants during the intervention phase of this trial was 
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documented using a treatment schedule. This treatment schedule has been tested for its 
reliability and has been used to record physiotherapy in a trial of functional upper limb 
strength training.159;312 
 
6.4.2 EXPERIMENTAL INTERVENTION 
The intervention group received usual practice rehabilitation (as described for the control 
group) and participated in repetitive training using the robotic device.  
ReachMan was located in the rehabilitation gym . 
The use of ReachMAN intervention had three distinct phases 
1. Initiation of practice.  The physiotherapist and engineer (Mr Che-Fai Yeong) 
worked with the patient to establish an appropriate physical set-up and task 
demand for the patient.  They prepared a schedule and instructions that formed 
the basis of regular practice. 
2. Establishing practice. The physiotherapist then worked with a rehabilitation 
assistant to set up the patient each time the patient wishes to practice, checking 
that the schedule clearly described how to set up both device and patient. 
3. Maintaining practice.  The rehabilitation assistant set up the device with patient 
when requested. 
Intervention quality was monitored on a weekly basis by the physiotherapist. 
The experimental invention had to fit around routine care and not interfere with therapy 
sessions, ward rounds, meal times, or medical investigations. In addition, when 
participants were using the ReachMAN device their experience of fatigue, their 
preferences for timing of using the device and the visits of their family and friends were 
taken into consideration. All these factors could potentially reduce the amount of time the 
subjects spent on the device. Consequently, the research therapist paid particular 
attention to communication with clinical staff and participants regarding the flexible timing 
of intervention. 
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The aim was that subjects would have a maximum of 30 (5 week days over six weeks) 
half-hour robotic therapy sessions during the intervention period, but less if they were 
discharged earlier than six weeks.  
During the robot rehabilitation session, the subject sat comfortably on a wheelchair or on a 
standard chair while the impaired hand was rested on the arm support. The height and 
distance of the robot were adjusted such that the elbow was flexed at 900, shoulder 
abduction at about 35o and shoulder flexion at 00 (all with a 100 tolerance). The hand 
grasped the robot handle and was secured with Velcro band. The sequence and number 
of sets were adapted to the performance of the subject, but all subjects started with the 
reaching exercise followed by pronosupination, grasping, then the combination of 
pronosupination and reaching. Each sets contained 10 trials, and maximally 10 sets were 
completed for each exercise. However, if there was no movement at all, the particular 
exercise was limited to three sets. The first session was for the subjects to familiarize with 
the robot. Subjects could try the exercise modules freely without having their performance 
assessed. During the second and last sessions, subjects were assessed with the robot on 
all four exercise modules, using a standard difficulty level (Seven.) From the third session 
onwards, each subject progressed from lowest level of difficulty on each of the exercises. 
Subjects could progress of maximally one level up on each day, if their score was over 
90% with 10 hits thrice in a row.  
ReachMan was programmed with eight difficulty levels (one the easiest up to eight the 
hardest).  Each level had an increased range of motion and resistance to the movement. . 
At the lower levels participants were only required to put in relatively little effort to move. 
For example, only 2N was required to trigger the reaching movement, 0.05Nm for the 
pronosupination and about 1N for grasping. However, in contrast level 8 required higher 
forces to trigger a movement, about 5N for reaching movement and 0.15Nm for 
pronosupination. 
 The protocol followed for the intervention phase can be found in Appendix II . This was 
devised following piloting of the intervention in three subjects. This pilot has been reported 
in Yeong et al244. 
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6.4.3 TRUNK RESTRAINT 
A modified form of trunk restraint was used with all participants when using the device (A 
photograph of this is shown in Photograph 6.1). Studies that have investigated normal 
reach to grasp pattern have found that stroke patients use compensatory trunk movements 
when reaching for an object within reach (as compared with normal controls who only use 
a trunk strategy when objects are placed beyond their reach).123Trunk restraint (this is 
where the subject trunk movements are limited by a strap or belt) has been shown to result 
in an immediate improvement in active range of movement and inter-joint co-ordination in 
moderately to severely affected stroke subjects.49  
Most trials using robotic devices use some form of trunk restraint ( ie a harness attached to 
the patient) 108;182(In the case of the MiTManus device this is in the form of a 3 point seat 
belt,193 or two shoulder and a waist belt seat belts which limit trunk movement.)  
The use of the non- assistive interface (p ReachMAn as described in Chapter 5) showed 
that subjects used compensatory trunk movements when using the device. Therefore to 
maximise arm movements alone a form of modified trunk restraint was used with all 
subjects who used ReachMan. A summary of this procedure with instructions as to how 
this was practically achieved can be found in Appendix II  
Photograph 6.1-Trunk Restraint used in the study.  
166 
 
 
6.5. OUTCOME MEASURES 
Chapter Four has described in detail the scale selection strategy used and selection of 
scales. Chapter Five has then discussed how these scales were tested for 
appropriateness and reasons why some scales were not used in this exploratory trial. The 
study therefore used the following outcome measures:  STREAM, CAHAI, ABILHAND, 
FMA, ARAT, EQ5D, Barthel Index, NIHSS and DASH 
 In addition to the scales used in Phase One, one additional scale was used in this phase 
of the study: the Ashworth score313. The Ashworth score was used in the study as it was 
felt it would be useful to record any increased tone participants had on baseline and 
whether this changed with the treatment interventions. The score is the most popular and 
consistently used clinical measure of spasticity. 314The most common version used of this 
scale in regards to the upper limb is the modified version, and this was the version used in 
this study. 
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 The modified Ashworth score is a five point scale : 
0   No increase in muscle tone 
1  Slight increase in muscle tone, manifested by a catch and release or by minimal  
resistance at the end of the range of motion when the affect ted part(s) is moved in flexion 
or extension 
1+  Slight increase in muscle tone, manifested by a catch, followed by minimal 
resistance throughout the remainder (less than half) of the ROM 
2  More marked increase in muscle tone through most of the ROM, but  affected 
part(s) easily moved 
3  Considerable increase in muscle tone, passive movement difficult 
4  Affected part(s) rigid in flexion or extension 
 
Other studies looking at robotic intervention have used this scale to look at increased tone 
in the upper limb with this use of a robotic device.200 Tests of inter and intra-rater reliability 
have had conflicting results and the scale is unable to distinguish between the reflex and 
non-reflex components of increased tone. Despite the limitations with this measure, due to 
the ease of competition, and repeatability with other studies it was chosen for use in the 
exploratory trial. 
6.5.1 MEASUREMENT BATTERY 
Measurement points were at baseline before randomization and at 6 weeks.  In addition, 
assessment for adverse events was conducted on each working day of the study period. 
6.5.2 SAMPLE SIZE 
The study aimed to recruit 20 subjects in each arm .This was a pragmatic recruitment 
figure, based on the length of time proposed for the trial to be carried out and the 
recruitment data gathered from phase 1 of the study (detailed in Chapter 5) In total 37 
subjects were recruited to the study.  
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6.6 RANDOMISATION  
Section 6.3 discussed different methods of randomisation. Block randomisation with blocks 
of size four was used in this trial to allocate patients to treatment group. This involved 
selecting groups of four consecutive patients recruited into the study. Within each group of 
four patients, two were allocated to the control group and two to the treatment group 
However, the order in which treatments were allocated in each block was random. This 
type of randomisation was used due to the small sample size to ensure that consecutive 
patients were distributed equally between treatment groups.   
Furthermore, this type of randomization was chosen to maximise access to the ReachMan 
device, as treating four patients simultaneously on the machine would not have been 
possible.  Following consent and the completion of baseline measures, the participant was 
given the next available place on the Excel spreadsheet that had a random group 
allocation. This allocated them to either control (B) or treatment group (A). The string was 
blocked in groups of 4 (see example below) A computerised randomisation programme, 
had previously determined the randomisation order. (There were six possible permutations 
of allocation  AABB, ABAB, ABBA, BABA, BAAB, and BBAA and the computer generated 
these block of permutations randomly for all of the recruited subjects).. 
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Table 6.1: Example of the block randomisation used in the study. 
Subject code 
Group: 
(A=Treatment 
B=Control) 
AH001 A 
JB105 A 
ER003 B 
JS102 B 
MG104 B 
CF105 B 
AW001 A 
MS106 A 
 
6.7 STATISTICAL METHODS/ ANALYSIS  
Baseline characteristics were compared between the randomised groups to check for 
approximate balance in patient characteristics. All analyses were carried out on an 
intention to treat basis.  
Advice was taken from, Pauline Rogers statistician (UCL), to facilitate the data analysis at 
this stage. Due to the low numbers and therefore data not being normally distributed non-
parametric tests were used to analyse the data. The Wilcoxon signed-rank test was used.  
The Wilcoxon signed-rank test is a non-parametric statistical hypothesis test used when 
comparing two related samples, matched samples, or repeated measurements on a single 
sample to assess whether their population mean ranks differ (i.e. it is a paired difference 
test). It can be used as an alternative to the paired Student's t-test, t-test for matched 
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pairs, or the t-test for dependent samples when the population cannot be assumed to be 
normally distributed.  Wilcoxon rank-sum test is a non-parametric statistical hypothesis test 
for assessing whether one of two samples of independent observations tends to have 
larger values than the other. It is one of the most well-known non-parametric significance 
tests.   
Results from analyses of the secondary outcomes were interpreted cautiously and 
considered as hypothesis generating rather than providing conclusive results. 
6.8 RESULTS 
6.8.1 RECRUITMENT 
Recruitment to the trial commenced in January 2010 and continued until March 2011. 
Following a nine month break (due to researcher going on maternity leave), the trial 
recommenced in December 2011 for five months. 14% of those admitted with a stroke to 
either the acute brain injury unit or two rehabilitation units and who were screened for 
eligibility was recruited to the trial. The main reasons for not meeting the eligibility criteria 
were unable to follow commands (27%); transfer to other hospital for rehabilitation 
(39.6%); unable to sit out for 30 minute period (17%). Of those eligible, 1% refused to 
participate (2 patients)  
Specific problems regarding recruitment related to a high proportion of potential 
participants from out of area and transferring to other hospitals for rehabilitation.  Cover for 
the Research Therapist was not available, and breaks in screening and recruitment were 
therefore required to allow for staff holidays.  This did impact on recruitment to the trial. 
Furthermore no cover was available when the Research Therapist went on maternity leave 
and this meant an extension of the study recruitment period and potentially lost subjects. 
 
6.8.2 PARTICIPANT FLOW 
All participants recruited to the control group completed the trial. One subject recruited to 
the intervention group ceased using the robot after a week as he was unable to use the 
device. This subject had arm apraxia and on reflection he should have been excluded from 
the study on the basis of this.  It was however possible to complete the outcome measures 
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for this participant and so his results are included in the analysis.   Another patient 
complained of shoulder pain after four weeks of using the device, he therefore 
discontinued to the use device (this will be discussed in more detail in adverse reactions 
below). It was also possible to complete measures on this participant and his results were 
also included in the analysis. A summary of the flow of participants through the trial is 
given in Figure 6.1 
 
Figure 6.1: Flow of participants through the trial (CONSORT diagram) 
 
 
6.8.3 BASELINE DATA 
The baseline characteristics for the participants in the trial are given in Table 5.3 (below).  
In total, 37 participants were recruited to the trial.  Both groups had equal numbers of 
females (8), the robot group had one extra male subject (11) than the control group (10). 
The age profile of the participants is illustrated in the histogram below (Figure 6.2).  The 
youngest participants were 25 years old, and the oldest was 85, giving a range of 60 
years.  The ages of the participants deviated from a normally distributed curve, with peaks 
255 Strokes admitted to NHNN hospital 
during the time period. 
Randomized (N=37) 
Excluded* (n=218) 
Group 1 Intervention  Group 2 Control 
1 unable to use device 
Completed outcomes 
Completed outcomes 
*Exclusions 
Did not meet inclusion 
criteria (n=130) 
Refused to participate 
(n=2) 
Discharge before 
randomisation or out of 
area (n=80) 
Unwell or died before 
randomisation (n=6) 
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in the younger age group and a peak between 75 and 85 years of age. The older group is 
in accordance with the increased incidence of stroke with older age. The younger peak is 
not explained by stroke incidence but may be site specific (this will be further discussed in 
the discussion and Chapter Nine). The ages were however evenly matched between the 
treatment and control groups. 
There was no significant differences between the groups at baseline on any of the 
measures. 
Figure 6.2: Histogram showing the age profile of participants in the study.  
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Table 6.2: Baseline characteristics by allocated group 
 
Treatment  Control  
Age  Mean (range)  
 (SD) 
53 (25-78)  
(19.31 
47(25-85)  
(17.32) 
Sex – female  44%  44%  
Weeks since stroke(range)  5.4 weeks (1-8weeks)  5.2 weeks (1-8 weeks)  
Type of stroke:  
Ischemic  65%  65%  
ICH  35%  35%  
Side Affected :  
Right  47%  52%  
Left  52%  47%  
Dominant side (Y)  35%  41%  
FMA UL  
Mean(Range) 
Median 
(IQR)  
 
19(5-51) 
18 
19 
 
19(5-54) 
20 
20 
NIHSS (baseline) 
Range 
Median 
(IQR) 
 
4-15 
9 
6 
 
5-15 
10 
5.25 
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65% of participants in both groups had suffered an ischemic event as opposed to the lower 
number of subjects who had suffered a haemorhagic stroke (35%). This represents a 
slightly higher number of haemorhagic strokes than the normal (where appropriately 15-
20% strokes are haemorhagic in nature315). Regarding recovery, it is generally believed 
that hemorrhagic stroke survivors have better neurological and functional prognoses than 
non hemorrhagic stroke survivors315.Therefore the higher than normal levels of 
haemoragic strokes may influence the results seen. However as these were evenly 
matched in both groups this should not significantly influence the results. 
6.8.4 COMPARISON OF THE BASELINE CHARACTERISTICS OF THE 
GROUPS 
The groups were evenly matched in terms of the total number of participants, age, gender, 
type of stroke, hemisphere and hand dominance. 
Mean time since stroke ranged from one week till eight weeks and the time period since 
stroke was evenly matched between both groups.  As these ranges fall within the sub-
acute period it is likely that the potential for recovery would be similar in each of the 
groups. It was hoped to recruit more subjects very early post stroke, but most subjects (as 
seen by the mean) were recruited at five to six weeks post stroke.  
The median baseline score for the FMA was slightly lower in the robotic group. The inter-
quartile ranges of the baseline scores were however very similar across the two groups.  
Severity of motor impairment early after stroke is thought to be an important prognostic 
indicator of motor recovery 316, so this could have impacted the results.  
ADVERSE EVENTS AND WITHDRAWALS 
Only one participant experienced an adverse event (pain over three consecutive days) 
during the study, during his fourth week of using the device.  The study protocol stated that 
participants should be withdrawn from the intervention if there was no cause other than the 
treatment for the pain.  The MDT monitored the participant very closely and advised that 
they considered the subjects  pain was not due to the use of the robotic device However 
the participant considered that the use of the robotic device was exacerbating his pain (this 
is also seen when he was interviewed – described in Chapter 7), and in adherence to 
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study proctol guidelines, it was therefore decided the subject should stop using the robotic 
device, and the intervention was ceased after four weeks.  
Another participant was withdrawn from the using the robot as he was unable to follow the 
program. This participant presented with arm apraxia and it was felt this impeded on his 
ability to use the device. In hind sight he probably should have been excluded from the 
study. The results of these two participants have been included in all of the analyses. 
ANALYSIS OF THE INTERVENTION  
A total of 475 (out of a potential 570) treatment sessions were completed by all 
participants using the robotic device. A number of sessions were missed due to the device 
breaking down and requiring support to get the device working again. Very few treatments 
were missed at the participants’ request.  Therapy and other ward commitments affected a 
large number of treatment sessions.  A number of sessions were missed due to the 
Research Therapists’ or Rehabilitation Assistants other commitments or absences. 
Table 6.3: Reasons for missed or shortened treatments 
Reasons for missed treatments (where details available) 
Reason Missed treatment 
Participant request 1 
Participant unavailable (e.g. visitors) 8 
Participant unwell 10 
Physiotherapy 5 
Speech and Language Therapy 3 
Occupational Therapy 4 
Other ward activities (e.g. ward round, 
wash) 
34 
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Therapist/RA  unavailable 14 
Device not working 16 
6.8.5 NUMBER OF TRIALS AND MOVEMENTS PERFORMED BY THE 
PARTICIPANTS ON THE ROBOTIC DEVICE 
The research team engineering partners at Imperial University are currently analysing the 
data stored on ReachMAN computer. However a preliminary analysis suggests 
participants performed 300 trials.   
On average participants spent 20 minutes on the device. Most expressed fatigue and that 
this was most time they could do on the robot (this is discussed further in Chapter Seven). 
 
6.8.6 ANALYSIS OF CONVENTIONAL PHYSIOTHERAPY 
The outcome of the trial may have been influenced by the conventional physiotherapy and 
occupational therapy received by the participants.  Recording forms were therefore given 
to the therapists in each unit with a request that they were completed for the six weeks of 
the trial.  It had been hoped to include an analysis of the conventional therapy received.  
Unfortunately, very few of these forms were completed. The integrated care pathway and 
Northwick Park Therapy Dependency Scores forms showed that each subject received on 
average 45 minutes of physiotherapy a day. However how much of this was spent on 
upper limb therapy is unfortunately unable to be analysed.  
 
6.8.7 OUTCOME MEASURES 
FUGL MEYER UPPER LIMB ASSESSMENT 
The primary outcome was the FMA. A histogram of the frequency of the outcome scores 
on the FMA across all groups was drawn to assess the distribution of the results (Figure 
5.10 below).  The results did not follow a normally distributed pattern and confirmed that 
non-parametric statistics should be used to analyse the data. 
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Figure 6.3 Histogram demonstrating frequency of outcome score on the FMA 
across all groups 
 
The Wilcoxon rank –sum test was applied to the data. No significant difference was found 
between control and Reachman population at the start of study (Wilcoxon rank-sum test 
p=0.685).  Significant change in pre and post scores of both control and Reachman was 
seen with a Wilcoxon signed-rank test (p=0.0001) in both cases. This shows that all 
subjects had improved arm movements following six weeks of treatment.  However no 
statistically significant change was seen between the control and the intervention group 
(p=0.210). Greater improvements for subjects who used Reachman however were seen. 
The standard deviation of difference between pre and post results of ReachMan were two 
times  higher than the pre-post difference in control group. (Control : Std(post-pre) = 6.4 
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whilst the Reachman: Std(post-pre)= 13.7 . These results are shown graphically in figure 
6.5 
 
Table 6.4: Summary of Results of the FMA score pre and post intervention. 
Group Sampl
e Size 
Pre Treatment Post Treatment Within Person 
Difference (Diff= Post –
pre) 
  Media
n 
IQR Mea
n  
SD Media
n  
IQ
R 
Mean SD Media
n 
IQ
R 
Mea
n 
SD 
Robot 19 18 13 17 10 37 31 36 17 15 24 18 14 
Contro
l 
18 20 14 20 14 33 33 28 17 6 9 8 6 
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Figure 6.4 Bar graph demonstrating total FMA scores pre and post 
intervention for both groups  
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Figure 6.5- Box plot showing differences in FMA scores in both groups 
 
 
A sub analysis of FMA scores was carried out to look for any relationships in the data. In 
particular a sub-group analysis was completed to assess whether people levels of function 
impacted on how much improvement they made following the intervention and whether 
this was different in the two groups. Although it was recognised that power would be lost 
by analysing this sub-group separately, it was considered that it might provide important 
information on trends in the data.  Correlations were performed using the non-parametric 
Spearman’s Test. A correlation was carried out comparing subjects baseline FMA scores 
and the difference in scores between pre and post FMA scores following the intervention 
period. This can be seen in graph 6.1. In the graph below the subjects with high FMA 
scores were removed from the correlation 
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Graph 6.1: Correlation between FMA scores at baseline and difference in scores 
following intervention in the robotic group 
 
 
Graph 6.2: Correlation between FMA scores at baseline and difference in scores 
following intervention in the control group 
 
 
A statistically significant relationship was found on correlation in the control group, whilst 
this was not seen in the ReachMan group.  This suggests that subjects in the control group 
with better movement initially made better gains in movement following a treatment 
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intervention (this would be expected). However this does not seem to be the case in the 
Robot group, where there does not seem to be a correlation between better movement 
(higher FMA scores) and improved scores following use of the device. This suggests that 
the robot can cause improvement in arm movement in patients with very little movement 
as well as patients with more movement initially and may explain the increase in SD in the 
intervention group.  
Three subjects in study presented with mild upper limb weakness (FMA scores on 
baseline above 40). Chapter 5 found that subjects with milder arm impairments found 
using the device less beneficial (it did not seem to challenge them enough). Therefore a 
further subgroup analysis with these subjects removed from analysis was also performed. 
This found the same results as a the full group analysis i.e  no statistically significant 
change was seen between the control and the intervention group (p=0.67) 
SECONDARY OUTCOME MEASURES 
ARAT 
The secondary outcome measure was the ARAT, which is also an ordinal scale.  The data 
from this outcome were not normally distributed.  The non-parametric statistical tests that 
were used to evaluate the results of the FMA have therefore been used to analyse these 
results. 
Table 6.5 Baseline and outcome ARAT scores by group 
ARAT scores by allocated group 
Group Median Baseline ARAT 
(IQR) 
Median Outcome ARAT 
(IQR) 
Control: no 
treatment 
 (n 18) 
1(6) 3(13) 
ReachMAN (n 19)  1(4) 6 (15) 
 
No significant difference was seen between the control and Reachman groups at the start 
of study Wilcoxon rank-sum test (p=0.620). Significant changes in pre and post scores of 
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both control and Reachman Wilcoxon signed-rank test was seen (p=0000), but just as in 
the FMA scores there was no statically significant difference between the control group 
and the intervention group (p=0.518). Figure 6.6 shows subjects initial and final ARAT 
scores and illustrates that both groups improved in the measure from initial assessment 
following the six week interval. As in the FMA outcomes, generally higher improvements 
were seen for subjects who used Reachman in comparison to the control group (Control : 
std(post-pre) = 7.282 Reachman: std(post-pre)= 12.13)  this can be seen visually in the 
box plot below (figure 6.8). Although higher improvements can be seen these are not 
nearly as large as the difference seen between the groups in the FMA score.    
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Figure 6.6: Bar graph demonstrating total ARAT scores pre and post 
intervention for both groups  
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Figure 6.7  Box plot showing differences in  ARAT scores in both groups 
 
CHEDOKE HAND AND ARM INVENTORY (CHAI) 
The data from this outcome were also not normally distributed.  The non-parametric 
statistical tests that were used to evaluate the results of the FMA were used to analyse 
these results. 
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Table 6.6 Baseline and outcome CHAI scores by group 
CHAI scores by allocated group 
Group Median Baseline CHAI 
(IQR) 
Median Outcome 
CHAI(IQR) 
Control: no 
treatment 
 (n 18) 
13(13) 17(26) 
ReachMAN (n 19)  13(13) 26(39) 
Wilcoxon rank-sum test analysis found no significant difference between control and 
Reachman population at the start of study (p=1.00). Significant change in pre and post 
scores of both control and Reachman were however found using the Wilcoxon signed-rank 
test (p=0001)(as was expected this illustrates that all subjects improved in their arm 
movements and functional abilities following the six week trial period). Just as in the 
previous scores there was however, no statically significant difference between the control 
group and the intervention group (p=0.343) . Generally higher improvements were seen for 
subjects who used the Reachman device in comparison to the control group. (Control : 
std(post-pre) = 8.22, Reachman: std(post-pre)= 16.88). Standard deviation of difference 
between pre and post results of ReachMAN is higher than the pre-post difference in 
control group and notably this was much higher than seen in the ARAT. This is shown 
graphically in figure: 6.9 
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Figure 6.8: Bar graph demonstrating total CHAI scores pre and post 
interventions in both groups  
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Figure 6.9  Box plot showing differences in  CHAI scores in both groups 
 
STREAM 
The control group had slightly lower median scores on baseline than the control group 
(indicating more impairment in their arms). 
Table 6.7: Baseline and outcome STREAM scores by group 
STREAM scores by allocated group 
Group Median Baseline 
STREAM(IQR) 
Median Outcome 
STREAM (IQR) 
Control: no treatment 
 (n 18) 
5(8) 7(11) 
ReachMAN (n 19)  7(6) 10 (6.5) 
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However Wilcoxon rank-sum test analysis found no significant difference between control 
and Reachman population at the start of study (p=0.927). Significant change in pre and 
post scores of both control and Reachman were however found using the Wilcoxon 
signed-rank test ( p=0.000)(as was expected this illustrates that all subjects improved in 
their arm movements and functional abilities following the six week trial period). Just as in 
the previous scores there was however, no statically significant difference between the 
control group and the intervention group ( p=0.385).  Generally higher improvements were 
seen for subjects who used the Reachman device in comparison to the control group. 
Standard deviations of  the difference between pre and post results of ReachMAN is 
higher than the pre-post difference in control group (Control : std(post-pre) = 1.4, 
Reachman: std(post-pre)= 2.5). This is shown graphically in figure: 6.11 
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Figure 6.10: Bargraph demonstrating total STREAM scores pre and post 
intervention in both groups 
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Figure 6.11 Box plot showing differences in  STREAM scores in both groups 
 
 
PATIENT REPORTED OUTCOME MEASURE 
DASH 
The control group rated themselves as higher levels of arm impairments initially in 
comparison to the robot group, although IQR (18) for both groups) were the same. 
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Table 6.8: Baseline and outcome DASH scores by group 
DASH scores by allocated group 
Group Median Baseline DASH 
(IQR) 
Median Outcome DASH 
(IQR) 
Control: no 
treatment 
 (n 18) 
63(18) 56(17.9) 
ReachMAN (n 19)  57(18) 45 (19) 
 
No significant difference was seen between the control and Reachman groups at the start 
of study Wilcoxon rank-sum test (p=0.822). Significant changes in pre and post scores of 
both control and Reachman on Wilcoxon signed-rank test was seen (p=0001), but just as 
in the FMA scores there was no statically significant difference between the control group 
and the intervention group (p=0.142)  Figure 6.12 shows subjects initial and final DASH 
scores and illustrates that both groups improved in the measure from initial assessment 
following the six week interval (The DASH scores are in reverse to the previous measures 
mentioned. Therefore a decrease in scores illustrates better perceived improvements in 
arm function). As in the FMA outcomes, generally greater improvements were seen for 
subjects who used Reachman in comparison to the control group (Control : std(post-pre) = 
7.76 Reachman: std(post-pre)= 10.6)  this can be seen visually in the box plot below 
(figure 6.13).  
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Figure 6.12: Bargraph demonstrating total DASH scores for pre and post 
intervention in both groups 
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Figure 6.13  Box plot showing differences in DASH scores in both groups 
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ABILHAND 
Each individual ABILHAND question score was processed through the web site: 
http://www.rehab-scales.org/abilhand-rasch-analysis-chronic-stroke.html this provides 
online analysis which converts the raw scores of the ABILHAND questionnaire into a linear 
measure of manual ability. Statistical analysis using SPSS version 21 was then carried out 
of the logit scores pre and post intervention for each subject. This found no significant 
difference between the control and Reachman groups at the start of study using Wilcoxon 
rank-sum test (p=0.78). Significant changes in pre and post scores of both control and 
ReachMAN Wilcoxon signed-rank test were seen (p=0.000) 
Unlike the other measures a statically significant difference was also seen between the 
control group and the intervention group (p=0.042). 
Table 6.9: Summary of Results of ABILHAND scores pre and post 
intervention. 
 
Group Sample 
Size 
Pre Treatment Post Treatment Within Person Difference 
(Diff=Post–Pre) 
  Media
n 
IQ
R 
Mea
n  
SD Median  IQ
R 
Mean SD Median IQ
R 
Mean SD 
Robot 19 -0.15 .82 -1.2 2.2 0.27 .85 0.36 17 0.9 1.5 1.5 1.9 
Contro
l 
18 -0.17 5.9 -1.9 2.8 -0.09 1.3 -0.44 17 0.5 2.1 1.5 1.9 
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HEALTH STATUS 
BARTHEL INDEX. 
 
Table 6.10 Baseline and outcome Barthel Index scores by group  
Barthel Index scores by allocated group 
Group Median Baseline 
Barthel(IQR) 
Median Outcome Barthel 
(IQR) 
Control: no 
treatment 
 (n 18) 
11 (12) 5 (5) 
ReachMAN (n 19)  14 (12.5) 6 (10) 
 
The data from this outcome were also not normally distributed.  The non-parametric 
statistical tests that were used to evaluate the results of the FMA were used to analyse 
these results. In similarity to the other measures used in the study, no significant difference 
was seen between control and Reachman population at the start of study using Ranksum 
test (p=0425).  Significant change in pre and post scores of both control and Reachman 
were seen with the Wilcoxon signrank test (p=0001) However no significant changes were 
seen between the groups (p=0.940).Generally higher improvements for subjects who used 
Reachman compared to the control group : std(post-pre) = 2.79 Reachman: std(post-pre)= 
4.05 but as the measure was looking at the general functional abilities of the subjects it 
was not expected that there would be a significant change between groups with the 
intervention.  
EQ5D 
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Table 6.11 Baseline and outcome EQ5D scores by group  
EQ5D scores by allocated group 
Group Median Baseline EQ5D 
(IQR) 
Median Outcome EQ5D 
(IQR) 
Control: no 
treatment 
 (n 18) 
0.55 (13) 0.61(16) 
ReachMAN (n 19)  0.55(14) 0.61(13) 
 
The data from this outcome were also not normally distributed.  The non-parametric 
statistical tests that were used to evaluate the other measures were used to analyse these 
results. In similarity to the other measures used in the study, no significant difference was 
seen between control and Reachman population at the start of study using Ranksum test 
(p=0.675)..Significant change in pre and post scores of both control and Reachman were 
seen with the Wilcoxon signrank test (p=0.000). However no significant changes were 
seen between the groups (p=0.964) . 100% of the REACHMAN subjects improved in the 
score following the period of intervention, while 89% of control subjects reported 
improvements. Just as in the Barthel Index the measure was looking at the general 
functional abilities of the subjects, it was not expected that there would be a significant 
change between groups with the intervention.  
OTHER MEASURES 
ASHWORTH 
Mean and Median Ashworth scores for the subjects at baseline was 2. No participants 
Ashworth changed during the intervention period.  
 
6.8.8 POWER CALCULATION 
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One of the aims of this exploratory study was to be able to use the data to perform a 
power calculation to explore sample size for a definitive RCT. This calculation was 
performed on the basis that each group would need to show a clinically important 
difference of 5 points in FMA score (This is based on the largest RCT performed (Lo et al 
(2010) 171) looking at a robotic device compared to normal therapy, which used this marker 
for clinically importance difference ) between the mean within person differences. The 
power calculation for 5% significance and 80% power predicted a definite study would 
need 73 subjects in each group. This power calculation was performed by Pauline 
Rodgers statistician at UCL’]. 
 
6.9 DISCUSSION 
The main implications of the trial will be now be considered and an analysis of the results 
will be presented here in relation to the research questions 
6.9.1 RESEARCH QUESTIONS 
 
What are the effects of using a robot on the motor performance of the hemiplegic upper 
limb in the sub-acute phase after stroke? 
The results of the study did not lead to a complete rejection of the null hypothesis.  All 
groups, including the control, improved from baseline to outcome.  The changes seen in 
the groups may have been due to natural recovery. Only one measure-the ABILHAND 
demonstrated statistically significant improvement when comparing the intervention to the 
control. This was not seen with the primary outcome measure the FMA. However there is 
a suggestion of positive trend in the invention group as a there was a larger difference 
seen between pre and post results in the ReachMAN group than in the control group with 
the FMA and the other outcome measures. 
This finding has similarities to the findings in previous literature evaluating the use of 
robotic device in the acute/sub acute phase (as discussed in Chapter Two). Nonetheless 
those studies found a statistically significant improvement in FMA scores with use of a 
robotic device 171;186;200;317 while this was not seen in this exploratory RCT (only a trend of 
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higher improvements was seen in this measure.) In contrast to those studies 171;186;200;317 
this study does also suggest a trend (with a statistical significance in a PROM) for 
functional and patient perceived improvement in arm function with use of the device. 
However the other studies did not use specific activity or participation measures in their 
studies so we are unable to make this direct comparison.  
 
Interestingly the ABILHAND was the only measure that demonstrated a statistical 
significance difference between the control and robot groups. This measure was one of the 
three measures from the systematic scale selection that was chosen and best met the 
psychometric criteria used (as described in Chapter Four). This could indicate that this 
scale was sensitive to change seen with the intervention. However due to the small 
sample number and that this was the only measure that did find statically significant 
change, this result must be treated with caution.  
It is likely that clinically significant changes are of greater importance to people with stroke 
and the therapists who treat them than purely statistically significant ones. A change that is 
statistically significant but which has little or no impact on the functional ability of the 
person’s arm is likely to be less important than a non-statistically significant change that 
involves an improvement in the use of the limb. The clinical significance of changes in the 
values obtained with the outcome measures used in this trial is difficult to assess.   In a 
population starting at a very low level, small changes may be neither statistically significant 
nor result in a change in functional use of the upper limb.  These changes may however 
indicate a response to the intervention and may therefore be of clinical significance; in 
particular, they may make it possible for an individual to participate in, or to benefit from, 
other therapeutic interventions that require more active participation.  
Little work has been completed on the clinical significance of changes as measured by the 
battery of scales used. In a study of the reliability of the ARAT, van der Lee et al (2006) 284 
suggest that the “minimal clinically important difference” (MCID) on the scale was a 
change of 5.7 points (10% of total score).  This was reported to be based on clinical 
experience and estimates from literature relating to outcomes in respect of spinal 
manipulation.  More recently, Lang et al (2008) 318 estimated the MCID of a number of 
upper limb outcomes in the context of a trial of CIMT in the sub-acute stroke population.  
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They conclude that MCID values for the limb vary between 12 and 17 points on the ARAT, 
depending on whether the stroke affects the dominant or the non-dominant hand. Recent 
literature has also looked at the MCID in FMA UL scores.  Arya et al (2011) 319  looked at 
71 subjects poststroke (mean duration, 8.42 weeks after stroke). They found that patients 
who achieve a 9 to 10 point increase in FMA score are more likely to experience or 
perceive a meaningful and clinically important improvement in their disability level than 
those who do not. However Page et al (2012) 320 looked at  one hundred forty-six 
individuals with chronic, mild to moderate upper-extremity (UE) hemiparesis and found that 
the estimated MCID of the score ranged from 4.25 to 7.25 points. Further discussion on 
this and on the scales use in this study will be given in Chapter Nine  
Participants only used the device for short periods (20 minutes) of time. This is less than in 
other clinical trials of robotics which have used intervention protocols of 30-60 minutes per 
day 205,206,171. However, these trials were carried out in a chronic stroke population, with 
patients more than six months after stroke and already discharged from inpatient 
rehabilitation. The participants in this study commenced using the robotic device within six 
weeks of their stroke and were concurrently engaged in an intensive, multidisciplinary 
inpatient neurorehabilitation programme. The intensity of the rehabilitation combined with 
the early stage post stroke may explain why participants were only able to tolerate short 
periods on the robot. Doornebosch  et al (2007)226 et al  reported similar findings, in sub-
acute patients who used a robotic device for on average 20 minutes a day, (when fatigue 
prevented using the device for longer periods). Frequent, short sessions may have suited 
the subjects better and may have been a way of delivering more intervention.  
Preliminary data from the robotic device suggest that participants performed 200-300 trials 
of arm movements during the robotic sessions. Literature is inconclusive as to the exact 
number of upper limb movements post stroke that promote functional recovery although 
300 and 800 repetitions per session has been, suggested 321. The participants in the 
intervention group in this study performed less than this recommended amount, however it 
is not know how many arm repetitions the subjects in the control group performed. It may 
have been that it is due to the small number of repetitions that no significant difference 
was found between the groups. However, as the results do suggest trends toward the 
intervention leading to better upper limb recovery, it may be that even a small increase in 
arm repetitions can improve arm function.  
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What severity of arm impairments could use the device and is there a difference in the 
potential benefit of the aid depending on the severity of arm paresis? 
 
The current literature looking at the effect of robotic devices on upper limb recovery, does 
not suggest that a particular level of activity in the arm leads to better improvements with 
use of robotics. However a middle range of motor impairments (falling between fifteen and 
23 inclusive on the proximal FMA) has been implicated to be the optimal for robotic 
intervention 174. The results of this trial however on sub hoc analysis of the difference in 
FMA score within subjects from pre to post this found there did not seem to be a 
correlation between better movement (higher FMA scores) and improved scores following 
use of the device. This suggested that the robot can cause improvement in arm movement 
in patients with very little movement as well as patients with more movement initially. 
However, as this is a post hoc analysis of the small sample size used in the study the 
results must be viewed with caution.   
Subjects in the robotic group with higher FMA scores seemed to make fewer 
improvements during the intervention. This fits with the data seen in the first phase of the 
study, where subjects with minimal upper limb impairments were able to interface with the 
robotic device but found it did not challenge them sufficiently.  This could also however be 
indicative with problems with the outcome measurement scales, with ceiling effects with 
the FMA.  
On a practical level patients with very little arm movement could use the machine. (Their 
perceptions of the use of the device are explored in the subsequent chapter.) This has 
clinical implications and could be of clinical importance as currently there is little in way of 
therapy for people with severe arm paresis and the use of a robotic device such as the 
ReachMan device, may be a way of delivering increased intensity of therapy, and 
repetition of movement (as recommended for upper limb recovery) in these severely 
impaired individuals. 
What resources are required in terms of staffing for use of the machine? 
202 
 
Rehabilitation Assistants were able to provide supervision to the subjects when using the 
device and it was found to be both a practical and feasible intervention as an addition to 
the therapy the participants were receiving on the rehabilitation units.  Time was needed 
from a trained physiotherapist to instruct the rehabilitation assistants how to adapt the 
program, adequately position the subject and which level to use on the device. Whilst 
regularly monitoring of how the invention was going was also needed. Unfortunately the 
device was unable to be used by patients independently and therefore a member of staff 
was needed at all treatment occasions. The device broke down on several occasions 
during the study period and this resulted in lost sessions on the device.  The cost of the 
device in terms of therapist training, therapy and RA and the time involved in the provision 
of the therapy should be considered in future evaluation of the intervention. Furthermore 
taking into consideration the cost of maintenance of the device and call out for repairs is 
also required.   
Power Calculation 
An aim of this exploratory study was to provide a sample size for a definite RCT. Although 
no statistical effect was found, with the intervention, a power calculation for 5% 
significance and 80% power predicted using the results from the FMA score, a definite 
study would need 73 subjects in each group.   This is relatively low numbers for a definitive 
RCT and again is suggestive that the results seen implicit benefit from the experimental 
intervention. 
6.9.2 METHODOLOGICAL LESSONS LEARNED FROM THE PRESENT TRIAL  
 
It is necessary to note aspects of the design of the study that worked well and should be 
included in future studies and aspects that require modification. 
The study design used in the trial has its limitations. Both control and subjects received 
conventional therapy, however only the robotic group participated in additional upper limb 
therapy (use of the device). Therefore it is difficult to differentiate if the trends for 
improvement seen in the study with the robot were due to the intervention per se or 
whether this was due to subjects receiving additional therapy. 
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Ideally a third intervention group should have been added to the study. This group would 
have  dose-matched practice of arm movements , to address the unanswered question as 
to whether subjects improved due to increased intensity or an specific effect of using the 
robotic itself. 
. However 20 min of daily additional therapy use is a very short amount of time as 
previously discussed and this again could hint to the improvements seen being specific to 
the experimental intervention.  
The number of treatment sessions that were missed or reduced in length due to other 
ward commitments (e.g. treatments, meals, investigations, visitors) challenges the view 
that stroke patients spend long periods unoccupied.  The team also noted high level of 
fatigue in the participants.  It is thought that sleep may play an important role in motor 
recovery after stroke 322,  and so providing sufficient periods of rest may be vital.   Future 
studies of the intervention may therefore need to consider the length and frequency of 
treatments. 
Conventional Therapy 
It had been hoped to include an analysis of the amount of conventional therapy received 
by the participants.  Unfortunately, too few treatment records were completed to make this 
possible.  It was not therefore possible to assess the impact of conventional therapy on the 
outcomes.  As the therapists were not blind to group allocation, it is possible that the 
participants in the control group received additional conventional therapy for the upper 
limb, thus introducing a source of bias.  Ways of capturing more information on the 
conventional therapies for the upper limb provided during the trial should be developed for 
future research studies. 
6.9.3 SOURCES OF ERROR 
 
The results may be subject to Type II error, where a treatment effect is present but is not 
identified by the trial, due to inadequate power or inappropriate analysis. Type II error 
(false negative) relates to sensitivity.  The use of ordinal scales and non-parametric 
statistical tests may increase the chance of Type II errors. 
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Wade (2001)323 discusses the difficulty of evaluating rehabilitation interventions, and 
suggests that failure to demonstrate a change due to one element of the rehabilitation 
package may be because it is interdependent with the other elements and may only have 
a small independent effect.  He defines this as a ‘Type III error’.  It is possible that this trial 
could be at risk of Type III error.  All participants received the normal stroke unit care and 
any additional benefit of using ReachMan may have been too small to measure using the 
outcome measures chosen. 
LIMITATIONS OF THE STUDY 
POPULATION SIZE 
The study was an exploratory RCT, with a small population size therefore results were 
interpreted cautiously and considered as hypothesis generating rather than providing 
conclusive results.  
 
RECRUITMENT 
Recruitment to research studies in the acute setting is always likely to be challenging, as 
the potential participants are often acutely unwell and are adjusting to their new 
circumstances after stroke.  Due to the ethical approval for the study being for a single site 
a large number of patients were from out of area and therefore unable to be recruited. The 
trend for shorter hospital stays after stroke, with discharge to either intermediate care 
facilities, or home with the community therapy meant that some people were discharged 
and the study was unable to provide the facilities to allow them to come in for daily use of 
the robot.  UCLH hospitals have a large number of research trials ongoing simultaneously 
and therefore recruitment was also affected by the co-recruitment of other upper limb 
research studies. The low proportion of eligible patients participating limits the 
generalisability of the trial The recruitment figures for this study were however higher than 
other studies that have looked at upper limb rehabilitation.. In a recently completed trial of 
the Armeo robot, for example 324 of 393 stroke patients who were screened over an 8-
month period 3.1% were recruited.  Whilst Donaldson et al 140, report a recruitment rate of 
8.1% and a refusal rate of 14.3% to a study of Functional Strength Training for the upper 
limb after stroke.,  
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The baseline data of the subjects recruited to the study showed that population distribution 
did not match normal distribution, with there being higher than normal stroke survivors in 
20-30 age range. This may have been site specific as one of the rehabilitation units the 
subjects were recruited from is a level 3 unit and tends to take younger patients who need 
a longer period of rehab than that usually afforded in stroke rehab services. However, the 
ages were equally distributed between the groups, but this does also limit the 
generalisabilty of the findings.   
ATTRITION 
The trial had a good completion rate, although one participant did withdraw voluntarily, 
although outcome measures were completed in all this case.   
BLINDING  
No blinding was used in this study. The nature of the intervention (the use of a robotic 
device) meant that it was not possible to blind either the participants or the therapists to 
the allocation group.  However outcome assessors could have been blinded to group 
allocation.  Future studies should include assessor blinding. 
The lack of blinding in the study is a significant limitation and should definitely be 
addressed in any future studies. 
 
STRATIFICATION 
Sub-hoc analysis of the FMA scores suggested a difference with the intervention 
depending on the severity of arm impairment. It would therefore be useful to explore this 
further in future studies by stratify subjects into impairment levels. The analysis also 
suggested that participants with higher level of FMA scores (nearer to the maximum score) 
benefited the least from the use of the robot, so a consideration could be to exclude these 
subjects from future studies. 
OUTCOME MEASUREMENT 
The outcome measures were mostly taken on the day after the final intervention.  Francis 
et al (2004) 325 suggest that functional outcomes after an intervention to treat spasticity in 
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stroke may not reach the maximum value immediately after treatment, and propose that a 
follow-up measure should be completed.  The rationale for completing a single outcome 
was that any change from the start of the intervention would be identified by a 
measurement after the final robotic intervention and there is no current literature that 
suggests that the effect of robotics is not immediately seen. Future studies may benefit 
from a follow-up measure to evaluate whether participants consolidate any improvements 
due to the intervention with subsequent independent use of the limb. 
Following the study limitations were found with the outcome scales selected in the 
participant population used. Further analysis of the outcome measures in the context of 
this study investigation is included in Chapter Eight. 
 
6.10 CONCLUSIONS 
The trial demonstrated that, even amongst the severely impaired stroke population, there 
could be improvement in motor performance in the sub-acute phase after stroke.  The 
relationship between the improvement and the use of the robotic device is harder to 
evaluate and the results do not disprove the null hypothesis that there would be no 
difference between the groups as measured by the battery of outcome measures. Only 
one measure the ABILHAND found that the intervention group improved more significantly 
than those of the control group. Post hoc analysis of the FMA score most suggests that 
there was no real correlation between arm severity and improvement with the robot, 
however severe arm impairment did seem to response to using the device. Limitations of 
the study related to the small population size, sensitivity of the outcome measures to 
assess change within this population; small proportion of those eligible participating in the 
trial; timing of the outcome measures; timing of the treatment; and the absence of a 
complete record of conventional therapy. 
The implications of this trial will be considered more fully in Chapter Nine. 
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CHAPTER 7: A QUALITATIVE STUDY: USING INTERVIEWS TO EXPLORE 
PARTICIPANTS AND CARERS VIEWS OF USING THE REACHMAN DEVICE. 
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7.1 INTRODUCTION 
Chapter six describes how the exploratory trial was undertaken and completed. It reports 
the findings from the study in terms of the clinical outcome measures and PROMS 
collected. However, it was felt to be important that participants and their carers perceptions 
of using the robotic device were also described.  Therefore, a qualitative approach was 
used to explore participant’s views of the impact of using the ReachMAN robot. This 
chapter describes the interview processes used and explores the experiences of eight of 
the participants in the exploratory trial and two carers.  
 
7.2 BACKGROUND 
Chapter Two described the literature that has looked at patient perceptions of the use of 
robotic devices (summary of the studies performed was also given in Table 2.2). This 
literature has shown that robotics are acceptable and appear safe to patients. However, 
there is a lack of in-depth and structured information on users’ perspectives of using 
robotic devices for rehabilitation of their upper limb. Existing research on user perceptions 
of the use of robotic devices in upper limb rehabilitation is limited to a few studies of either 
patients195;224 or therapists231, or both226 In these studies the scope of response is often 
predetermined by the use of closed questionnaires or Likert Scales  Furthermore, it has 
not always been made  clear how the questionnaire was developed or administered, 
leading to possible bias. In some of the studies the questions or statements used were 
often unpublished and frequently there were no clear tables of results. 
One recent publication has tried to address this gap. Hughes et al (2011)227 conducted a 
study on five participants who had upper limb problems six months or more  post-stroke. 
Each subject used a used a novel robotic device. Following a six week trial, a purpose 
designed set of questions was developed and individual interviews were conducted. This 
found that participants had a positive response to the system, and provided feedback 
regarding the novel devices’ service, function and effectiveness. Overall participants 
expressed they would have liked a home-based system targeting their whole arm. This 
study is the first that has explored more in depth views of people with stroke perceptions of 
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using a robotic device in upper limb rehabilitation. However the study was limited by its 
small study population. Furthermore interviews were very structured in nature, consisting 
of a questionnaire which included Likert questions, with only limited opportunities for the 
subjects to express in depth their views of the device. The authors acknowledge this 
limitation, and also acknowledge that a further limitation with the closed nature of their 
interview structure meant that the formation of the broader issues which may affect how 
people with a stroke may perceive robots in their rehabilitation could not be addressed. 
For robotic aids to be effective, their design and protocols for use must be driven by 
clinical need and developed as a result of engagement with all interested parties: 
engineers, therapists, patients and their carers 210. Ultimately, it is the interaction of the 
patient and carer with the robotic aid that will determine the regular use of and hence the 
effectiveness of robotic devices as a rehabilitative intervention 169. Understanding the 
users perspective is essential to ensure that future devices will be acceptable, relevant 
and accessible132. It was therefore felt to be important that participants and their carers 
perceptions of using the robotic device were explored. 
Establishing the opinion of a stroke patient may be challenging in the presence of 
expressive language problems and cognitive impairments. However, the carer's 
perspective may not be taken as a substitute for the patient’s own opinions. Proxy 
interviewing risks discrepancies between the conclusions of the patient and carer and the 
failure of the proxy to predict or interpret the patient’s preferences accurately331. Lloyd et al 
(2006)331also express that the only way to effectively capture the patient’s perspective is 
through direct questioning, providing support as necessary Therefore, the aim of soliciting 
the carer’s perspective was to capture their experiences and observations of the use of 
robotic devices as distinct from, and complementary to, the experiences of the patient. 
 
7.3 CHOICE OF RESEARCH METHODOLOGY 
To gain this understanding of both participants and carers views of using robotic devices 
as part of upper limb rehabilitation, it was felt that a qualitative methodology would be the 
most appropriate in this part of the study. Health researchers are increasingly using 
designs that combine qualitative and quantitative methods,332 and this is often called mixed 
methods research. It was felt that by using both qualitative and quantitative methods in 
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these studies a more complete picture could be gained  
Holt et al (2007)134 echo this view commenting that qualitative research into the perceived 
benefits and barriers into the use of robotic devices in upper limb rehabilitation is required 
to inform the design and development of these devices   Furthermore, Coote and Stokes 
(2003) 224 suggest that examination of user attitudes is essential to aid the translation of 
using robotic devices from the research environment to clinical practice. The National 
Institute for Health Research (2010)5 comment that involving users in the research process 
leads to research that meets their needs, is more reliable and is more likely to be put into 
practice  
 
7.3.2 STUDY AIMS AND OBJECTIVES 
Amid unanswered questions remaining over stroke survivors opinions of using robotic 
devices as a rehabilitation tool, and with the overriding aim of this thesis in mind (which 
was to bridge the gap between research into robotic devices and clinical practice)  The 
aims of this study were to: 
Aim: 
To explore patients’ perceptions of using a robotic aid for upper limb rehabilitation after 
acute stroke, in order to inform future robotic design and treatment protocols 
Objectives: 
 
Subjects were explained that the aim of the study was to find out how they felt about using 
The ReachMan device as part of their rehabilitation. In particular the aim was to find out 
their views and experience on using the device itself.  
 
7.3.3 SELECTION OF QUALITATIVE RESEARCH APPROACHES 
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There are several approaches to qualitative research including, ethnography, action 
research, grounded theory and phenomenology 333  Each approach offers unique 
perspectives, which were all considered when choosing the most appropriate qualitative 
research design to address the aims of the study.  
Ethnography is concerned with the study of a culture or subculture 333. Large-scale macro-
ethnographies examine a large culture with its institutions, communities and value 
systems. Small scale micro-ethnographies investigate a single social setting such as a 
ward or small group of people 333 Data collection involves immersion in the setting by 
means of participant observation 334 . 
 Action research aims to interpret and explain social situations while executing a change 
intervention aimed at improvement and involvement 334. This approach is problem-focused, 
context specific and future orientated  242. Action research is a group activity based on a 
partnership between action researchers and participants whom are involved in the change 
process 334 333. 
Grounded theory (as developed by Glaser, Strauss, Corbin and their co-workers) is an 
attempt to develop a set of strategies for conducting rigorous qualitative research. It uses 
inductive strategies for analysing data. The researcher begins with no pre-existing theory, 
hypothesis, or expectation of findings but rather permits a theory to emerge directly from 
the data – that is, the theory is grounded in the data. The aim of the approach is not only to 
describe well the topic of study but also to develop adequate theoretical conceptualisations 
of findings.  
The phenomenological approach allows in-depth exploration and interpretation of the 
experience of a phenomenon through an intensive study of individual cases of a small 
sample of people. This approach emphasises the value of describing and interpreting 
human experience, using descriptions and /or interpretations of everyday experiences as 
sources of data 335. 
Ethnography was rejected as a method as it is only appropriate when addressing the 
experience of groups, cultures and subcultures with prolonged engagement and 
immersion in the setting under study.   
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Action research is a cyclic process in which research, action and evaluation are 
interlinked; involving change management and collaboration with participants  242 . This 
would be challenging in the context of the research question and research studies. 
Ground Theory  was also rejected as a method, as this methodology premise is focused 
on producing a new theory, and this was not felt to be the main focus of this  study but 
rather to evaluate and gain an in depth understanding of  subjects  perspectives of using 
robotics in their arm rehabilitation 
Phenomenology also did not quite fit the model to explore the aims required, as it aims to 
provide rich detail of lived experience of small numbers, narrative knowledge and an 
interpretation of human experience 335 333 
 
7.3.4 FRAMEWORK ANALYSIS 
After careful consideration of the different types of methodology, it was decided to use 
Framework Analysis Method for this study.(developed by the National Centre for Social 
Research and described by Ritchie and Spencer (1994)336. 
Framework Analysis is a thematic content analysis method that involves summarising 
and classifying data using a thematic framework 336 .Framework Analysis is actually by 
definition a  method of data analysis rather than a research paradigm such as 
ethnography, phenomenology, or grounded theory337, It has been noted to fit into a 
thematic methodology 338 .  
There was a number of reason why Framework Analysis was chosen: Firstly, In its 
theoretical commitment, this research is both interpretive and phenomenological. It 
seeks to make sense of the participants’ experience, explores a concept from the 
perspective of the participant and acknowledges that each person’s experience of the 
world is different and there is no one 'true experience' of the world 339 It is Heideggerian 
in that it seeks to understand the way people give meaning to experience of being-in-
the-world and acknowledges that while each person shares being, their experience of 
being is always different 340 The use of Framework Analysis allowed both these 
elements to be address. However, unlike entirely inductive and iterative approaches 
such as grounded theory, Framework Analysis may be shaped by existing ideas and is 
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less focused on producing a new theory337, which also fitted well with the concepts of 
this study. 
Furthermore, Framework Analysis has a well-defined method of synthesising and 
interpreting qualitative data which makes it an accessible analytic tool for a novice 
researcher 336 such as the researchers performing this study. This systematic and 
sequential process provides a trail of evidence and hence enhances the dependability, 
consistency and conformity of the data  341.  
 
7.3.5 DATA COLLECTION METHOD 
Quantitative methods such as questionnaires have previously been used to measure 
patient attitudes towards rehabilitation robotics 162 195 224 134 216 226 225. However, this 
approach was considered inappropriate as the data generated from questionnaires lack 
depth and detail and is insufficient when exploring the complexity of factors that shape 
personal opinions and experiences. Furthermore, predetermined questions limit the 
opportunity for participants to discuss aspects of their experience that fall outside the remit 
of the questionnaire 242. 
Semi-structured interviews were chosen as the data collection method as they are 
effective in gaining the participant’s detailed views and experiences of a particular topic 
or phenomenon 242 . Interviews should provide sufficient richness of data to analyse the 
insights and narratives of the individual participants. In a semi-structured interview the 
researcher sets the agenda in terms of the topics covered, but the participant’s 
responses determine the amount and type of information provided about those topics 
and their relative importance 334. The participant shares control over the conversation 
which allows for expansion on the topics most salient and preserves the ability for the 
participant to foreground issues personally relevant to them 342 . The fluid two-way 
communication structure allows the researcher to clarify responses, prompt elaboration 
and probe further in areas of particular relevance to the research objectives 334. Semi-
structured interviews also allow a forum for the researcher to be attentive to a 
participant’s beliefs and perspectives and how they may affect their health behaviours  
334
. This balance of flexibility and structure best fitted the research aims of exploring the 
participants’ perceptions of rehabilitation robotics.  
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Semi-structured interviews were favoured over open in-depth interviews as the research 
question was very focused around rehabilitation robotics rather than the total 
experience of stroke rehabilitation. Semi-structured interviews were preferred to focus 
groups because the experience of stroke rehabilitation is intensely personal and 
dependent on one’s level of impairment, which makes group comparisons less useful. 
Furthermore, cognitive and language impairments affect group dynamics and the 
participants finished their robotic intervention at different times, making focus groups 
logistically difficult.  
 
7.3.6 INTERVIEW TOPIC GUIDE 
The interview topic guide (see Appendix V111) was based on the study’s aims and 
objectives and also reflected questions posed in previously published research 134;231. A 
pilot interview was carried out with a stroke patient who had used an earlier prototype of 
the robotic aid to explore areas to generate possible topics and gain experience in 
interview technique. The topic guide included the following: expectations of the robotic 
aid; benefits of robotics; acceptability of treatment protocol; design of the robot; use of 
robotics to enhance motivation; and opinion of having a robotic device at home. The 
topic guide was not intended to provide a rigid structure for the interview as the priority 
was to allow the participant to express their opinions and experiences freely. Rather, it 
was used as a prompt to focus the data collection and ensure that all relevant topic 
areas were explored during the interview.  
 
7.3.7 ESTABLISHING RIGOUR IN THE STUDY 
A number of strategies were used to improve the rigour of the study. This included detailed 
description of the process and the context in which the data was gathered both in the 
methodology and in reflective memoing. Participants were questioned during the interview 
process to clarify any points that were unclear to validate information.  Analysis of the 
transcripts by a second researcher was used to validate the results gained. A reflective 
memo diary was used during the data analysis to show transparency  
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During this study the researcher developed reflexivity acknowledging the role of the 
researcher and the researchers’ professional experiences, in the research process, from 
design, data collection and analysis through to completion.  
 
7.3.8 RECRUITMENT  
Following the robotic intervention, described in the previous chapter, all participants were 
invited to be interviewed by a physiotherapist to explore their experiences of using the 
robot. An independent physiotherapist (BS), who had had no involvement with the 
intervention, was chosen to complete the interviews to encourage honesty in the 
responses. The analysis was undertaken by the primary researcher and research team. 
Ethical approval for this stage of the study was obtained from the joint research ethics 
committee of the NHNN and the ION. All participants signed a consent form (see Appendix 
V11). 
 
7.3.9 SETTING 
Once the intervention phase has ceased, participants were contacted in person (usually in 
the rehabilitation unit where the participant was still ongoing rehabilitation) or by phone (if 
they had gone home) to ask if they would be willing to be interviewed. The interviews were 
carried out at a time and place convenient to the participants. Most participants chose to 
carry out the interview in the rehabilitation unit immediately prior to discharge. Three 
participants were interviewed at home. Although the researcher attempted to ensure a 
quiet, relaxed environment for all interviews, one participant chose to use a communal 
recreation room, which resulted in background noise and disturbances.  
7.3.10 PARTICIPANTS 
Eight out of 18 people who participated in the exploratory trial reported in chapter six were 
recruited to the interview stage, and two carers participated. The interviews were carried 
out in 2010, unfortunately the physiotherapist performing the interviews was unable to 
perform any further interviews with participants recruited in 2011/2012. Of the 13 people 
recruited into the exploratory trial, intervention arm during that time period two people 
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refused to be interviewed; and one had not yet finished the intervention arm preventing 
participation.  The participants who agreed to be interviewed, all were early post stroke 
suffered either haemorrhagic or ischemic strokes ranging from two weeks to six weeks 
prior to recruitment to the study; three had a hemiparesis of the right side and five of the 
left side. Participant ages ranged from 25 to 78 with a mean age of 55 years. Participant 
characteristics are summerised in Table 7.1 
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Table 7.1: Characteristics of participants who were interviewed: 
ID  Gender Occupation Age Location of Stroke 
Affected 
UL  
Location 
of 
Interview 
Time 
started 
intervention 
P1 Female Occupational 
Therapist 
60 Right MCA 
Infarct 
Left NHNN  6 weeks  
P2 Female Retired 
Secretary 
72 Right 
Lacunar 
Left Home 1 week 
P3  Male Retired 
Admiral 
78 Right 
Lacunar 
Infarct 
Left NHNN 3 week 
P4  Male Unemployed 28 Left ICH Right NHNN 4 week 
P5  Female Full-time 
mother 
39 Left MCA 
Infarct 
Right NHNN 4 week 
P6  Male Floor layer 25 Left 
subcortical 
Right NHNN 4 weeks 
P7 Female Housewife 37 Right MCA 
infarct 
Left Home 4 weeks 
P8 Female Unemployed 39 Right ACA 
infarct 
Left NHNN 6 weeks 
 Carers 
Two participants P6 and P5 had language impairments. Individuals with language 
impairments are often excluded from qualitative studies in favor of the most verbally 
articulate  331 . However it was felt to be important to include participants with language 
impairments. This was to allow a more comprehensive perspective of individuals to be 
noted. A number of strategies were employed when interviewing patients with receptive 
and expressive dysphasia 331. These included identifying communication strengths and 
strategies in advance with the participant and their speech and language therapist, the use 
of mainly closed questions to facilitate expression, and incorporating written 
communication to aid comprehension. The resultant limitations in the richness of the data 
were considered an acceptable compromise when compared with the alternative of 
excluding these participants from the research.  
7.3.11 INTERVIEWS 
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Interviews were conducted by the interviewer (BS) on average a week after stopping using 
the robotic device. The interviewer was not involved in the delivery of the intervention and 
the interviews were conducted away from the device to reassure participants that they did 
not have  to report favourably on the intervention. All interviews were tape recorded. Each 
interview covered the same general topics, although the participant was free to structure 
the conversation within each topic. Guiding questions were developed by the interviewer, 
the primary researcher (KB) and the primary investigator (DP) of the whole study.  
 
7.3 12 ANALYSIS 
Interviews were transcribed verbatim. The analysis was undertaken primarily by the 
primary researcher and the interviewer. The interview data were analysed using the 
Framework Analysis. Framework involves six stages: 1) identifying initial themes, 2) 
labeling the data, 3) sorting the data by theme, 4) synthesizing the data, 5) developing 
descriptive accounts and 6) exploring explanatory accounts. First, recurring themes were 
identified and developed. Then the themes were grouped into a number of main and sub-
themes. At this stage an initial thematic framework was created. Labels were then 
attached to each section of the transcripts which is called indexing; the labels represented 
the theme to which it was associated. The thematic framework was then further developed 
to add any new themes. The next step was sorting the data by theme where sections of 
data with the same label were brought together. Charts were then created for each of the 
main themes using the context and language found in the data. The entire transcripts were 
also reread regularly to minimize fragmentation. The nature and content of each theme 
was described and discussed between the researchers. Explanation of links between 
themes were developed and further discussed. (Appendix VIV shows an example of this 
process). 
NVivo 8 qualitative data analysis software was used to help organise the data during the 
indexing and charting stages and this facilitated collation of data under the identified 
themes. The use of computer aided qualitative data analysis software  such as NVivo 8 
was not intended to replace the researcher’s data analysis but was used to organise the 
data in a systematic way, while maintaining the integrity of the original transcripts  242 
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7.4 RESULTS 
 
The results are presented as the themes that emerged from the data. Quotes are used to 
support and illustrate points. The main themes identified were:  
1. Impressions of the robot 
2. Impact on symptoms and arm movement  
3. Progress, Challenge and Encouragement 
4. Fatigue 
5. Use of the robot 
The results will be described within these five themes where applicable (Table 7.2). 
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Table 7.2: Themes and subthemes from the interviews 
Themes Subthemes 
Impression of the robot Initial impressions 
Use of technology  
Impact on symptoms and movement Pain 
Physical Gain 
Confidence/ use of arm 
Enjoyment 
Progress, Challenge and Encouragement Making Progress 
Maintaining Progress  
Challenge 
Fatigue Physical tiredness 
Cognitive tiredness 
Practical Use of the robot Independent use 
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7.4.1 IMPRESSION OF THE ROBOT. 
INITIAL IMPRESSIONS 
On initial use of the robot, some participants expressed some fear and doubts on initially 
encountering the robot:  
“I had mixed feelings about that really. I was a bit dubious of it.” (P4)  
However, these fears were not long-lasting and dissipated as the participants got used to 
the robot:  
 “Well, first impression, I was frightened of it. [...] Because I hadn’t been on 
anything like that before [...] but by the time I’d taken my last little session on it, I 
was absolutely thrilled with it! Very impressed with it. Loved it!” (P2).  
“I did not realise how it will work....but then I realised what and how it was going to 
help me and where it was running.  “ (P8) 
They were concerned that these first impressions may worry other users:  
“I think that some people might find it a bit more intimidating, but it’s not, I didn’t 
think…I thought it was …Once you got used to it and you realised what you could 
do with it…then it was good.” (P1) 
None of the participants were worried about the safety of the device:  
“I felt safe all the time... Yeah it’s safe. Again, I had no issues like that, not at all, 
got no issues like that.” (P4) 
TECHNOLOGY 
Participants expressed a variety of opinions of using technology in their upper limb 
rehabilitation.  Some participants found using the device as a novelty:  
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“To be introduced to this kind of device is a thrill in itself, of course it is!” and “Well, 
it showed was that the therapy was in the 21st century as opposed to the 19th 
century!” (P3) 
P4 felt that having computer games or virtual reality technology would help to stimulate 
stroke patients both cognitively and physically: 
“Both would be good for you. [...] And at the same time your brain’s getting 
stimulated with the games [...]and then virtual reality is using your arms to pick up, 
to pretend you’re picking up things. So, in both ways… it’s helping you in both 
ways.” (P4) 
Participants also made general comments about ReachMAN itself. They did not report any 
problems with understanding the graphics and following the desired movements, but the 
sensitivity of the graphical feedback from the finger and wrist movements was confusing 
for one of the participants: 
“The other motions were not nearly so clear as to whether you had scored or 
whether you hadn’t scored[…] I think they need some more work them to make 
them more precise. […] So you can tell, what is the result of your effort – visually 
tell”. (P3) 
The participants were generally positive about incorporating computer games into the 
robot. Computer games were suggested as a means to challenge and engage stroke 
patients: 
“a good idea, probably quite a good idea, that you could challenge yourself a bit 
more on it. […] I think that if you were winning something you would probably want 
to keep on doing it.” (P1) 
The older participant expressed they were happy with the current robot and liked it 
simplicity 
“Ah, no I mean you just want the basic, the most basic functions to help exercise 
the hand endlessly , like the robot [...] in the right and proper manner to get it back 
to life.”(p2) 
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While the younger participants would have been happy for the machine to have been more 
‘high tech’  
“There could be a bit more to look at, a bit more to be, you know, even could 
maybe possibly use creatures, like little creatures running around and trying to get 
them.  You know, stuff like that... make it a bit more high tech “(p4) 
7.4.2 IMPACT ON SYMPTOMS AND MOVEMENT 
Participants reported a variety of impacts on their arm symptoms and arm movement with 
using the robot. These are grouped into subthemes: pain, physical and functional gains, 
confidence, enjoyment. 
PAIN 
Although only two participants (P5 and P6) spoke about experiencing arm pain as a result 
of using the robot, in one participant his experience of pain was such that it prevented him 
from continuing to use ReachMAN. Both of these participants had significant expressive 
language impairments, and could only express their experience in response to closed 
questions. 
BS: I think I understand but [P5: Yeah] I’m going to say it again [P5: Yeah] to 
check with you, I don’t want to pick things up wrong from you so…Once you took 
your hand out of the robot, having used it, it would be stiff and painful?  
 P5: Yes. Yeah.   
P5 directly attributed his arm pain to the robot, as explained by P6's carer: 
“he wasn’t over keen on it because it caused a pain in his shoulder [...] But since 
he’s not been doing it, he’s got a lot better, so it obviously was aggravating what 
was there” (C6) 
However other participants also discussed pain that they had in their arms and expressed 
that felt that the using the robot eased pain and stiffness they were experiencing: 
“My fingers were stiff at the beginning.  I found it hard to press with my finger.  
Gradually I found it easier...stiffness and pain got easier”   (P7) 
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PHYSICAL GAIN 
In contrast to the pain experienced by two of the participants, the remaining six 
participants clearly articulated the gains and benefits they obtained from using the robot. 
Positive language was used to describe this. The participants spoke about improved arm 
movement and better ability to carry out different functional tasks following using the robot, 
in particular, improvements in grip strength and the ability to pick up objects:  
“it was after using it that I was able to start picking up bottles and things […] Also 
when I first used it I moved my… started to move my… arm around a lot… and grip 
which I couldn’t do before.” (P1) 
Another subject decribed that improved hand movement resulted in better performance of 
activities such as, holding a cup and opening a door: 
“Yes my hand is much better... I can hold papers, book, a  cup and it is easier to 
open doors” (p7) 
 
Furthermore, P4 felt that the robot helped to relax his hand:  
 “It’s made my hand more relaxed and made my hand work more.” 
Improved physical appearance was also mentioned by the participants as a benefit of 
using the robot. 
 C3 mentioned how the robot “stops that awful claw-like arrangement, that you’re stuck 
with after a stroke” and P2 describes how her arm “not only felt stronger, it looked 
stronger.”  
CONFIDENCE 
A number of participants spoke about how physical improvements in their UL led to 
improved confidence. P1 described how improved UL function enhanced her ability to 
cope with having a stroke:  
“I think, I think that when you’ve had a stroke, you just don’t know how much…all 
the problems are...Ahm… and what I found was that this, the more I can do with 
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this hand, because it will hold things…the more, the more it makes you feel more 
confident in actually managing your stroke.” 
P3 describes how this confidence is directly related to the effectiveness of the intervention:  
“You really gain a great deal of confidence in some piece of kit or some exercises if 
they actually do make a difference [...] but if there is no sign of that, then it will 
quickly… confidence will fall.”  
ENJOYMENT: 
The participants spoke about the enjoyment or pleasure they got from using the robot. P2, 
in particular, was very vocal about enjoying RMT and taking part in the research process: 
“Well, I…if, given the chance I’d have gone on it everyday. I really would, cos I 
enjoyed it. When I knew, you know, anticipation of knowing I was going down was 
great and I used to swank a bit really, you know. They’d say ‘are you gonna come 
and, you know, do this?’ and I’d say ‘Sorry, I’m going to help the… University about 
the, you know, about the robot arm’ [...] I was delighted to do it!”  
 
7.4.3 PROGRESS, CHALLENGE AND ENCOURAGEMENT 
An overriding theme used in almost every interview was participants speaking about their 
progress and the encouragement they took from reflecting on their development and rising 
to the challenge of the robot. These concepts were inextricably linked in the participants' 
dialogue and are therefore combined here to form one theme.  
MAKING PROGRESS 
Making progress in their recovery was a common theme expressed by the participants. 
Progress was expressed as a positive and pressing concept: “always urgent to make 
progress” (C3) and “anything that’s gonna help progress then is good” (C6). Lack of 
progress was experienced as disappointment and self blame to some extent, as evidenced 
in these statements by P3:  
“I’m just disappointed that I… with myself that I didn’t make greater progress.”  
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“But of course that doesn’t quite work out like that… And the great thing is not 
necessarily to blame the  robot, is you blame yourself or blame the illness or 
whatever it is.” 
The expectation that the robot could help progression of UL recovery was described along 
a continuum from hope to certainty. Comments from P3 and C3 depict this range of 
opinion: 
“Well I hoped that it would [help]. Confident, one can’t really say that, because you 
just don’t know, you haven’t a clue… but you could lay a hope, that it was certainly 
going to contribute.” (P3) 
“It was obvious, it was obvious that it was something that would help! [...] I mean, 
not tomorrow, but, you know it would start the process of helping, yeah.” (C3) 
MONITORING PROGRESS 
The robot was not seen as encouraging in itself: 
 “I can’t really say how much it either encouraged me or discouraged me. It didn’t 
do either really.” (P3) 
Instead it was the feedback from the robot that allowed the participants to monitor their 
progress, that was found to be encouraging. P3 explains how the robot was sensitive 
enough to perceive movement that a therapist may not be able to detect: 
“it measured some movement in the muscles which was not otherwise evident in 
terms of ‘here’s your hand’, and it didn’t shift one iota. But the fact is, the robot 
measured that it was trying [...] and that was encouraging.” 
The participants described monitoring their progress as they advanced through the 
difficulty levels and achieved better scores on the robot:   
“Yeah. I’ve progressed…I can tell I’ve progressed cos I started on level one and now I’m 
on level eight[...] I’m at 100% on level eight…So, you know, that’s progress!” (P4) 
They described how achieving this progress was experienced as encouraging:  
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“And when you’d sorta mastered that one, and it was, you had high numbers again. 
You know, you feel quite proud of yourself, you know, it lifts, lifts your spirit.” (P2) 
CHALLENGE:  
Progressing through the difficulty levels gave the participants something to aim for and 
encouraged them to continue to challenge themselves: 
“When he puts it up a notch and it goes from 1 to 2 or up to 7 or 8, I think it was in 
this, Ahm, that was a clear distinction between one level and the next, and that was 
jolly good. Cos it gave you something to aim at, once you got going on it, but you 
had to get going on it. [...] so that was well designed.” (P3) 
The ability to monitor their progress and the challenge to constantly improve their scores 
was seen as an element of competition: 
“No. You could see it. It was visual. The feedback that you were getting was there, 
for you to see [BS:Yeah] itself you know. It couldn’t have added any more to it. 
[BS:Mmhmm]And ahm.. no that was very satisfying  what you could see on 
the screen. You could see you were progressing, and maybe beating the computer 
a little bit sometimes! It was like a little bit of a competition going on!” 
One participant (P4) had progressed to the most difficult level and felt that the robot no 
longer challenged him sufficiently. He wanted to add extra levels:  
“Probably four or five weeks I’ve been on here and I’ve hit level 8 and got the 100% 
and now […] I said, 'what’s the next level?' He said 'there’s not a next level'. So I 
was like, well I’ve hit the challenge. [...] So, 'what happens now then?'” 
 
7.4.4 FATIGUE 
The issue of fatigue frequently arose during the interviews, with all participants and carers 
mentioning this with relation to using the device.  The participants discussed the mental 
and physical effort required for rehabilitation and the tiredness they felt as a result. The 
participants spontaneously described the robot as a device that required both cognitive 
and physical effort: 
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“You really have to use your brain. You have to think about it. It’s a two-sided thing 
this really. You really do have to use your thinking and you do have to use your 
own arm.” (P2)  
The tiredness described by the participants was both physical and mental. P3 illustrated 
how this fatigue was an unexpected feature of stroke rehabilitation:  
“what one doesn’t realize for a stroke situation, what one doesn’t realize, is how 
much effort you need to put into the whole process of working on rehabilitation and 
how tiring that is. And it’s not just physical tiring; it's mental tiring, as much as 
physical tiring.” 
Tiredness impacted on how long the participants were able to use the robot for in one 
session. P4 explained that using the robot for a half an hour session was too long due to 
physical fatigue: 
“You’d be tired, you’d be physically shattered by the end of it. I’d still say that, and 
I’m getting better quicker, quick and I’m finding it tired [...] and I’m only young.”  
He suggested that 10 or 15 minutes was the optimal length time to use the robot for in one 
session. C3 described the general fatigue in the acute period following stroke and 
suggested gradually building up the frequency to assist with fatigue management: 
“I think, once a day, certainly when you begin, because you’re so tired […] but 
maybe, you know, when you’re getting fitter, and ahm more into your physiotherapy 
and better, then morning and afternoon would be even better.”  
P1 described her difficulty maintaining concentration whilst using the robot and how she 
quickly she got distracted when she was tired:  
“I think that after a while I used to start… one is I got distracted, so if I got 
distracted I didn’t always follow [...] what was happening. The other thing is, is that I 
found sometimes after a while just looking at the, the program itself [… ] I started to 
get a bit sleepy or started to get a bit distracted and starting, starting to close my 
eyes… when I was watching it.”  
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Only one participant wanted to use the robot for longer periods than prescribed. P2 
recalled being on the robot for up to an hour. Tiredness was not an issue for her, she was 
not concerned about  fatigue, unlike her therapists: 
 “They worried more about me getting tired than I did [...] I was enjoying it too 
much!”  
The two carers also commented how tired their family member appeared to be after using 
the robot: 
 “his arm tired quickly,... he was so tired... couldn’t use the machine for long” (C3) 
7.4.5 PRACTICAL USE OF THE ROBOT 
INDEPENDENT USE 
The  participants' express a  desire to carry out using the  robotic device on their own 
outside therapy hours and they barriers they identified to being able to do it. The 
participants expressed frustration at the lack of opportunities available to continue upper 
limb therapy outside of structured therapy time. They believed that the robot could provide 
this type of therapy: 
“One of the frustrating things about the hospital, even at Queen Square, we always 
thought, some of us, was that you couldn’t do things at the weekend! […] Saturday 
and Sunday was wasted! Or very largely wasted. There were some things that 
were set up ‘specially […] But for, for the most part, it was wasted time, you could 
have been doing something like this for example.” (P3) 
They spoke more specifically of their frustration at the fact that they could not use the robot 
independently:  
“that’s what irritates me, that I can’t use it when I want. [...] So I have to, it 
frustrates me cos it should be in the corner of the gym where you go in there and 
do it all yourself, put your arm in there and then it’d be good.” (P7) 
 The main barrier to independent use of the robot was that the participants were not able 
to set themselves up in the robot:  
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“One of the problems is that you can only do it whilst you’ve got people with you, 
when you’ve got the technician and somebody with you.” (P1).  
Problems with the physical hand-robot interface and the complexity of the computer 
interface were identified as the main issues. The difficulty of getting a weak arm positioned 
into the robot was described by the participants and they suggested that the link between 
the hand and the robot could be redesigned to make this easier: 
“I suppose if you had, if you actually had…ahm. Sort of a, sort of a stick or 
something like that that you could position your hand onto…then that would be, 
that would be possible. You’d need someone, or someone who had one- functional 
arms, in order to set it up.” (P8) 
P4 did not believe that he had the computer skills to navigate the software used to run the 
robot: 
“ you need to set up and it looks very complicated to set up and you need them to 
do it”  
He suggested that a touch screen interface, which would automatically load the robot 
computer program, would make it simpler and more accessible to patients:  
“You’d go in there, touch the screen, touch the screen, to work it out, so it does it 
all there for you” (P4) 
 
 
7.6 DISCUSSION  
The objectives of this study were to understand participants’ experiences of using the 
ReachMan device, and using a robotic device as part of their arm rehabilitation, and to 
gain greater insight as to how the system might be improved in the future 
The interviews found that participants expressed generally that they enjoyed using the 
robotic device and were mostly very positive about using the device, provided that it did 
not cause pain or stiffness (one participant stopped using ReachMan due to shoulder 
pain). With the exception of this one participant, all the others attributed improvement in 
231 
 
their arm movements with the use of the robot and the primary focus in all was 
improvement. These findings support previous research in that the majority of stroke 
patients are positively disposed to using robotics for upper limb rehabilitation 
162;195;224;216;226;134;
 
225
. The participants were initially cautious about the robot and reported 
needing to get used to it. In previous studies, therapists cited safety issues and 
appearance as a concern 224;231;134.  None of the participants in this study reported 
concerns about safety. Neither did appearance of the robot itself emerge as a theme, with 
participants expressing more concern with the effectiveness and usability of the device.  
7.6.1 PERCEIVED BENEFITS OF USING THE ROBOT 
A principal theme of the interviews was the positive language used by the participants 
when describing their thoughts of using the robotic device. They described both physical 
and psychosocial gains arising from using the machine. Participants reported improved 
confidence, enjoyment, better appearance of the hand and improved performance in 
functional activities. Prior research studies have also shown that stroke patients find 
robotics helpful and beneficial, and are content with the results from using robotic devices 
but do not expand on what aspects of the robot patients find beneficial. The participants in 
Coote and Stokes(2003)224mention improved stiffness and ability to perform activities but 
further detail is not provided. Participants questioned in study by Hughes et al (2010) 
227also describe improvements in arm and hand function.  
This interview study design enabled participants to expand on the gains they perceived 
they had made from using the device. They described that improved hand movement 
resulted in better performance of activities such as picking up a bottle, holding a cup and 
opening a door. Achievement of these specific markers of independence signifies a return 
to valued activities, which has been postulated to be key to stroke patients’ definition of 
recovery 132. The participants attributed their improved functional ability directly to using 
the robot.  
This perceived gain however was not captured in the clinical rated objective outcome 
measures, reported in Chapter Six, although a patient reported measure (the ABILHAND) 
did show statically significant change.  Results from the clinical study did show that trends 
suggesting arm improvement with the clinical measures. The finding of perceived 
improvement in function in their arms, suggested the value in using interviews and 
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questioning participants, as this strengthens the findings  and trends suggested  by the 
more general outcome measures used.   
It must however be noted that the proportion of motor recovery attributable to using 
ReachMAN in these participants cannot be quantified to the use of the robot alone, as 
participants were also simultaneously engaged in intensive MDT rehabilitation and were 
also in the subacute post-stroke period where the most spontaneous recovery occurs 109.  
  
Participants reported improved confidence which may indicate better self-efficacy. This is 
the confidence in one’s ability to carry out a behavior or task 343.  Improved self-efficacy 
has been linked to enhanced participation in rehabilitation, leading to better functional 
outcome 344. 
Participants expressed enjoyment in using the robotic device, however part of the 
enjoyment experienced appeared to derive from participating in the research project. One 
participant in particular was very proud of her contribution and attained a certain social 
status on the ward by being involved in the project (P2). The same enthusiasm may not be 
shown if using a robotic device is introduced as a standard therapeutic adjunct, which may 
adversely affect motivation to use it. Therefore, it is possible that an element of the 
Hawthorne effect occurred, where the participants are merely reporting more benefit due 
to being involved in the study.  
 
7.6.2 PAIN AND STIFFNESS 
In previous studies, the effect of using robotic device on patient’s experience of pain and 
stiffness was minimal. Coote and Stokes (2003) 224reported no effect of using GENTLE/s 
device on pre-existing pain in two patients and Colombo et al (2007) 216reported low 
scores on the pain subscale of the IMI which indicates no exacerbation of pain. In contrast, 
two out of the eight stroke patients in this study (P5 and P6) reported experiencing pain, 
which one (P5) related directly to the use of the robot and this participant ceased using the 
robot due to pain. Hale et al (2012)345 also found similar reports of pain from subjects using 
a virtual reality device for upper limb rehabilitation. 
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The development of pain with the use of Reachman is a significant issue and one that was 
fully explored with the participant in question (as discussed in Chapter Six). Coskun et al 
(2013)346 highlighted the complexities of diagnosising the cause of shoulder pain post 
stroke, with many potential reasons which could cause this, including abnormal patterns of 
muscle activation. The fact that this participant did express pain that was directly attributed 
to use of the machine, highlights the need to be vigilant when participants use ReachMAN. 
This also reinforces the need that arm movements, with future use of the machine should 
be introduced with a gradual build up of duration and intensity. The actual movements that 
occur in the arm during the use of the robot should also be carefully examined (Both these 
strategies were employed in the clinical trial and in light of the pain experienced show that 
this would need to be continued in the future). 
 
7.6.3 TIREDNESS AND ITS IMPLICATION FOR TREATMENT PROTOCOL  
This study found that fatigue was a major issue for the participants and this impacted on 
their interaction with the robotic aid. The robotic sessions were scheduled to be as long as 
the participant wished to use the device. Most participants found robotic exercise to be 
both mentally and physically tiring and 20 minutes was seen to be the maximum duration 
that they could use the machine for. Frequent shorter sessions were preferred by the 
participants. To date, clinical trials of robotics have used intervention protocols of 30-60 
minutes per day 205;206 171 However, these trials were carried out in a chronic stroke 
population, with patients more than six months after stroke and already discharged from 
inpatient rehabilitation. The participants in this study commenced using the robot within six 
weeks of their stroke and were concurrently engaged in an intensive, multidisciplinary 
inpatient neurorehabilitation program. Doornebosch et al (2007)226 reported similar 
findings, where sub-acute patients used the robot in passive mode for 20 minutes or less if 
the therapist noticed that the patient appeared tired. The intensity of the rehabilitation 
combined with post-stroke fatigue and reduced endurance may have been contributing 
factors as to why participants were only able to tolerate using the robot for short periods. 
Fatigue is a very important factor to consider when developing a therapeutic intervention 
for acute stroke patients and further work is needed to investigate this further. However, 
the findings of these interviews suggest that frequent, short sessions are recommended. 
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This area and its implications for all phases of the research study will be discussed in 
Chapter Nine.  
 
7.6.4 INDEPENDENT USE 
The participant’s desire to use the robotic aid independently was a strong theme 
throughout. The participants displayed frustration at not being able to do this 
independently due to the arm attachment and computer software. Participants were unable 
to switch on the programme independently to use the machine. The main physical barrier 
to independent use was the inability to place the paretic arm into the robot arm support 
independently. Previous studies have also reported difficulty with independent arm 
attachment 226 224 134. In light of the participants’ desire to use Reachman independently, 
this represents a need for the machine to be redesigned. One participant suggested a 
touch-screen computer interface to facilitate the patients to initiate and control the device 
during a session. This design feature was successfully used in the ACRE 2 device 226 and 
could be considered for the next model of the ReachMAN device. The ultimate goal of 
rehabilitation robotics is to facilitate supplementary independent practice210 ,requiring 
assistance to set up the robotic aid was disappointing to the participants and limited the 
ability to perform this independent practice. 
 
7.6.5 USE OF TECHNOLOGY IN REHABILITATION 
All patients were generally positive about using a novel device as part of their upper limb 
rehabilitation. However, studies of technology use, attitudes, and abilities do show that 
older adults are less likely to use technology ( as discussed in chapter one, a larger 
percentage of stroke patients are over 65) compared with younger adults and can be 
fearful of using technology347.The older participants in the interviews expressed no 
problem with using the machine after their initial impressions and were happy with the 
simple graphics used in the ReachMAN program. The younger participants however, did 
comment that they would have like these graphics to have been more complicated. These 
are important areas to consider when looking at any design changes to the device. Further 
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piloting perhaps with some more complex graphics and games that retain their simplicity 
would assist in bridging this mismatch between the ages.   
 
7.6.6 IMPLICATIONS OF THESE RESULTS 
 
This is one of the first studies to have captured what is important to people with stroke 
when using a robotic device for upper limb rehabilitation. The study has also encapsulated 
how they felt their movement was changing in ways meaningful to them as individuals, and 
how the ReachMan device met their requirements. 
The wider implications of these results (in combination with the previous literature) are that 
the use of robotic devices in general is acceptable and enjoyable, but that patients would 
like future rehabilitation robot systems to be designed that could be used at home 
independently. Participants wished to use the machine for only short periods throughout 
the day 
 
7.7 WEAKNESSES AND LIMITATIONS IN THE STUDY 
The generalisability of the study is limited by the small participant population. The interview 
data did not reach a level of saturation, as each consecutive interview continued to raise 
new issues. A larger, more diverse sample population would be required to address this.  
The independent interviewer (BS) by her own admission was inexperienced and this was 
found to be apparent in the interview data. Some opportunities to probe for clarification or 
a further example were missed, and occasionally there was insufficient use of pauses to 
encourage the participant to expand on their previous comments 242 .However, this 
improved as the researcher became more comfortable in her interviewer role.  
It is acknowledged that some element of researcher influence is unavoidable in the 
interviews. However each interview was looked at by at least two (sometimes three) 
different people and were critically examined and all attempt to minimise the impact of 
biases, preconceptions and influences during data collection and analysis was made. The 
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interviewer was introduced to the participants as a physiotherapist, which may have 
opened the possibility of a social desirability bias whereby the participants may have 
presented a more positive experience of the robotic device to please the researcher.  
It is well acknowledged that interviews only give access to what people say, not what they 
do 334. In line with the interpretivist approach, no attempt was made to verify the 
participants comments to achieve a ‘true story’334.  
It is acknowledged that using a semi-structured interview rather than an open in-depth 
interview may have resulted in missing some of the broader experiences and perceptions 
participants had of using the robotic device. Furthermore participant’s general experiences 
of having a stroke, having an UL impairment, participating in inpatient neurorehabilitation 
and expectations of rehabilitation and recovery following discharge were also missed.  
7.7.1 TIMING OF INTERVIEWS: 
Interviews were performed immediately prior to discharge in most cases, and this 
functioned to minimise recall bias, and allowed the experience of using the robot to be still 
fresh in the participants’ minds. However, this time of transition is often fraught with 
anxiety, anticipation and worry as the stroke patients finish inpatient rehabilitation348 and 
return home with significant functional limitations. This may have impacted on the 
participant’s engagement with the research process.  
 
 
7.8 CONCLUSION 
This chapter explores the qualitative experiences of eight participants and two carers of 
using the ReachMAN robotic device. The qualitative methodology used semi-structured 
interviews which were analysised using Framework Analysis. The interviews were 
performed in parallel with the quantitative study reported in Chapter Six. The main findings 
were that using the device was a positive experience, which participants enjoyed and they 
attributed physical gains in their arm function with its use, provided it does not cause pain. 
Crucially, participants found they could only use the device for short periods, as it was 
found to both be mentally and physically taxing. To avoid this participants suggested that 
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use of the device should be short and frequent. The opportunity to practice independently 
was important to the participants.  
 
7.9 SUMMARY 
This chapter has discussed the qualitative research study that was performed to 
investigate participants perceptions of using the robotic device.  The following chapter 
details a psychometric analysis of two of the outcome measures used in the study  
238 
 
CHAPTER 8: PSYCHOMETRIC ANALYSIS OF THE MEASURES USED IN THE 
STUDY 
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8.1 INTRODUCTION 
Chapters five, six and seven have detailed the research studies that were carried out to 
evaluation the use of robotic devices in upper limb rehabilitation. This chapter will discuss 
a comprehensive psychometric analysis that was completed on two of the outcome 
measures used in the studies, using the results from the studies performed. 
 
8.2 BACKGROUND 
There is a growing consensus that the conclusions made from neurologic studies are 
partially dependent on the rating scale used 259 258. Rating scales must therefore be 
clinically useful and scientifically sound. Clinical usefulness has been described as the 
successful incorporation of a measure into clinical practice and its appropriateness to the 
study sample245. Scientific soundness refers to the demonstration of reliable, valid and 
responsive measurement of the outcome of interest.245 In regard to upper limb recovery 
post stroke, Woodbury et al (2009)280 comment that there is a real need to ascertain 
whether assessment tools commonly used in research are accurately quantifying 
impairment and characterizing recovery. 
A means to achieve this scientific soundness is to perform thorough psychometric 
evaluations of outcome measures and this is endorsed by  FDA  248, EMEA349 guidelines 
and MRC 237 framework. Work by Hobart et al (2009) 259 and others 280 argue that use of 
traditional psychometric analysis alone to evaluate outcome scales is insufficient and can 
leed to weaknesses in scales being overlooked. The use of newer psychometric analysis 
(such as Rasch) can highlight strength and weakness of scales, which could otherwise go 
unseen. 245  
This Chapter will therefore describe the psychometric analysis, using new and traditional 
methods, that was carried out on the results, from two of the scales that were used in the 
studies- a patient reported outcome measure- DASH , and a clinician rated scale FMA 
The use of Patient-reported outcomes (PRO) measures in stroke research is a relatively 
new development.254 Patient reported outcomes are patient-derived questionnaires that 
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measure any aspect of a patient’s health status ranging from symptoms to other complex 
concepts such as quality of life, which is a multifaceted construct involving physical, 
psychological, and social components. 350 Although there is a growing call to include 
participation measures in stroke research, as an important component of disability, few 
measures look at this aspect254. Specifically, few PRO measures scores have been found 
for the upper limb post stroke351.  
The Disabilities of the Arm, Shoulder and Hand (DASH) is a 30 item scale which measures 
everyday active function in the arm and is a 30-item, self-report rating scale developed for 
use in orthopaedic populations.300 It has been described as being the most widely used 
upper limb rating scale.352 It has not been widely used in stroke populations214;351 .However 
due to the lack of PRO measures it was felt to be useful to evaluate the psychometric 
properties of the DASH in people with stroke to determine its suitability as an outcome 
measure in this population. 
The Fugl- Meyer Assessment Score (upper limb section)272 is the most widely used clinical 
outcome score of post stroke arm impairment280. It is widely used in stroke research to 
evaluate the success of novel upper limb interventions where it has been used as the 
primary outcome measure . The measure has also been extensively studied to examine its 
psychometric properties and it is often referred to as a “gold standard” measure with which 
other upper limb measures are compared to.  
Newer (“modern”) psychometric analysis methods (such as using Rasch analysis) have 
been performed on the FMA upper limb score to examine the dimensionality and construct 
validity of the scale. 280  However studies to compare and contrast traditional and newer 
psychometric analysis methods to evaluate the measure have not been performed. 
 The FMA measure consists of 33 items which are scored on a 3 point rating scale: 
0=unable to perform, 1= partial ability to perform and 2= near normal ability to perform. 
The scores are then summed to produce a score of 66.  
 
8.3 TRADITIONAL PSYCHOMETRIC ANALYSES 
Traditional psychometric analysis is based upon correlational or descriptive analyses to 
evaluate scaling assumptions, reliability and validity. Usual traditional psychometric 
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analyses examines five psychometric properties353:  data quality, scaling assumptions, 
acceptability, reliability (internal consistency), convergent and discriminant construct 
validity. These terms will now be defined: 
 
Data quality 
 This is the extent to which an instrument can be used successfully in a clinical 
setting354 . In the analysis used in this thesis, this was determined to be high if items 
had low missing data (<10%), and if a high percentage of scale scores were 
computable for each patient. 
Scaling assumptions  
This is the legitimacy to sum item scores without weighting or standardisation to 
generate a total score. In the psychometric analysis performed in this section the scores 
were examined by determining whether items in each scale had roughly similar 
response-option frequency distributions, equivalent mean and variances, and equivalent 
item-total correlations.353;354  
Acceptability 
 This is the targeting of a scale to a sample so that score distributions adequately 
represent the true distribution of health status in the sample 353;354 This was achieved by  
the scores being examined to determine that observed scores were well distributed, 
353;354
  mean scores were near the scale mid-point353;354 ,floor and ceiling effects were 
low, and skewness statistics ranged from -1 to +1. 353;354  
Validity  
Validity is an assessment of whether an instrument actually measures what it purports to 
measure. It can be broadly defined as the extent to which the instrument measures the 
concept it purports or is intended to measure355;356. In this analysis measures construct 
validity was examined. This is examining the relation between the measure and other 
measures or behaviours240;355This is performed using convergent and discriminant 
construct validity. 353;354 Correlations between scales were examined to determine the 
extent to which each instrument: 1) measures what it is supposed to measure (convergent 
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construct validity) and 2) does not measure what it is not designed to measure 
(discriminant construct validity).  
Reliability 
Reliability is an estimate of the reproducibility and internal consistency of an outcome 
measure356. A reliable measure is one which produces results that are accurate, 
consistent, stable over time, and reproducible. Internal consistency of a measure is usually 
evaluated when looking at the reliability of that measure 353;354 . This is the extent to which 
items comprising a scale measure the same concept – that is measure of the homogeneity 
of the scale. In this evaluation this was examined using Cronbach's alpha coefficient. 353;354  
It is recommended that alpha >0.80. 353;354 
“New” Psychometric analysis-Rasch Analysis 
Rasch analysis allows the transformation of ordinal data to interval data.  It assumes that 
the likelihood of any item being endorsed is based on item difficulty and person ability. 
Rasch analysis, therefore, is a probabilistic mathematic modelling technique used to 
assess properties of outcome measures. Where data are shown to accord with model 
expectations, the internal construct validity of the scale is supported, and a transformation 
of ordinal data to interval scaling is possible 258  This helps to improve the accuracy with 
which to measure differences between people and clinical change.  It has been argued 
that Rasch analysis has a greater potential to identify the merits of a rating scale than 
traditional psychometric methods258 . 
There is no agreed standard method to perform Rasch analysis. However Tennant and 
Conaghan (2007)357 outlined seven criteria with which a measure can be analysised 
against. This criteria has been used in studies investigated the psychometric properties of 
rating scales used in neurological populations 358 These criteria were therefore used in the 
analysis for this thesis. There are specifically  
1. Item response-threshold ordering. The threshold between two response options is the 
location, measured in logits, where the two options are equally likely. If correctly ordered, 
the threshold between response options 1 and 2 will occur at a more negative location 
than the threshold between options 2 and 3, for example. However, response options can 
be disordered, particularly for items with a higher number of response options, indicating 
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that the extra response options do not provide additional information about a person’s true 
location on the variable that the item represents. In such instances, Rasch analysis can be 
used to reduce the number of response options by combing two or more options into a 
single option. .  An example of this can be seen in the Functional Independence Measure. 
An item on this measure asks raters to rate whether an individual is able to manage their 
bladder .There is a rating of  50% dependence for assistance in bladder management, 
which is difficult to quantify. This can disorder the scoring and is best reduced to 0 
independent, 1 needs some help, dependent. 
2. Tests of fit to the model. This is the extent that observed data fits the Rasch model and 
this can be examined at both the scale and item level. At the scale level, summary item fit 
residuals are examined, which ideally should have a mean of zero and a standard 
deviation of 1 (a standard deviation of > 1.4 can indicate misfit at the individual item level), 
summary person fit residuals (where a high standard deviation can indicate individual 
participants who mistfit the model and thus severely reduce the fit of the model to the 
data), as well as the chi-square for the item-trait interaction, which should be non-
significant. At the item level, item fit residuals were examined, which should fall between ± 
2.5 (overly positive residuals indicate that responses to an item do not fit the Rasch model; 
overly negative residuals indicate that an item shares so much variance with other items in 
the scale that the item provides very little additional information, and so is redundant, and 
item chi-square values, which should be non-significant (p >.05, Bonferonni adjusted).  
To give an example to explain this clearer: Figure 8.1 illustrates the Rivermead mobility 
index. The ideal is that the Item response categories work in a logical manner to reflect a 
continuum of mobility i.e.- start with poor mobility, to gradually improve to good mobility via 
a series of steps (items) However, where a scale diverges from this, this is called a misfit. 
I.e ability to climb stairs does not necessary prevent someone being able to walk outdoors 
and these two items therefore misfitted. The stairs item could therefore be omitted from the 
scale. 
3. Differential item functioning. This examines the extent to which items functioned 
differently by gender, age, ethnicity, marital status, number of days since the stroke, 
clinical diagnoses, and walking status., For example, men and women use different 
language so in a ‘high stakes’ language test (for example one that allows entrance to 
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university) women will outperform men if the language tested is around clothes, food and 
colour, and men will outperform women if the language is centered round fast cars  
4. Item locations. The location on the Rasch continuum, measured in logits. Ideally, items 
will have locations that are evenly spaced over a wide range rather than being clustered at 
the same location. Also, ideally this range of item locations will adequately target the range 
of locations of the target population.  Often this doesn’t occur with change on an ordinal 
scale is ‘easier’ often in the mid point of the range.  Hobart et al 258 demonstrates this in 
their paper on the use of Rasch analysis. 
5. Reliability. The Person Separation Index (PSI) was used to assess reliability. This 
statistic can be considered equivalent to Cronbach’s alpha, with values ≥ .70 regarded as 
adequate. 
6. Local dependency. High standardised residual correlations (SRCs) between two items 
indicate that the responses to these items covary to a greater extent than predicted by the 
Rasch model. This can indicate the presence of local dependency, where the response to 
one item is dependent on the response to another item. SRCs > .3 can indicate local 
dependency among items For  example . Scales which measure mobility have items such 
as: A person can work 500m, 50m, 5 m. However, if you can walk 500m you can walk 50 
m and 5m so the answers to questions 2 and 3 are dependent on the answer to one. 
7. Unidimensionality. An assumption of the Rasch model is that the items of a scale form a 
unidimensional variable, in other words a single construct. Unidimensionality of the final 
scales was tested using paired t-tests to compare person scores from the two most 
divergent subsets of items 241. For this procedure, subsets were formed by selecting the 
items loading most positively and most negatively on the first factor extracted in a principle 
component analysis of residuals. If no more than 5% of t-tests are significant, or if more 
than 5% are significant but the lower confidence interval corresponds to less than 5%, the 
assumption of unidimensionality has not been violated. 
 
 
Figure 8.1: Rivemead Mobility Index 
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8.4 PROCEDURE 
The data from the DASH outcome measure and FMA measures from subjects in the first 
phase of the study (125 subjects), as described in detail in Chapter Five and from 
subjects recruited into the exploratory RCT (37 subjects)( described in Chapter Six) 
were used for the analysis. Work by Linacre (1994)359 suggests that a sample size of 
150 or more  will provide 99%  confidence of item calibration +/-0.5 logits when 
performing Rasch analysis. In order therefore to be able to produce best results (taking 
into account floor and ceiling effects on some of the subjects measures which can be left 
out of Rasch analysis.) Further data from patients who had been on rehabilitation units 
in the hospital were also included in the analysis (12 patients). Therefore the data from 
174 subjects was used for both the traditional psychometric analysis and Rasch 
analysis. 
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8.4.1 ANALYSIS 
Anaysis of the traditional psychometrics was performed using Statistical software 
package SPSS version 21.  Rasch analysis was conducted using RUMM 2030 software. 
Dr Afsane Riazi, (Senior Lecturer in Health Psychology, Royal Holloway, University of 
London) assisted in the analysis of the traditional psychometrics, and checking of the 
Rasch analysis.  Dr Trefor Aspden (Psychology, Royal Holloway, University of London) 
assisted in the Rasch analysis.   
 
8.5 RESULTS 
174 DASH and FMA scores were entered for Rasch analysis. The scores entered were 
baseline scores for all participants. Due to missing values on two data sets, analysis was 
performed on 172 subjects.  
The mean age of the stroke survivors were 62.6 years (SD 17.7), mean time after stroke 
was 3 weeks (SD 2.9), 41 % were women. Thirty–five percent of participants had 
suffered a Middle Cerebral Artery Stroke , with 15% having suffered haemorrhagic 
bleeds. 
 
8.5.1 DASH ANALYSIS  
TRADITIONAL PSYCHOMETRIC ANALYSIS OF THE DASH 
The results of traditional analysis mostly supported the DASH as a reliable and valid 
measure of upper limb function. Data quality was high (no missing data , meaning scale 
scores were computable for 100% of respondents). Scaling assumptions were satisfied 
(similar item mean scores, and roughly equivalent corrected item-total correlations). 
However scale-to-sample acceptability was moderate. Scale scores spanned the scale 
range and were not notably skewed. However mean scores at 36.0 were not near the 
scale mid-point, and ceiling effects were high.  The  internal consistency reliability of the 
score was found to be  high (Cronbach’s alpha =0.99) (Table 8.1 details the scores 
found on the analysis). 
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Tests of convergent and discriminant validity supported the validity of the DASH. 
Convergent and discriminant construct validity360 was determined by examining 
correlations between the DASH and other measures the ABILHAND, FMA, Barthel 
Index. It was hypothesized that correlations would be highest with the ABILHAND, 
(another patient reported outcome measure) and then the FMA . Low correlations were 
predicted for the DASH compared to the Barthel index (as this is a focal measure of 
functional recovery post stroke, this is described in more detail in Chapter Four). The 
direction, magnitude and pattern of correlations were consistent with predictions. As 
forecast, correlations were highest with the ABILHAND ( -.85), and then the FMA (-.78). 
Low correlations were seen for the DASH compared to the Barthel index (-.16). 
Table 8.1: Data quality, scaling assumptions, acceptability and reliability of 
DASH (N=172) 
 
DASH total 
DATA QUALITY  
 Item missing data % 0 
 Computable scale scores % 100 
  
SCALING ASSUMPTIONS  
 Item mean scores 1.58 -3.04 
 Item sd 0.79-1.61 
 Item total correlation 0.56-0.95 
  
ACCEPTABILITY  
 Scale range (possible) 0-100 
 Score range 0-88.3 
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DASH total 
 Mean score (sd) 36.0 (28.6) 
 Floor/ceiling, %  0/19.8 
 Skewness 0.008 
  
RELIABILITY  
 Alpha 0.99 
 Mean inter-item correlations 0.72 
 
RASCH ANALYSIS 
Item response-threshold ordering: The threshold between two response options is the 
location, measured in logits, where the two options are equally likely. Analysis found that 
three items had disordered response options (two pain questions 24 and 25, and a 
question regarding ability to write, Question 2), indicating that the proposed scoring 
function was not working as intended for these items. Respondents seemed to find 
difficulties in differentiating between moderate and severe response with regards to 
describing their pain.   
Tests of fit. The fit residual test of fit examines the response of each person to each item, 
and provides evidence that an item might discriminate between different levels of 
‘symptoms/ disability either more or less than is expected. The fit residual test found that of 
the 30 items in the questionnaire, 13 had fit residuals outside the recommended range (-
2.50 to +2.50). Seven of these items had prominent misfit: ‘prepare a meal’ (-3.792), 
‘performing heavy chores (-3.604), ‘garden’ (-4.111),’ make a bed’(-3.726), recreational 
activities: little effort’ (-4,066), ‘sexual activities’ (þ5.463) less capable’ (þ 
10.053(þ5.07)(Table 3) (item location is expressed in Rasch as (þ) 
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The chi square test of fit examines, for groups of people with similar total scores (class 
intervals), the magnitude of departure of the mean score for an item in each class interval 
from the mean value predicted by the model. This is the most general test of fit and 
provides a graphical counterpart (the ICC).Chi square probabilities for six items were 
significant (Table 8.3). Examinations of the graphical indictor of fit (ICC), suggested that 
the item which under-discriminated the most was writing (question 2). Therefore, patients’ 
responses to items were not consistent with those predicted by the Rasch model.  
Differential Item Functioning: No differential item functioning was found in regards to 
gender or age. 
Item locations: This is the location on the Rasch continuum, measured in logits. Ideally, 
items will have locations that are evenly spaced over a wide range rather than being 
clustered at the same location. Also, ideally this range of item locations will adequately 
target the range of locations of the target population. The item locations spread out (from -
1.44 to 2.93 logits) indicating that the DASH defined a reasonable continuum (Table 8.3). 
However examination of the item locations showed that items were not evenly spread 
along the continuuum (Figure 8.2), with a gap at the lower end of the continuuum , and two 
(pain questions 24 and 25) items at the extreme upper end of the continuum removed from 
the upper reach of person location.  
Reliability. Scale reliability was suggested by high Person Separation Indices (0. 958).This 
is comparable to Cronbach’s alpha 
 Local Dependency: Five pairs of items had residuals that were highly correlated (> 0.60), 
implying that a response to one influences the response to the other.  Four of these items 
appear sequentially in the scale. These pairs of items also had similar content: (questions 
7+8 , 7+11,18+ 19,24+ 25,25+ 26.) Therefore response bias and dependency is likely to 
be due to both an overlap of content between items as well as the item ordering.  
 Tests of unidimensionality: 54 (31.76%) of t-tests of person scores from the item subset 
comprising the most positively loading items with that comprising the most negatively 
loading items were significant at the p < .05 level. Further, the lower 95% confidence 
interval corresponded to 28.5% of t-tests significant at the p = .05 level. This demonstrated 
that the assumption of unidimensionality did not hold for this scale. This suggests that the 
DASH consists of more than one dimension. 
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8.5.2 THE FUGL- MEYER ASSESSMENT SCORE (UPPER LIMB SECTION) 
ANALYSIS 
 
TRADITIONAL PSYCHOMETRIC ANALYSES 
The results of traditional analysis mostly supported the FMA as a reliable and valid 
measure of upper limb function. Data quality was high (no missing data , meaning 
scale scores were computable for 100% of respondents). Scaling assumptions were 
satisfied (similar item mean scores,). However there was a wide range in item-total 
correlations (an equivalent correlation demonstrates best scaling). Scale-to-sample 
acceptability was moderate. Scale scores spanned the scale range and were not 
notably skewed and mean scores at 69 were near the scale mid-point. However ceiling 
effects were high, (showing that almost 35% of subjects had near normal ability for all 
items, and achieving the highest score possible.) The internal consistency reliability of 
the score was found to be high (Cronbach’s alpha (0.99). (Table 8.2 details the scores 
found on the analysis). 
Tests of convergent and discriminant validity supported the validity of the FMA. 
Convergent and discriminant construct validity360 was determined by examining 
correlations between the FMA and other measures the ABILHAND, DASH, Barthel 
Index. It was hypothesized that correlations would be highest with the ABILHAND, 
(although a patient reported outcome measure, is a measure of upper limb activity) 
and then the DASH . Low correlations were predicted for the FMA compared to the 
Barthel index. The direction, magnitude and pattern of correlations were consistent 
with predictions. As forecast, correlations were highest with the ABILHAND (.78), and 
then the DASH (.72). Low correlations were seen for the FMA compared to the Barthel 
index (-26). 
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Table 8.2: Data quality, scaling assumptions, acceptability and reliability of 
FMA (N=172) 
 
FMA total 
DATA QUALITY  
 Item missing data % 0 
 Computable scale scores % 100 
  
SCALING ASSUMPTIONS  
 Item mean scores 1.08-1.97 
 Item sd 0.21-0.84 
 Item total correlation 0.21-0.95 
  
ACCEPTABILITY  
 Scale range (possible) 0-100 
 Score range 0-94 
 Mean score (sd) 69(32.6) 
 Floor/ceiling, %  0/34.9% 
 Skewness -1.082 
  
RELIABILITY  
 Alpha 0.99 
 Mean inter-item correlations 0.71 
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RASCH ANALYSIS 
Item response-threshold ordering: The threshold between two response options is the 
location, measured in logits, where the two options are equally likely. However, response 
options can be disordered, particularly for items with a higher number of response options, 
indicating that the extra response options do not provide additional information about a 
person’s true location on the variable that the item represents. For items 1.1.1/1.1.2 
thresholds were disordered such that at no point on the ability continuum was option 1 the 
most probable response option. For a further item 1.6 (another reflex item) whilst 
thresholds were ordered the response pattern was similar to item 1.1.1/1.1.2 such that 
response 1 was only the most probable option for a narrow ability range (as seen in 
diagram 1: Category Probability Curve).This suggests that for these three items a 
dichotomous  response format would be more appropriate.   
Tests of fit: The fit residual test of fit examines the response of each person to each item, 
and provides evidence that an item might discriminate between different levels of 
‘symptoms/ disability. 8 had fit residuals outside the recommended range (-2.50 to +2.50). 
four of these items had prominent misfit: Tremor (4.360), wrist flexion/extension-elbow 90◦ 
(3.516), volitional movement mixing dynamic flexor and extensor strategies, forearm 
pronation (3.244), wrist stability-elbow 90◦ (3.155)(Table 3) 
The chi square test of fit examines, for groups of people with similar total scores (class 
intervals), the magnitude of departure of the mean score for an item in each class interval 
from the mean value predicted by the model. This is the most general test of fit and 
provides a graphical counterpart (the ICC).  
Chi square probabilities for five items were significant (Table 8.4). Examinations of the 
graphical indictor of fit (ICC), suggested that the item which under-discriminated the most 
were the reflex items (1.1.1 and 1.1.2 ). Therefore, patients’ responses to items were not 
consistent with those predicted by the Rasch model.  
Differential Item Functioning (DIF): No items demonstrated DIF by gender or age. 
Item locations: This is the location on the Rasch continuum, measured in logits. Ideally, 
items will have locations that are evenly spaced over a wide range rather than being 
clustered at the same location Also, ideally this range of item locations will adequately 
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target the range of locations of the target population. The Item locations were spread over 
a wide range (-4.473 to 3.071) (Shown in Table 8.4) and targeted the range of person 
abilities with the exception of a number of individuals who demonstrated no impairment 
(who demonstrated full ability). 
Reliability. Scale reliability was suggested by high Person Separation Indices (0.96).This is 
comparable to Cronbach’s alpha 
Local Dependency: The ability on one type of hand grasp was seen to be highly correlated 
with the ability on other types of hand grasp. This was also seen in the wrist items There 
was dependency amongst different shoulder items such that performing some shoulder 
movements were dependent on being able to perform other shoulder movements. As 
these shoulder movements may represent different points along the recovery/ability 
continuum it may be preferable not to delete dependent items. Instead a testlet could be 
formed out of shoulder items, to provide an item representing the range of shoulder 
movement ability. 
Tests of unidimensionality:18 (10.59%) of t-tests of person scores from the item subset 
comprising the most positively loading items with that comprising the most negatively 
loading items were significant at the p < .05 level. Further, the lower 95% confidence 
interval corresponded to 7.3% of t-tests significant at the p = .05 level. This demonstrated 
that the assumption of unidimensionality did not hold for this scale. This suggests that the 
FMA score consists of more than one dimension. 
 
8.6 DISCUSSION 
The aim of this chapter was to look at the measurement properties of the upper limb 
scales used in the study. In particular this was performed in detail for two of the 
measurements used- DASH a patient reported outcome measure and a clinician reported 
measure –the FMA upper limb scale.  
This detailed analysis was performed in line with the MRC framework, and in keeping with 
FDA 248 and EMEA guidelines 349. These guidelines discuss that to formally evaluate an 
intervention it is essential that the outcome measures used capture the benefits of that 
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intervention. Furthermore, rigours testing of scales allows identification of which outcome 
is most sensitive to change.  
This discussion will now focus on the results from the analysis of the two measures 
separately. 
 
8.6.1 DASH  
Traditional psychometric evaluation mostly suggested that the DASH was a robust 
measure, although marked ceiling effects were found.  Rasch analysis found a number of 
problems with the scoring and items in the DASH. Each of these analyses will now be 
discussed separately: 
More than the recommended 20% 353 of participants (34.9% ) were found to rate that their 
upper limb did not cause them marked difficulties with use of the DASH score on 
traditional psychometric analysis. Previous literature361  looking at the scaling qualities of 
the DASH as an upper limb outcome score in the Multiple Sclerosis population did not find 
this marked ceiling effect (Cano et al (2011)361 found no problems with the DASH score 
when using traditional psychometric analysis.)  It is difficult to evaluate why these different 
results were found. This may be due to the different sample populations used in the two 
analyses (the analysis described in this chapter and the analysis described in Cano et al 
(2011)361, which analysis the DASH in people with MS). As far as the author of this thesis 
is aware, the DASH has not been previously evaluated in a stroke population. Further 
analysis of this measure in stroke is therefore required to see whether the high ceiling 
effects noted in this current analysis is sample specific 
A high ceiling effect was also found when performing psychometric analysis on the 
measures from the results of the recruitment study, detailed in Chapter 5.  A possible 
explanation for the problems seen in targeting of the measure was the high proportion of 
participants recruited into the first part of the study that had no upper limb deficit. This also 
raises the need to perform further analysis of the DASH in acute/subacute people with 
stroke to reveal whether this effect is seen in other samples. 
Rasch analysis of the DASH also illustrated some other problems with the measure. These 
will now be discussed. Rasch analysis showed that several items (pain questions 24 and 
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25 and writing question 2) had a high amount of variance not explained by the rest of the 
scale and that several items were redundant, in that a very high proportion of their 
variance was explained by the rest of the items in the scale. This means that these 
questions could be left out of the score.   
Previous studies using the DASH in a sample of people with MS found that four categories 
may have worked better than five259. In contrast to this previous work361 the five response 
options worked well in this study for most questions. The exception to this was seen in 
regard to the pain questions where floor effects were observed with the majority of 
respondents choosing the first two response categories (no or mild pain). These floor 
effects in the pain items may be specific to the population of respondents in the present 
study, all of whom were very recently post stroke (mostly six weeks after stroke). It would 
therefore be important to repeat these analyses in this patient group and other stroke 
groups to determine whether the findings of this study are generalisable. 
A high number of items were found to ‘misfit’ (13). This has also been seen in previous 
literature361, which found similar misfit. The fit problems may be a reflection of the scale 
contents. This is because from a clinical perspective, the DASH items cover a wide range 
of constructs; some items measuring symptoms, others physical function, and others 
psychological well-being.361 Cano et al (2011)361 argue that although these items are 
clinically relevant, they form conceptually disparate elements, therefore summing these 
together into a ‘symptom disability score’ is inappropriate.  This has led Cano et al361 to 
suggest that the DASH is capturing a wider construct than just upper limb functioning.  
Analysis of the unidimensionality of the scale also suggested this, as analysis found the 
scale not to be unidimensional.  
Few participation measures are available in stroke research254, and this is particularly so 
when looking at use of the upper limb post stroke214 . However, there is a growing call to 
use these measures in stroke research.  The DASH was originally developed using 
traditional psychometric methods for people with musculoskeletal disorders. It is therefore 
unsurprising that there are problems translating this measure to a stroke population. 
However, this analysis has shown that traditional psychometric evaluation implied good 
validity and reliability in the measure, although found a high ceiling effect. Rasch analysis 
unmasked further limitations in the scale with disordered response categories, and item 
misfit. However, to allow the findings of this study to be generalisable to the acute stroke 
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population, it would be important to repeat the psychometric analysis, in a larger size 
population with upper limb difficulties.  
 
8.6.2 FMA UPPER LIMB SECTION 
Similar findings to that of the DASH were seen when performing psychometric evaluation 
of the FMA upper limb section. Just as in the DASH evaluation, traditional psychometric 
evaluation found marked ceiling effects with the measure. The scale has been considered 
in the literature as a ‘gold standard’ measure275;276;362, and considerable tradition 
psychometric evaluations have been performed looking at its measurement properties 
275;276 which have been found to be excellent. Some work has commented on ceiling 
effects with the measure in people who have mild stroke362 (This was substantiated in this 
analysis.)  
Rasch analysis also found a number of problems with the scoring and items in the FMA  
This is consistent with previous literature which has examined the psychometric properties 
of the FMA using Rasch  analysis280. 
The pattern of response thresholds for the three reflex items indicates that people are 
responding to these items in a dichotomous manner. Therefore, a dichotomous response 
format would be more appropriate.  The reflex items, particularly the flexor and extensor 
reflex items, under discriminated between patients, with patients of all ability levels tending 
to score the maximum on the flexor and extensor items.  Thus these items do not 
contribute to the scales ability to differentiate between people of different ability levels in 
patients who have had  acute stroke. This has also been seen in previous work which has 
evaluated the FMA using Rasch analysis280.  Woodbury et al280 removed the reflex items 
from the scale to improve the scales validity. 
Ability to perform one type of hand grasp was seen to be highly correlated with the ability 
to perform other types of hand grasp. This was also seen in the wrist items. A dependency 
amongst different shoulder items was also seen (in the flexon synergy section of the 
score), such that performing some shoulder movements were dependent on being able to 
perform other shoulder movements. Hsieh et al363  removed some wrist, hand and 
shoulder items when making a shorter Fugl Meyer score following Rasch analysis. 
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However as these movements may represent different points along the recovery/ability 
continuum it may be preferable not to delete dependent items. Instead a testlet could be 
formed out of the wrist, grasp and shoulder items, to provide an item representing the 
range of arm movement ability.  
Woodbury et al280 looked at the item arrangement and ordering of the FMA. They discuss 
that the measure was initially devised with the intention of measuring upper limb recovery. 
Items were therefore ordered from easy to hard to map this process. As part of Woodbury 
et al280 assessment of the validity of the FMA they looked at the difficulty ordering of items 
and found Rasch generated item difficulty ordering to be different from than that proposed 
by Fugl- Meyer. This was not looked at in detail in this current study, as the aim of this 
work was to compare traditional and newer psychometric methods in regard to the FMA. 
However the dependency in some items as described above may point to similar findings 
with the ordering and items in the measure. Both this dependency and ordering issues in 
the measure may also explain why testing of the unidimensionality of the measure found 
that it was not unidimensional. 
 
8.7 CONCLUSION 
The evaluation of novel interventions (such as the use of a robotic arm in upper limb 
rehabilitation post stroke)  increasingly depends on the use of valid, reliable and 
responsive outcome measures306 . Psychometric analysis of scales plays a key role in 
scale development and testing, to ensure that scales provide scientifically robust, clinically 
meaningful, and clinically interpretable results245 . This study has highlighted the 
importance of using both ‘newer’ psychometric analysis methods such as Rasch analysis, 
along with traditional psychometric analysis to uncover limitations and problems with a 
scale. This current analysis provided an initial evidence base to improve/ change the 
DASH and FMA upper limb score for use as a research tool in acute stroke research.  
Marked ceiling effects were found with both of the measures. This corresponds to the work 
discussed in Chapter Five where similar ceiling and floor effects were found with the 
measures in the first phase of the study. This could be a reflection of the complex nature of 
upper limb recovery following stroke.  Some patients, with relatively mild injury, have 
potential to recover useful function such as the ability to use the hand to hold and 
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manipulate objects, others with more severe injury may not be able to use their arm for 
tasks such as that but may use it to stabilise an object (such as rest hand on a page of a 
book to allow unaffected hand to turn the page). This complexity makes it hard for a scale 
to reflecting clinical important change in clinical and research practice in arm function. The 
analysis performed in this chapter elucidated limitations in measures that have been used 
as “gold standard” upper limb scales 362.However there is a lack of a validated measure 
suitable 214.306 Chen and Winstein (2009)97 echo this view suggesting that there is an 
urgent need to develop such measures. The work performed in this thesis concurs with 
these views. Further discussion on this will be made in the next and final chapter. 
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Table 8.3. Dash Item  fit statistics ordered by chi-square probability 
    Fit Statistics 
Item Item label Location SE Residual Chi-
Square 
I0001 Open a new jar -0.572 0.125 -2.832* 10.7 
I0002 Write 0.817 0.102 2.966* 69.962* 
I0003 Turn a key 0.266 0.114 1.816 5.356 
I0004 Prepare a meal -0.643 0.13 -3.792* 9.697 
I0005 Push open a heavy door -0.138 0.125 -1.62 6.091 
I0006 Place an object on a shelf -0.247 0.123 -3.104* 7.281 
I0007 Do heavy chores -0.91 0.122 -3.604* 4.906 
I0008 Garden  -1.004 0.122 -4.111* 4.358 
I0009 Make a bed -0.617 0.122 -3.726* 7.841 
I0010 Carry a shopping bag -0.684 0.122 -1.676 2.983 
I0011 Carry a heavy load -0.858 0.124 -2.865* 2.843 
I0012 Change a light bulb -0.948 0.124 -3.258* 4.318 
I0013 Wash your hair -0.143 0.123 -3.097* 13.369* 
I0014 Wash your back -0.227 0.124 -1.727 4.869 
I0015 Put on a pullover 0.295 0.124 -2.094 7.337 
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    Fit Statistics 
Item Item label Location SE Residual Chi-
Square 
I0016 Use a knife 0.046 0.123 -1.559 5.79 
I0017 Recreational activities: little effort -0.368 0.125 -4.066* 12.897 
I0018 Recreational activities: force or 
impact 
-1.394 0.122 -2.113 0.429 
I0019 Recreational activities: move arm 
freely 
-1.439 0.122 -1.776 0.325 
I0020 Transportation needs -0.253 0.11 -0.575 5.505 
I0021 Sexual activities 0.273 0.106 5.463* 12.272 
I0022 Interference with social activities -0.21 0.11 0.833 1.133 
I0023 Limited in work -0.411 0.121 -1.599 1.407 
I0024 Pain in arm, shoulder or hand 2.93 0.138 0.87 16.213* 
I0025 Pain performing an activity 2.881 0.137 0.934 17.548* 
26 Tingling in arm, shoulder or hand 1.296 0.123 1.654 38.637* 
I0027 Weakness in arm, shoulder or hand 0.103 0.121 -1.11 4.154 
I0028 Stiffness in arm, shoulder or hand 1.182 0.119 1.092 6.452 
I0029 Difficulty sleeping 1.588 0.128 1.626 5.72 
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    Fit Statistics 
Item Item label Location SE Residual Chi-
Square 
I0030 Feeling less capable -0.614 0.125 10.053* 58.348* 
*indicate items falling outside of recommended limits 
 
Figure 8.2: Graph showing item location for the DASH 
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Table 8.4:. FMA Item fit statistics ordered by chi-square probability 
    Fit Statistics 
Item Item label Location SE Residual Chi-Square 
1.1.1  -4.473 0.256 0.035 19.518* 
1.1.2  -4.301 0.25 0.229 29.158* 
1.2.1  -3.54 0.298 0.462 1.499 
1.2.2  -1.827 0.234 0 0.134 
1.2.3  -1.332 0.229 -0.375 0.507 
1.2.4  -0.732 0.224 0.219 0.482 
1.2.5  -1.258 0.234 -0.395 4.925 
1.2.6  0.021 0.225 -2.503 6.304 
1.3.1  -0.953 0.226 -1.507 5.161 
1.3.2  -0.328 0.223 -2.888 8.604 
1.3.3  -0.131 0.223 -1.883 6.088 
1.4.1  -0.18 0.226 -0.461 0.15 
1.4.2  -0.487 0.224 -1.9 5.159 
1.4.3  0.393 0.224 -3.244 8.509 
1.5.1  -1.287 0.228 -1.447 3.598 
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    Fit Statistics 
Item Item label Location SE Residual Chi-Square 
1.5.2  -0.529 0.223 -0.905 1.942 
1.5.3  0.2 0.224 -2.787 5.177 
1.6  -2.912 0.229 0.625 48.462* 
2.1  0.297 0.223 -2.288 2.813 
2.2  0.659 0.225 -3.516 7.591 
2.3  0.969 0.225 -3.155 5.854 
2.4  0.905 0.224 -2.919 5.164 
2.5  1.239 0.224 -0.384 0.342 
3.1  0.629 0.227 -0.765 1.819 
3.2  1.184 0.229 -1.813 3.03 
3.3  2.718 0.263 -0.375 0.182 
3.4  3.071 0.264 -1.167 3.799 
3.5  2.516 0.24 -0.746 5.96 
3.6  2.442 0.242 -1.147 4.168 
3.7  2.296 0.237 -1.118 3.178 
4.1  0.584 0.223 4.26 37.322* 
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    Fit Statistics 
Item Item label Location SE Residual Chi-Square 
4.2  1.589 0.234 0.408 21.701* 
4.3  2.555 0.258 -0.541 8.245 
*indicate items falling outside of recommended limits 
 
Figure 8.3 Graph Showing Item locations for the FMA. 
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CHAPTER 9: FINAL DISCUSSION 
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9.1 INTRODUCTION 
This chapter will draw together the interrelated strands  of this thesis, providing summary 
and discussion. Initially a synopsis of each chapter will be given and then the main aims 
and findings will be explored with discussion of limitations and strengths. Finally future 
work that has been identified through the studies will also be explored. 
9.2 BACKGROUND AND SUMMARY OF FINDINGS 
Stroke is currently the single largest cause of adult disability in the United Kingdom with 
one third of people who have had a stroke left with long-term disability. Arm recovery post 
stroke is particularly poor.  
This thesis was concerned primarily with recovery of arm movement following stroke. The 
main aim was to investigate the feasibility and practicality of the use of a novel adjunct to 
arm rehabilitation (use of ReachMAN robotic device) in the clinical setting, building on the 
available literature to explore the translation of robotics from experimental research into 
use in clinical practice.  This overriding aim also encompassed 1) investigating who would 
benefit from use of the device, 2) investigating whether the novel intervention itself was of 
benefit to assist arm recovery post stroke 3) Evaluation of upper limb outcome measures 
in order to truly assess the value of the novel intervention. 
First, Chapter One gave a general background on stroke, and the impact a stroke can 
have functionally, cognitively and psychologically. In particular the paucity of upper limb 
recovery was described. The use of increased intensity, with increased repetitions of 
movements was discussed as a way of improving arm movement and recovery.  The use 
of rehabilitation robotics emerged as a means to achieve these aims.   
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Chapter Two, then presented a literature review of the evidence behind the use of robotic 
devices as an adjunct to arm recovery. This review highlighted unanswered questions 
regarding the use of this invention, in particularly the translation of rehabilitation robotics 
from research to clinical practice: Chapter Three reiterated the unanswered questions that 
the thesis hoped to address which were to: clearly define the best outcome scales to use, 
evaluate who could potentially use the device, then test the efficacy of the intervention 
within a defined population using appropriate outcome measures and a mixed 
methodological approach, finally perform psychometric analysis using new & traditional 
methods to evaluate and select the most appropriate outcome measures for future trials. 
Chapter Four described a systematic literature review to establish the most reliable, valid 
and responsive available limb outcome scales to use in the trials described in the thesis. 
This found that three measures best met the psychometric criteria:  Chedoke Arm and 
Hand Inventory, Stroke Rehabilitation Assessment of Movement upper limb section, and 
ABILHAND. However additional measures were also included to ensure the results were 
understood by the wider research community and were reproducible.  The battery of 
measures chosen incorporated a mixture of clinical rated and patient reported outcome 
measures: These were the: STREAM, CAHAI, ABILHAND, FMA, ARAT, EQ5D, SF36, 
Barthel Index, NIHSS and DASH. 
Chapter Five described an evaluation of consecutive acute stroke patients to establish the 
proportion of acute stroke patients that could potentially benefit from rehabilitation using 
ReachMAN.  This found that people with severe arm impairments could use the device. 
Participants needed to be able to sit out for at least ten minutes, if not longer to be able to 
interact with the device, and be able to attend to the task for this time with adequate vision 
to see the screen. 125 people who were within a week of having a stroke were recruited to 
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this phase of the study. 45% of these participants presented with some degree of upper 
limb deficit, of which 46% were able to interface with a mock up of the ReachMAN device 
(pReachMAN). There were some problems found with the targeting and acceptability of 
the battery of outcome measurement scales (this will be further discussed later in this 
chapter) 
Chapter Six described a preliminary randomised control trial aiming to determine how the 
use of a robotic device (ReachMAN) could be delivered in practice. This found that the use 
of ReachMAN was practical and feasible in a sub acute stroke population in participants 
who were inpatients in rehabilitation units. This study did not completely disprove the null 
hypothesis that the use of a ReachMAN makes no significant difference to the recovery of 
the arm after stroke. This was because from the battery of outcome measures only one 
measure the ABILHAND found a statistical significant change between the control group 
and the intervention group .A trend for improved arm movements was seen in the 
intervention group with the other measures. This was particularly seen with the FMA upper 
limb score where an almost doubling of the Standard deviation (when compared to the 
control group) of change scores between baseline and six weeks. Correlations were found 
on subgroup analysis of FMA scores in the control group with level of arm impairments 
(severely armed impairment correlated with lower change in FMA scores on six  week 
measurement). However this was not found in the robotic (intervention) group, this 
suggested that level of impairment did not influence any potential benefit from the device.  
Qualitative interviews with participants who used ReachMAN provided rich data on 
perceptions of the robotic device (Described in Chapter Seven). Participants generally 
described the intervention, when it did not cause pain, as having a positive impact on 
function and movement in their arms. They found it motivating and enjoyable. However 
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they also found it tiring. This fatigue was also noted in the RCT, where 20 minutes use of 
the robot was the average length of time it was used for. This is a shorter period than 
previous literature, but had been reported in one other study on early stroke participants. 
Doornebosch et al (2007) 226 found  sub-acute stroke patients were able to use a robotic 
device for on average 20 minutes a day (when fatigue prevented them using the device for 
longer periods). 
Chapter Eight described detailed psychometric analysis of the two of the outcome 
measures used: DASH and FMA. This was performed to rigorously test the measures to 
ensure targeting and acceptability in order to truly assess the value of the novel 
intervention. This analysis found problems with both measures. In particular ceiling effects 
were seen with both, suggesting that  in any future studies any participants with mildly 
impaired arms, if included in the study, may need other measures to assess their change 
with the intervention. The analysis also suggested means to improve the measures for 
future use (such as removing the reflex questions from the FMA). 
In summary the main messages identified from this thesis are: 
1) The use of a robotic device was found to be a feasible and practical intervention for 
subacute strokes who were undergoing inpatient rehabilitation.  
2) The device was able to be used by a wide range of arm impairments, including 
people with severely impaired arms. The level of severity of arm impairment did not 
seem to impact on any benefits in arm function seen with use of the device. 
3) Although significance was found with only one of the measures, trends were also 
seen to suggest benefit from use of the robotic device and this was strongly 
reported by participants.  
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4) Problems were seen with the targeting and acceptability of the battery of outcome 
measures suggesting a need to develop an upper limb measure that addresses the 
shortfalls found. 
9.3 LIMITATIONS  
The studies were designed in accordance with the MRC framework for the development of 
complex interventions and in correspondence with this guidance 238 a multi-layered 
approach was used, combining a number of different studies and methodological 
approaches.  
However, there were weaknesses in the studies and these will now be discussed: 
9.3.1 GENERAL LIMITATION WITH THE METHODOLOGY USED IN THE 
STUDIES 
The studies were carried out in a single center in central London which provided 
specialised stroke care. This limits the abilities to generalise the results found to the wider 
stroke population, for a number of reasons:  Participants were recruited from a Level One 
(complex specilaised rehabilitation in a tertiary referral) rehabilitation unit in the RCT study, 
which tends to take younger patients who need a longer period of rehabilitation than that 
usually afforded in stroke rehabilitation services; both of these factors could have 
influenced the results as well as the generalisabilty of the study. 
The studies were exploratory in nature, with low population numbers in all stages of the 
study which also makes it difficult to generalise results to the wider stroke population. 
Work by Lincare (1994)359 suggests  a sample of 150 is required for accurate psychometric 
evaluation (data was collected in Phase One on 125 participants only). The pilot RCT did 
not recruit to its ideal number of a total of 40 participants, and power calculation from the 
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results of this study suggests that 146 subjects are required to fully test the hypothesis 
(using the assumption of 5% significance and 80% power). 
The effects of a therapeutic intervention for the stroke population may vary, depending on 
the phase of recovery of the individuals included in the study.  More rapid recovery can be 
expected within the first six months after stroke, and, this may be due to natural recovery.  
The extent to which natural recovery is facilitated or obstructed by external factors is not 
known. In the chronic phase, where recovery may have slowed or plateaued, it may be 
easier to evaluate the effects of an intervention. The effect of natural recovery may well 
have influenced the results seen in these studies.  However, natural recovery would have 
influenced the results of both the control and intervention group in the exploratory RCT.  
The prevailing aim of the studies was to bridge the link between research and clinical 
practice, more patients are seen clinically in the subacute phase when potential for 
recovery is greater109.  Furthermore, fewer studies have looked at robotics in the subacute 
phase post stroke, and this gap in the literature was another focus for the thesis. 
The people recruited to the studies represented a heterogeneous population, including 
those with both haemorrhagic strokes and infarcts. Although this mirrors the population 
treated in clinical practice, the research design could be criticized for including people with 
haemorrhage as this type of stroke has a different aetiology and, sometimes prognosis, 
from infarcts that comprise the majority of strokes. The participants with haemorrhage 
were evenly distributed across both groups in the RCT and so it is unlikely that the results 
were affected by the different diagnoses. If people with haemorrhagic stroke are to be 
included in future studies it may be that the groups should be stratified by stroke 
classification.  
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Furthermore, a broad upper limb impairment inclusion criteria was used in the RCT, this 
again was a heterogeneous population and no stratification for arm function was used. 
Future trials would benefit from subjects being stratified according to severity of arm 
impairment (such as stratification according to FMA UL scores at baseline: A FMA scores: 
0-15 representing severe impairment, moderate impairment 15-38, mild impairment 38-66 
272). The recruitment study (phase 1) found that subjects with mild upper limb deficits found 
using the robot too easy. Due to the marked ceiling effects seen with the measures, in 
conjunction with this finding in the recruitment phase, suggests that subjects with mild 
upper limb deflects could perhaps be excluded from future trials. 
In practical terms this would have meant excluding three subjects from the RCT (two in the 
control group and one in the intervention group) who had baseline FMA scores of above 
38. Subgroup analysis (as reported in Chapter Six) found no significant change if these 
subjects were excluded from the analysis.  
Research trials often have difficulty in recruiting to target and both trials experienced some 
problems in recruitment. The recruitment study took a year to complete (longer than had 
been anticipated). It had also been hoped that the RCT trial would be completed by the 
end of January 2011.  In fact, although recruitment continued until the end of March 2011, 
it was not possible to reach the target of 40 participants.  Factors that may have affected 
recruitment to both phases included the increased use of thrombolysis, and the reduced 
length of stay within the hyper acute stroke unit and ABIU.  Data on the use of 
thrombolysis and length of stay are not available in entirety over the time frame of the 
studies and so it is not possible to confirm whether or not these factors influenced 
recruitment. Although recruitment was higher than used in other research studies 324;140 the 
low recruitment rate limits the generalisability of the results as only a small proportion of 
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the eligible population took part and may not therefore have been representative of the 
population as a whole. 
9.3 2 SPECIFIC LIMITATIONS WITH THE STUDIES. 
Each chapter has detailed limitations within the studies. A further critique of some specific 
issues from the studies will now be explored.  
With reference to the RCT described in Chapter Six, the trial was not blinded. Wade et al 
(2006) 323 have commented on the difficulties of performing double blind RCT to evaluate 
rehabilitation.  It is difficult to blind either the participants or the therapists in studies of a 
novel treatment adjunct.  Some clinical trials of robotics have the control group performing 
sham tasks on the robot 199;364;173 but this could be argued involves additional upper limb 
movement, so could impact on the results. However an independent assessor who is 
blinded to the group allocation could have performed the outcome measurements. This 
should be included in any future trials looking at the ReachMan device. 
A further  limitation of the RCT is that it could be argued that any improvements seen in 
the intervention group was due to the additional input the group received (time spent on 
the robot in additional to their usual therapy) and that any additional arm therapy, 
regardless of the content of this therapy may lead to improved arm function.  Any future 
studies looking at the intervention would benefit therefore from adding matched additional 
arm therapy in the control group to the time intervention group spends on the robot. ( A 
third “active control” group). 
Recent clinical trials looking at robotic intervention have used this strategy. Masiero et al 
(2011)202performed a clinical  trial on 21 subacute stroke subjects. This study compared 
conventional therapy (40 minutes of treatment to the proximal arm in additional to patients 
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normal inpatient therapy), with use of the NeReBot robotic device for two 20 minute 
training session (these patients also received their usual inpatient therapy). Interestingly 
this study found improvements in arm movements in both groups but no difference 
between the groups.  This suggests that additional therapy in whatever form assist with 
improving arm recovery. A study by Burger et al (2011)199  also found similar results when 
matching the intensity of conventional therapy to robotic therapy. In contrast, Liao et al 
(2011) 186investigated the use of Bi-Manu –tract in ten participants in chronic stroke 
subjects, and compared dose-matched control and intervention groups. This study found a 
statistically significant improvement in the FMA measure with use of the robot in 
comparison to the control group.  The disparity of results between studies adds further 
weight for the need for further clinical trials to investigate dose-matched control and robotic 
therapy. 
Records of the conventional therapy provided to the participants were not available in all 
cases.  It was not therefore possible to evaluate how much time was spent on the upper 
limb in the control group. There is no easy way to resolve the problem of ensuring the 
completion and return of conventional treatment records.  Although the information 
required from the therapists was kept as brief as possible (a single sided sheet, mainly 
completed by ticking boxes), Therapists reported this was not completed if they felt they 
had other duties which were more pressing.  Furthermore, due to the length of time the 
trial ran for, there was a considerable change in staffing of therapists (due to rotations, and 
staff leaving), requiring regular training of staff. Similar findings were found in a RCT of an 
upper limb treatment intervention161 where again insufficient completed record of 
conventional therapy made analysis of this not viable.  
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Unpacking the black box of what conventional therapy comprising of, and how much time 
is spent on upper limb activities as part of routine therapy remains an important area323. 
One way of addressing this is to try and made the completion of conventional records a 
part of routine clinical practice therefore it is already established before a clinical trial is 
commenced. This may be possible in a single site centre (and is being initiated at NHNN), 
but may prove to be harder over a multi site trial. 
9.3.3 LIMITATIONS WITH THE REACHMAN DEVICE ITSELF 
The novel robotic device used in the studies discussed in this thesis was designed 
uniquely for the trials themselves. The device was designed in collaboration with clinicians 
(Research Therapist Karen Baker, Consultant Physiotherapist Ann Holland, and 
Consultant Neurologist Diane Playford) and engineers (at Imperial College). This allowed 
the machine to be designed with specific recommendations in mind (to be low cost, simple 
to use, place arm in good alignment) however this also meant it was very much in the 
preliminary stage of design.  
In practice this presented with a number of issues: the machine broke down on numerous 
occasions during the trial, and this impacted on the number of sessions the participants 
were able to use it for. The hand and wrist component of the machine (which allowed hand 
opening and closing) was extremely sensitive and regular adjustments were needed to this 
component of the device. The device was not able to be used independently by 
participants (this will be explored later in Section 9.4.3), was not portable in nature in its 
current design and was found not to be challenging for people with mild arm impairments. 
Chapter Seven described participants ideas on areas that needed changing with the 
device, and these areas would need to be addressed and an updated model of the 
machine required prior to future use   
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9.4 FACTORS AFFECTING THE TRANSLATION OF ROBOTICS INTO 
CLINICAL PRACTICE. 
Chapter Two outlined the unresolved issues and questions impacting on the translation of 
robotics from research into clinical practice. This thesis attempted to address some of 
these areas and these will now be discussed. 
9.4.1 INTENSITY OF PRACTICE 
Research on upper limb recovery, suggests that increased intensity of therapy and 
repetition of practice are seen as the best means to maximise recovery of arm movement 
and function.164 Up to 300-500 repetition of a movement has been recommended to 
enhance motor learning321. It has already been previously discussed that it is unknown the 
amount of movement and repetition the subjects in the control group of the RCT were 
receiving. In the intervention group, subjects were found to move their arm 150-200 reps 
and for a maximum of 20 minutes five days a week. This is lower than the additional 
practice the literature321 suggests is beneficial for improvements in arm movement. This 
may therefore be indicative for the lack of statistically significant differences between the 
groups (although statistical significant change was found with the ABILHAND). However 
trends toward improvement in almost all outcome measures were seen in the robotic 
group compared to the control group. This points to a suggestion that even a small 
increase in the time and repetition of arm movements can made a difference to arm 
function in sub acute stroke patients.    
The interviews highlighted that participants in the intervention group reported they were 
unable to spend more than this time using the robot.  However some expressed they 
would have liked to use the robot more than once a day. This could be a means to 
increase the intensity of using the device, for example its use for two 20 minutes session a 
277 
 
day. The practicality of achieving this in a rehabilitation environment may however prove to 
be difficult. The loss of robotic sessions described in Chapter 6, Table 6.3 illustrated the 
busy nature of subjects day when in the rehabilitation units, adding extra session to this 
may prove challenging. 
 
9.4.2 PATIENTS PERCEPTIONS OF THE DEVICES 
Interviews with participants who used the robot (included in Chapter Seven) described that 
they reported that they enjoyed using the robot and found it motivating. They also 
expressed enjoyment in participating in a research project and the fact that the study 
involved using a novel device added to their enthusiasm. The same enthusiasm may not 
be shown if using a robotic device is introduced as a standard therapeutic adjunct, which 
may adversely affect motivation to use it. Therefore, it is possible that an element of the 
Hawthorne effect occurred, where the participants are merely reporting more benefit due 
to being involved in the study. Theories of learning suggest that the perceived relevance of 
an activity to an individual has an effect on learning 218.  If the person considers that the 
treatment may lead to an improvement in the hand and arm then they may be more 
motivated to attend during the treatment sessions. This may have been an element to 
consider in the intervention group and also if the device was to be used in routine clinical 
practice. 
9.4.3 INDEPENDENT USE OF THE ROBOT 
Another view that was raised from the interviews was that participants expressed a strong 
desire to independently use the robotic device. Participants were unable to switch on the 
programme independently to use the machine. The main physical barrier to independent 
use was the inability to place the paretic arm into the robot arm support independently. 
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Previous studies have also reported difficulty with independent arm attachment 224;134;226. 
The ACRE 2 device 226 utilised a touch-screen computer interface to facilitate the patients 
to initiate and control the device during a session. This could be considered for the next 
model of the ReachMAN device. 
The ultimate goal of rehabilitation robotics is to facilitate supplementary independent 
practice 210. However independent use of the device (or with help from a relative/carer) 
would itself raise a number of issues: 
• Is there something special about the patient-therapist relationship that enhances 
the intervention? 
• Does the therapist have skills that allow them to progress the treatment, and 
respond to changes in the presentation of the patient, that an un-qualified person 
would lack?  If so, could this be adequately addressed by regular reviews with a 
trained therapist? 
• Would there be a benefit in using a robotic device on a daily basis (rather than 
weekdays only)? 
• Would patients with self- directed practice actually use the device daily? 
• Is too much expected of carers already, and would they feel obliged to provide the 
treatment if they were asked to? 
The RCT found that rehabilitation assistants were able to guide the participants with using 
the device, and weekly reviews by a trained therapist were sufficient. How this could be 
achieved with people with arm impairments using the device independently needs further 
thought. 
 The interview with carers did not throw any information as to whether they would be 
happy to assist  their relative with independent use of the robot. As this was not a reality 
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during the study, this may have explained why carers did not mention this when being 
interviewed.  This information may only come to light when this does become an 
applicable option. 
9.4.5 RISKS WITH THE DEVICES 
Chapter Two discussed that current robotics literature suggests that dropout rates from 
clinical trials using robotic devices  were very low and adverse reactions with were rare205.  
This was also seen in the RCT were only one person dropped out of the study due to 
shoulder pain. Chapter Six and Seven explored in further detail this subjects wish to cease 
the intervention and his shoulder pain, and although the MDT felt use of the robot did not 
hugely impact on his pain, he himself felt this was the case.  It is difficult from this single 
incident to infer risk with the use of the device. However this did demonstrate the 
importance of systematic reporting of adverse events and stressed the importance of the 
continuation of this with any future trials.  
9.4.6 WHAT PROPORTION OF ACUTE STROKE PATIENTS COULD 
POTENTIALLY BENEFIT FROM USING A ROBOTIC AID?  
The first phase of the study aimed to address the question of how many people could 
potentially benefit from using a robotic aid. This found that almost half of people who had a 
stroke and who had arm impairment were able to interface with the robotic device, and 
could potentially benefit from its use.  
This is of important clinical significance as it illustrates that a large stroke population (wide 
range of arm impairments) can potentially benefit from the intervention. This is in contrast 
to constraint-induced movement therapy which has been found to have the most robust 
evidence supporting its use365 . A major challenge with constraint-induced movement 
therapy is that trials focus on selective populations (in particular those with some 
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preservation of wrist and finger extension) who are able to tolerate long periods of 
constraint. 
9.4.7 WHAT SEVERITY OF ARM IMPAIRMENT CAN USE THE DEVICE AND 
IS THERE A DIFFERENCE IN THE POTENTIAL BENEFIT OF THE AID 
DEPENDING ON THE SEVERITY OF ARM PARESIS?  
A wide range of impairment levels were found to be able to use the robotic device, and this 
led to a wide range of differing arm impairments levels in the RCT.  
Sub analysis of the FMA scores looking at any potential difference depending on severity 
of arm impairment seemed to suggest that participants with severely impaired arms 
benefited as much from using the device as did people with more movement in their arms 
(while this did not seem to be the case in the control group where more arm movement at 
baseline correlated with better improvement in movement following six weeks of 
conventional therapy).  
Severe arm impairment is prognostic of poor recovery 92.At present there is little therapy 
specifically to promote recovery of the severely paretic or paralysed upper limb after stroke 
In patients with severe upper limb paresis. This may be because the ability to participate in 
repetitive task –orientated activities is limited because they have insufficient underlying 
movement 154 This may explain why stroke patients with severe paresis show limited 
improvement 154 . Robotic devices may be a means for these patients to perform repetitive, 
task-specific activity. The RCT suggested that the use of the device may be beneficial for 
those with severe arm paresis. .  
Other trials161;366 looking at different treatment modalities to assist with upper limb recovery 
have also found that although, the group as a whole may struggle to achieve significant 
change, some stroke survivors respond more than others to the same intervention. Rather 
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than the “one size fits all” treatment that is currently used in research, it may be possible to 
determine which individuals will respond to which treatment by looking for predictors of 
response in their baseline physiology or impairment 54. In this way therapy and treatment 
could be tailored by selecting from a range of valid interventions those which are most 
likely to benefit the individual.  
 
Stinear  et al (2007, 2010, 2012)54;115;116, have completed some work on this in the acute 
stage after stroke. They used a combination of analysis of shoulder and finger movements 
(SAFE score), TMS measures, fMRI, and diffusion tensor imaging (DTI) to develop an 
algorithim for selecting individual rehabilitation strategies based on the prediction of 
functional potential. Further work is required regarding the PREP algorithm proposed in 
Sinear et al.’s work; however this could be used to as a basis to stratify acute patients in a 
larger RCT, comparing normal therapy to robotics.  
 
9.4.8 WHAT RESOURCES ARE REQUIRED IN TERMS OF TRAINED AND 
UNTRAINED STAFF?  
The use of robotics devices as an adjunct in upper limb rehabilitation has emerged as an 
innovative means of delivering quality therapy without increasing staffing capacity or 
service costs162. However, little work has looked at the cost implications of using robotic 
devices in the clinical setting.  Wagner et al (2011)229 is currently the only study that has 
looked at the cost impact of the use of a robot. They found that the average cost of 
delivering both intensive comparison therapy and robotic therapy was more expensive 
than normal care. The cost of both intensive therapy and the use of the device were 
comparable.  
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This pilot RCT found that rehabilitation assistances were able to provide supervision of the 
robotic sessions with weekly checks by a skilled therapist.  This is a preliminary indicator 
for future cost analysis. Cost analysis of the use of device in comparison to normal 
conventional treatment would need to include: the cost of the machine itself, training staff 
to use the robot, therapy time required to monitor participants progress on the device, 
maintenance, cost of fixing the device, and engineering time if it does need repairing . 
A debate in the robotic literature has revolved around whether the expensive actuator 
(motor) components of the robot devices are necessary for the therapeutic effects 
associated with use of a robot 230. Recent literature has examined the use of smaller 
portable devices, which are either non actuated, or EMG triggered 367 , allowing them to be 
cheaper. Page et al (2013)367 compared the cost of commercially available robotic devices 
such as InMotion device ,which is in the range of $75,000, with their EMG triggered device 
“Myomo” costing $7,500. This work is still very much in its infancy. In the studies described 
in this thesis a mock up of the robot – pReachMAN was devised to look at participant’s 
ability to interface with the device. This device was portable, and although it would need 
adapting this device could potentially be used in comparison with the actuated version 
(ReachMAN itself ) to investigate this area further. 
9.4.9 DOES THE USE OF DIFFERENT UPPER LIMB OUTCOME MEASURES 
THAT LOOK AT PATIENT FUNCTION BETTER REVEAL ANY ACTIVITY AND 
PARTICIPATION BENEFIT WITH ROBOTIC DEVICES?  
Few of the clinical trials that have investigated the use of robotic in the people with arm 
difficulties following stroke have incorporated activity and participation level outcome 
measures in their studies. Liao et al (2011)186 study is one of the few studies that have 
used activity and participation outcome measures to look at functional gains with the use 
of a robotic device. This study found that the group who used the robot appeared to 
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incorporate their affected arm more in daily tasks than the control group and found the 
robot group reported significant difference in ability to use their arm when completing the 
ABILHAND (a patient reported outcome measure). In constant a study by Reinkensmeyer 
et al (2012)190 using the Pneu -WREX robot did not find functional improvements on the 
Motor Activity Log. 
The RCT described in this thesis found statistical significant  change with using the robot 
in the ABILHAND (similar to the Liao et al (2011) 186 study) and trends for improvement 
with function were also seen in other activity and participation measures used in the trial 
(CAHI and DASH).  Further larger studies would however be required to see if these 
trends were of significance. 
One aspect that was not assessed in the studies was the participants’ actual use of their 
hand and arm in daily life. Accelerometers were used in the Liao et al(2011) 186 study, and 
have been used in other studies in an attempt to quantify the amount that people move 
their arm after stroke (e.g. Lang et al, 2007129).  Accelerometers have some limitations and 
one source of unreliability may be that trunk movement can cause passive upper limb 
movement that may then be recorded as upper limb activity.  Additionally, although upper 
limb movement may be recorded, no information will be provided as to whether the 
movement was intentional or not, and if it was functional.  Lang et al (2007)129 however 
reported good correlation between movements as recorded using an accelerometer and 
Functional Independence Measure (FIM) scores, suggesting that it may provide an 
indication of the functional use of the arm. Whilst, accelerometers and the ABILHAND 
score found increased arm use following the use of the Bi-Manu-Tract robot in ten chronic 
stroke patients186  
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Other studies199;190 have used the Motor Activity Log. This scale also measures 
participants’ actual use of their hand and arm in daily life.  Ashford et al (2008) 214 in their 
systematic review of outcome measures found this measure to be a robust measure of 
upper limb function. They however found, as did the systematic review carried out in 
Chapter Four that this measure has psychometric flaws306. It was due to these 
psychometric flaws that the measure was not used in this study. However it may have 
been a useful inclusion as a means of looking at the subject’s actual use of their impaired 
upper limbs. 
9.4.10 BATTERY OF OUTCOME MEASURES USED IN THE STUDY 
The battery of outcome measures used in the study has been found to be valid and 
reliable in the stroke population.  However on analysis of targeting and acceptability, 
marked floor and ceiling effects were found in the measures.  
The outcome measures used to assess changes within the trial population may not have 
been sensitive enough to detect clinically significant differences within the severely 
impaired population and the mildly impaired population.  Ashford et al(2008)214  in their 
review of upper limb measures echo this view commenting that there is a scarcity of 
validated tools to assess passive and lower level arm function.  Subjects with severely 
impaired arms who were interviewed regarding using the robotic device remarked  that 
they thought following treatment they were able to use their impaired arms for more 
functional activities such as holding a page of a book to stabilize while turning the pages, 
placing a book under their impaired arm to carry it. Marked ceiling was also found with the 
measures for the subjects with mild arm impairments. 
Ashford et al (2013)368 have developed an outcome measure the ArmA that looks at both 
active upper limb movement and also “passive”  function (making it easier to care for the 
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limb (e.g. maintain hygiene) if no motor return is possible. This may be a useful measure 
to include in future trials when looking at subjects with severely impaired arms. However 
the measure does not look at iems such as the ease in using the affected hand to holding 
a page of a book (such as described by participants in the interviews in Chapter Seven). 
There is a requirement for psychometrically robust instruments capable of reflecting 
clinically important change in clinical and research practice to cover the full range of upper 
limb impairments214;306. Particularly there is a need for more sensitive measures of change 
in those with more severe levels of impairment.  Developing a new outcome measure 
using both tradition and newer psychometric methods (such as Rasch analysis) would 
address this gap. 
 
9.5 SUMMARY OF LIMITATIONS IN THE STUDIES 
The studies described in this thesis comprised of  modeling, phase 11 studies which 
investigated the acceptability, the likely rate of recruitment and retention of subjects and 
the calculation of appropriate sample size (as described in the feasibility and piloting stage  
of the MRC framework for complex interventions238). Therefore no firm conclusions can be 
drawn from the studies described.  
The studies were hampered by small sample numbers, heterogeneous subject groups, 
lack of blinding, no follow-up period, not matched comparator groups, no record of the 
exact treatment in the conventional therapy group and problems with the targeting and 
acceptability of the outcome measures. 
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9.6 FUTURE WORK 
The present study has been able to answer some of the questions raised and gaps 
identified in the evidence base regarding the use of robotic devices. However it has also 
identified a wide range of areas that would merit further study. The MRC guidance 238 
provides a framework in which interventions can be tested.  This approach is supported by 
Dobkin (2009) 209 who proposes a progressive series of pilots, prior to larger-scale trials. 
With this in mind, further pilots investigating the potential benefits of ReachMAN could look 
at: 
1) Newer upgraded version of the device, which allows self directed practice 
2) Different intensity and dose of using the device ( i.e. its use over seven days a 
week, twice daily) 
3) Comparing the use of ReachMAN with an non actuated device such as 
pReachMAN 
4) Looking at the use of ReachMAN in different stroke populations, such as the 
chronic stroke populations. 
5) Cost data of the use of a robotic device compared to conventional therapy is 
required. In an increasingly financially pressured NHS this cost data will be 
essential for any recommendations for nationwide provision of robotic devices in 
clinical settings. 
6) It would be beneficial to perform a definitive RCT using the data from the pilot study 
to allow definitive conclusions as to the potential benefits of the novel device on 
arm recovery.  
7) As discussed the results from both the qualitative and quantitative data imply that 
the battery of outcome measure used were ineffective in capturing change in arm 
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function. Future work to  develop an outcome measure that can capture change in 
patients with severe arm impairment would be extremely beneficial.  
 
9.7 CONCLUSION  
Stroke is a significant cause of disability in the population.  When the hand and arm are 
affected by stroke, functional recovery may be poor.  There is a range of factors that affect 
the upper limb after stroke and impact on recovery. The mechanisms by which recovery 
occurs remain unclear; although, repetitive task-specific training appears to be beneficial. 
The use of robotic devices as an adjunct to rehabilitation of the arm post stoke has 
emerged as an innovative means to deliver repetitive arm movements.  Although, there is 
evidence to suggest that the use of robotic devices may have beneficial effects on upper 
limb recovery after stroke, there remain unanswered questions regarding the use of this 
intervention. This is particularly apparent regarding the translation of rehabilitation robotics 
from research into clinical practice. 
This thesis aimed to bridge between research and clinical utilisation of a robotic device. It 
is difficult to evaluate ‘complex interventions’, such as rehabilitation. Appropriate outcome 
measures that are valid, reliable and sensitive are required. Initially a systematic review 
looking at upper limb outcome measures found that the STREAM, CAHAI, ABILHAND, 
FMA, ARAT, EQ5D, Barthel index , NIHSS and DASH were the most appropriate 
measures to use to evaluate the use of a robotic device in sub acute strokes.  
A recruitment study found that out of 125 subjects, of the people who had upper limb 
difficulties, almost half were able to use the robotic device. A subsequent pilot RCT found 
statistical significant change in one of measures used ABILHAND, but not the primary 
outcome measure the FMA. . The efficacy of using the device in comparison to subjects 
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normal therapy was therefore not proven in a sub acute stroke population. However as 
well as one measure showing statistical significance, there was a trend towards 
improvement in motor performance and function in the robotic group. The trial 
demonstrated that, even amongst the severely impaired stroke population, there can be 
improvement in motor performance. Subjects were only able to tolerate 20 minutes use of 
the device due to participant fatigue. Limitations of the study related to the sensitivity of the 
outcome measures to assess change within this population; the absence of blinding in the 
study; no matched intensity of therapy in the control group to that in the intervention group.   
Interviews with subjects found that they described a positive impact of using the device on 
function and movement in their arm and it to be motivating and enjoyable. They wished to 
be able to use it independently and reinforced that they found 20 minutes the maximum 
amount of time they could use the device for.  Problems were seen with the targeting and 
acceptability of the battery of outcome measures, while use of Rasch analysis allowed 
deeper analysis of the measures and also suggestions on how to improve the measures 
for future use.   
In summary, further work is required to investigate therapeutic interventions for the upper 
limb in all phases of stroke recovery, and specifically the use of robotic devices. Although 
the null hypotheses were not rejected the trends seen with use of the device, support 
further investigation into the use of REACHMAN in the stroke population. This work should 
identify appropriate ways of measuring changes that are clinically important and 
meaningful for individuals with stroke.   
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APPENDIX 1 CONVENTIONAL UPPER LIMB PT / OT TREATMENT RECORDING 
FORM 
Conventional Upper Limb PT / OT Treatment Recording Form 
Date:     Patient ID:  Therapist ID: 
Individual treatment session Y/N  Upper limb group Y/N 1:1 Y/N 
No. PT(s) used:  No. OT(s) used:  Number rehab assistant(s) used:  
Estimated duration of UL Rx:   Aim of session: 
Postural set(s) utilised: Stand…. Sit…. Supine…. Prone standing…. Side lying….Other….. 
Setting: Gym:.....  Ward:....  Bathroom:......Kitchen:....Home environment…… Work 
environment:.... 
Equipment used: 
Treatment Activities: 
1.0 Soft tissue mobilisation / realignment 
2. 0 Joint mobilisation  
3.0 Hand oedema management 
4.0 Facilitation of muscle activity / movement 
5.0Sensorimotor integration 
5.1Tactile stimulation and muscle activation 
5.2Proprioceptive stimulation and muscle activation 
5.3Electrical stimulation and muscle activation 
6.0 Strengthening 
 6.1Resistance from therapist 
6.2Resistance from body weight 
6.3Resistance from object weight 
7.0 Task orientated training 
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 7.1Reach to grasp with facilitation 
7.2Reach to grasp without facilitation 
7.3Manipulation 
7.4Bimanual task with facilitation 
7.5Bimanual task without facilitation 
8.0 Balance and mobility tasks incorporating upper limb activity 
 8.1In or from lying 
8.2In or from sitting 
8.3In or from standing 
8.4In walking 
9.0 Positioning 
9.1In bed 
9.2In armchair  
9.3In wheelchair 
10.0Seating 
10.1Anti-sag in situ 
10.2Scaffolding of pelvis 
10.3Trunk support 
10.4Tray 
10.5Other 
11.0Splinting /taping 
 11.1Shoulder 
 11.2Elbow 
 11.3Wrist / hand 
12.00Education for patient and/or carer 
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12.1Self monitoring of UL 
12.2Assistance with stretches 
 2.3Assistance with transfers 
12.4Limb handling and positioning skills  
13.00Practice 
13.1Exercise programme with assistance 
13.2Exercise programme with set up of the environment 
APPENDIX 11 REACHMAN PROTOCOL 
 
 
 
2010 
Karen Baker 
UCL Institute of Neurology 
 
Instruction Manual for 
ReachMAN  
320 
 
SUMMARY 
 
***************************************************************************** 
SWITCH ON 
1. Switch on computer with password ‘1234’ 
2. Open ReachMAN.lvproj  open both host.vi and target.vi 
3. Click run (white arrow) on the HOST.vi first.  
a. 3D window will pop out and adjust it to the other monitor.  
4. Click run (white arrow) on the TARGET.vi and make sure the robot is in safe position. 
5. Change the name and date as required on the TARGET.vi interface. 
 
***************************************************************************** 
INITIALIZATION 
6. Robot is ready to go and first step is to INITIALIZE the robot position. 
a. Go to host.vi and select ‘INIT’ (default setting).  
b. Choose required left or right hand. 
c. Make sure robot is in good position – around in the middle of the linear guide and 
the grasping is in close position. 
d. Click the START button 
e. Robot should move. If not, check the emergency button if it’s switched off.  
f. Do not touch the robot while moving.  
g. When the robot stop completely, manually adjust the ‘rotation’ and then click on 
the ‘Reset Rot’. 
 
7. Now can place patient to the robot. Adjust the ideal comfortable position for the patient. 
Make sure the shoulder is parallel with body trunk and elbow flexed to about 90º and the 
robot position should be at initial position (mark by a marker) 
 
8. Position with trunk restraint.  
 
9. Select Game and select one of the four different modes to play; Reaching, 
Pronosupination, Grasping and Combination. Select the appropriate level and make sure 
to click the ‘Reset Level’ each time the level is changed.  
 
***************************************************************************** 
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TREATMENTS 
10. Treatment should start with reaching, pronosupination, grasping and finally combination. 
Perform about 5 on each one. Only train combination if patients are able to perform in 
more than level 2 for reaching and pronosupination. Skip the exercise if patient could not 
do it. 
 
11. In the first session, level should start from lowest or based on the performance from 
assessment. The next day session’s level should follow the previous session. 
 
12. One Level increased when patient is able to score perfect 10 with score more than 90% 
for three consecutive exercises. Only 1 level increment per session. 
 
13. When treatment is finish, stop the program by pressing the ESC button. This will close 
the program properly and save all the required data. 
 
14. The data is saved at ftp://192.168.0.40/data/. 
 
***************************************************************************** 
ASSESSMENT 
15. Assessment is done on the second and last sessions. Two measurements are done 
here which are the forces and score on each exercise.  
a. FORCE measurements 
Choose both the ‘AUTO ASSESS’ and ‘Reaching’ together. Measure 
pushing&pulling forces and pronation&supination torques. Ask the patients to 
perform each of the four movements as hard as possible for about 3 seconds 
and twice on each one. 
b. PERFORMANCE of exercises 
Train at least twice on level 7 for reaching, pronosupination and grasping. 
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Step by step Guidance to operation 
 
1. Switch on computer and enter password ‘1234’ 
2. Click on the ReachMAN.lvproj shortcut in the desktop and proceed to step 5. If click onto 
folder ‘Shortcut to 1.Labview’ on the screen, then proceed to step 3.   
 
 
3. Select the most recent ReachManNUM folder with NUM is the most recent number. The 
software is updated regularly and the most recent program is updated with the highest 
NUM number. In the screenshot below, the most recent one is ReachMan151. 
 
4. Choose and open ReachMan.lvproj.  
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5. Double click and open host.vi and target–single rate–variables.vi:  
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6. Your computer screen should look like this. The right is your HOST VI (Virtual 
Instrument) and bottom left is the VI for target (the robot)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. Click play on the host (the arrow on top left). Once it’s running, you will have a window 
screen showing 3D visual pop up. Drag and enlarge the screen on the second monitor 
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as it’s shown below. Adjust the Host.vi position so the score and the big blue progress 
bar is overlapping a small part of the leftmost of the 3D window screen so patient can 
see both the 3D visual and the score.  
 
 
 
 
8. Now, click run on the target (the arrow on the top left). Write the Name of the subject, 
Month, Day and Seq for naming a filename to be saved. You can do this before or after 
running the target. Example below shows the filename is Subject03_100128_01.txt. All 
files are saved in C:\Data. 
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9. Once you done that, go to INIT bar (default) and then choose which hand to exercise. 
Then, click the START and press the ‘green’ button on the emergency button. Make 
sure the robot grasping mechanism is fully closed and the robot is at about the central 
position. The robot should move on it’s own to initialise its position.  (do not touch or 
block the robot’s way during the initialise movement).The robot starts to move backward 
linearly and then rotate anti clockwise until reaching the limit. Then, the robot will move 
to start position for both linear (labelled with a yellow sticker) and rotation clockwise to 
zero degree for chosen left or right hand. Make adjustment manually on the rotation to 
exactly vertical position and click ‘Reset Rot’. Press the emergency’s red button if robot 
has to be stopped.  
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10. Position patient to robot handle and wrap as required. Height of the robot is adjusted so 
the elbow and hand are placed nicely on the arm support.  
11. Click on the game bar where you can select what exercise mode to choose and which 
level to start with. There are 4 exercise modes to choose which are reaching, 
pronosupintation, grasping and combination.  There are 9 levels on each exercise. Make 
sure to click on the ‘Reset Level’ to submit the changes each time the level is required 
to modified. You have to do this individually on each of the mode.  
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12. Choose desired exercise’s mode and level, and then click Start. Patient has to move the 
handle (shown as green object) to match the target (red object). Each start has 10 
targets to reach and patient progress is shown as number of hit and score. The score is 
inclusive of progress in movement, speed and stability.  
13. Once they finish the experiment, double check with the filename again and then press 
Esc or click on the STOP button (below Start button) on the Host.vi. (do not use other 
possible ways to stop the program as that will cause the program not to save the data 
correctly. 
14. Data are saved at ftp://192.168.0.40/Data/ and can be retrieved either using windows 
explorer or any internet browser. 
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POSITIONING THE PATIENT 
 
Adjust the ideal comfortable position for the patient.  
 
 Make sure the shoulder is parallel with body trunk 
 Elbow flexed to about 90º and the robot position should be at initial position 
(mark by yellow marker) 
 Ensure patient is sat well in chair/wheelchair. 
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USING TRUNK RESTRAINT 
 
 
This is to prevent excessive trunk movement; ensuring movement is from the arm. 
 
 
 Place two folded towels into a pillowcase 
 This forms an abdominal pad (place pillow cases on subjects abdominals) 
 Secure in place with a sheet 
 Tie at back of chair. 
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APPENDIX 111  PSYCHOMETRIC EVALAUATION  CRITERIA WITH DEFINITIONS 
Psychometric evaluation criteria with definitions  
Content validity. The extent to which the domain of interest is 
comprehensively sampled by the items in the meausre 
Floor and ceiling effects. The measure fails to demonstrate a worse 
score in patients clinically deteriorated and an improved score in 
patients who clinically improved 
1) Patients were involved during item selection and/or item 
reduction. 
1) Descriptive statistics of the distribution of scores were presented. 
2) Patients were consulted for reading and comprehension. 2) 15% of respondents achieved the highest or lowest possible score. 
Rating: Rating: 
+ patients and (investigator or expert) involved + no floor/ceiling effects 
± patients only – more than 15% in extremities 
– no patient involvement ? no information found on floor and ceiling effects 
? no information found on content validity 
 
  
Test-retest reliability. The extent to which the same results are 
obtained on repeated administrations of the same questionnaire 
when no change in physical functioning has occurred 
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Internal consistency. The extent to which items in a (sub)scale are 
intercorrelated;a measure of the homogeneity of a (sub)scale 
1) Calculation of an intraclass correlation coefficient (ICC); ICC > 
0.70. 
1) Factor analysis was applied in order to provide empirical support 
for the dimensionality of the questionnaire 
2) Time interval and confidence intervals were presented. 
2) Cronbach’s alpha between 0.70 and 0.90 for every 
dimension/subscale 
Rating: 
Rating: + adequate design, method, and ICC > 0.70 
+ adequate design & method; factor analysis; alpha 0.70–0.90 ± doubtful method was used 
± doubtful method used – inadequate reliability 
– inadequate internal consistency ? no information found on test-retest reliability 
? no information found on internal consistency Agreement. The ability to produce exactly the same scores with 
repeated measurements 
Construct validity. The extent to which scores on the measure 
relate to other measures in a manner that is consistent with 
theoretically derived hypothesis concerning the domains that are 
measured. 
1) For evaluative questionnaires reliability agreement should be 
assessed. 
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1) Hypotheses were formulated. 2) Limits of agreement, Kappa or standard error of measurement 
(SEM) presented. 
2) Results were acceptable in accordance with the hypotheses. Rating: 
3) An adequate measure was used. + adequate design, method and result 
Rating: ± doubtful method used 
+ adequate design, method, and result – inadequate agreement 
± doubtful method used ? no information found on agreement 
– inadequate construct validity  
? no information found on construct validity  
Responsiveness. The ability to detect important change over time 
in the concept being measured 
Interpretability. The degree to which one can assign qualitative 
meaning to quantitative scores 
1) For evaluative questionnaires responsiveness should be 
assessed. 
Authors provided information on the interpretation of scores: 
2) Hypotheses were formulated and results were in agreement. 1) Presentation of means and standard deviation of scores before 
and after treatment. 
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3) An adequate measure was used (effect size (ES), standarized 
response mean (SRM), comparison with external standard). 
2) Comparative data on the distribution of scores in relevant 
subgroups. 
Rating: 3) Information on the relationship of scores to well-known functional 
measures or clinical diagnosis. 
+ adequate design, method and result 4) Information on the association between changes in score and 
patients’ global ratings of the magnitude of change they have 
experienced. 
± doubtful method used Rating: 
– inadequate responsiveness + 2 or more of the above types of information was presented 
? no information found on responsiveness ± doubtful method used or doubtful description 
Minimal clinically important difference (MCID). The smallest 
difference in score in the domain of interest which patients perceive 
as beneficial and would mandate a change in patient’s management. 
Information is provided about what (difference in) score would be 
clinically meaningful. 
? no information found on interpretation 
Rating: Time to administer. Time needed to complete the questionnaire 
+ MCID presented Rating: 
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– no MCID presented – more than 10 min 
 + less than 10 min 
 ? no information found on time to complete the questionnaire 
Administration burden. Ease of the method used to calculate the 
questionnaire’s score 
 
Rating:  
+ easy: summing up of the items  
± moderate: visual analogue scale (VAS) or simple formula  
– difficult: VAS in combination with formula, or complex formula  
? no information found on rating method  
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Measure  Time Administrative 
Burden 
Content 
Validity 
Internal 
consistency 
Construct 
validity 
Floor/ 
ceiling 
effect 
Reliability Agreement Responsiveness Interpretability MCID 
ABILHAND     – + + + + – + + + + + 
CAHAI - + + + + - + + + + ? 
  
STREAM + + + + + - + ? + ? ? 
            
            
            
 
MCID: minimal clinically important difference; method or result was rated as: + adequate; ± doubtful; – poor; ? no data available;  
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APPENDIX 1V-CONSENT AND INFORMATION SHEET FOR PHASE 1 
 
 
Date 17th June 2008 
Centre Number:       UCLH Project ID number: 
08/0107 
Patient Identification Number for this study:    Form version: 2 
 
 
CONSENT FORM 
 
 
Title of project: A feasibility study of use of a cheap, portable robotic aid for delivering repetitive 
practice of reach, supination, and manipulation in acute stroke:  Phase 1 
 
 
Name of Principal Investigator: Dr ED Playford 
Name of Research Physiotherapist: Karen Baker 
 
          Please initial box 
 
1. I confirm that I have read and understood the information sheet dated …….. 
(version ……..) for the above study and have had the opportunity to ask 
questions. 
 
 
   
2.  I confirm that I have had sufficient time to consider whether or not want to 
be included in the study  
 
 
 
   
3. I confirm that I am happy for my general practitioner to be informed of my 
participation in this study 
 
 
   
4. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal 
rights being affected. 
 
 
 
 
   
5. I understand that sections of any of my medical notes may be looked at by 
responsible individuals from (company name) or from regulatory authorities 
where it is relevant to my taking part in research.  I give permission for these 
individuals to have access to my records. 
 
   
 
6. 
 
I agree to take part in the above study. 
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         Continued on next page 
 
 
1 form for Patient;  
1 to be kept as part of the study documentation,   
1 to be kept with hospital notes 
 
Centre Number:       UCLH Project ID number: 
08/0107 
Patient Identification Number for this study:    Form version:  2 
 
 
CONSENT FORM 
 
 
Title of project: A feasibility study of use of a cheap, portable robotic aid for delivering repetitive 
practice of reach, supination, and manipulation in acute stroke:  Phase 1 
 
 
Name of Principal Investigator: Dr ED Playford 
Name of Research Physiotherapist: Karen Baker 
 
 
__________________________ _________________  
 _____________________ 
Name of patient    Date     Signature 
 
 
 
 
________________________         _____________________ 
 ______________________ 
Name of Person taking consent  Date     Signature 
(if different from researcher) 
 
 
Karen Baker    k.baker@ucl.ac.uk  t: 0845155500 x 723821 
Researcher (to be contacted   Email/phone number     
if there are any problems)  
         
 
 
Comments or concerns during the study  
 
If you have any comments or concerns you may discuss these with the 
investigator.   If you wish to go further and complain about any aspect of the 
way you have been approached or treated during the course of the study, you 
should write or get in touch with the Complaints Manager, UCL hospitals.  
Please quote the UCLH project number at the top this consent form. 
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1 form for Patient;  
1 to be kept as part of the study documentation,   
1 to be kept with hospital notes 
APPENDIX V-- ETHICS APPROVAL AND ADMENTS TO ETHICS APPROVAL 
 
 
The National Hospital for Neurology and Neurosurgery  
& Institute of Neurology Joint REC 
Dr Diane Playford 
 
National Hospital for Neurology and Neurosurgery 
Queen Square 
London 
WC1N 3BG 
 
Our Ref 09L 476 
REC Office 
South House 
Royal Free Hospital 
Pond Street 
London 
NW3 2QG 
Tel:  020 7794 0500 ext. 31342 
Fax: 0207 7941004 
Email: 
Sasha.Vandayar@royalfree.nhs.uk 
Website:  www.uclh.nhs.uk 
 
02 December 2009 
Dear Dr Playford 
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Study title: A feasibility study of use of a cheap, portable robotic aid 
for delivering repetitive practice of reach, supination, and 
manipulation in acute stroke 
REC reference: 08/H0716/13 
Amendment number: 1 
Amendment date: 05 November 2009 
 
The above amendment was reviewed at the meeting of the Sub-Committee held on 02 
December 2009. 
 
Ethical opinion 
The members of the Committee taking part in the review gave a favourable ethical opinion of 
the amendment on the basis described in the notice of amendment form and supporting 
documentation. 
Approved documents 
The documents reviewed and approved at the meeting were: 
 Document  Version  Date  
Protocol  2  30 September 
2009  
Notice of Substantial Amendment (non-CTIMPs)  1  05 November 
2009  
 
Membership of the Committee 
The members of the Committee who took part in the review are listed on the attached sheet. 
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R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D approval 
of the research. 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees (July 2001) and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
08/H0716/13:     Please quote this number on all correspondence 
Yours sincerely 
Miss Sasha Vandayar 
COMMITTEE CO-ORDINATOR 
 
E-mail: Sasha.Vandayar@royalfree.nhs.uk 
Enclosures: List of names and professions of members who took part in the 
review 
 
Copy to: R&D - UCLH 
The National Hospital for Neurology and Neurosurgery & Institute of Neurology Joint 
REC 
 
Attendance at Sub-Committee of the REC meeting on 02 December 2009 
 
Name   Profession   Capacity    
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Dr Yogi Amin  Consultant in Neuroanaesthesia & 
Neurocritical Care  
Expert  
Ms  Katy  Judd  Consultant Nurse  Expert  
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APPENDIX V1- - CONSENT FORM AND INFORMATION SHEET FOR  RCT 
 
Version 1. 
Date 5.03.08 
UCLH Project ID number:  
 
Patients information sheet:  Part 1 
 
 
1. Study title 
 
Phase II of A feasibility study of use of a cheap, portable robotic aid for delivering repetitive 
practice of reach, supination, and manipulation in acute stroke:   
 
 
2. Invitation  
 
We would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it would involve for you. Please take time 
to read the following information carefully. Talk to others about the study if you wish.  (Part 1 
tells you the purpose of this study and what will happen to you if you take part.  Part 2 gives you 
more detailed information about the conduct of the study).  Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not you wish to take 
part.  
 
 
3. What is the purpose of the study? 
 
Following stroke approximately 30% of patients are left with some weakness in the arm.  There 
is growing evidence that increasing use of the arm early after stroke improves outcome.  
However, augmenting therapy time is difficult.  Currently most stroke units have one 
physiotherapist for every six patients, and patients receive about one hour of therapy each day. 
To increase therapy time to 4 hours a day would mean that a physiotherapist would have to be 
employed for every 2 patients.  The use of robotic aid is a potential solution to the difficulties in 
increasing practice time. ‘Robotic’ aids can provide high-intensity, repetitive, task specific, 
interactive treatment of the affected arm.   The aim of this study is to determine how a robotic 
intervention would be delivered to patients in a randomised controlled trial.  We hope to 
establish how long it takes to set up the equipment so that a patient can use it, and to establish 
how often and for how long patients use the device. In addition we want to know how easily the 
measures we use detect any differences between a group who use the device and a group who 
do not.  
 
 
4. Why have I been chosen? 
 
You have been chosen because you have been recently diagnosed with stroke, your arm is 
affected  
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5. Do I have to take part? 
 
It is up to you to decide whether or not to take part.   If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form.  If you decide to take 
part you are still free to withdraw at any time and without giving a reason.   Decisions to 
withdraw at any time, or a decision not to take part, will not affect your future medical care. 
 
 
6. What is involved in the study? 
 
If you agree to take part you will be assigned to one of two different groups.  Because we do not 
know if the robotic intervention will be helpful, we need to make comparisons.   You will have a 
fifty-fifty chance of being in either group A or group B. 
 
One group, group A, will undergo ‘usual practice’.  They will be provided with physiotherapy and 
occupational therapy appropriate to their needs as determined by the clinicians looking after 
them.  Typically this would be a physiotherapy session everyday of the week and an 
occupational therapy session 2 or 3 times each week.  
 
The second group, group B, will be usual practice rehabilitation but in addition they will be asked 
to practice for at least an hour each day, and for as long as they want to using the robotic aid.  
They will be asked to continue this practice daily for six weeks.  We will record how long you 
practice for in order to work out what is practical for most patients.  We will also ask you about 
your experience of using the robotic aid.  
 
All patients will have the the function on the affected arm tested at entry to the study and six 
weeks later using a series of simple tests and questionnaires.  The tests will include activities 
such as lifting blocks or put small pegs into a hole.  Each of these assessments will take 
approximately 45 minutes.   
 
 
7. What is the procedure being tested? 
 
The procedure being tested is the ability to use ‘robotic’ aid for repetitive practice.  It is not, at 
present a treatment but may be one in the future.  
 
 
8. What are the alternatives for treatment? 
 
Currently robotic aids are not in use for routine treatment.  All patients who need it will receive 
physiotherapy and occupational therapy. 
 
 
9. What are the possible disadvantages and risks of taking part? 
 
The disadvantages of taking part in this study is that it will require time and effort when you may 
be feeling distressed by what has happened to you.  The main risk to those in group B is that 
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repetitive practice may make your hand, arm, shoulder, neck or back ache.  If this happens you 
should tell the doctors and nurses looking after you at the time, who will be able to give you 
some pain killers.  In addition should tell the research physiotherapist who will advise you about 
whether you should modify your practice in anyway.   
 
 
10. What are the possible benefits of taking part? 
 
It is possible that those in the repetitive practice group will get some improvement in arm 
function greater than that that would have occurred anyway.  There is some evidence that this is 
the case but the evidence is not strong. 
 
 
11. What if there is a problem? 
 
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed. The detailed information on this is given in Part 2.  
 
 
11 Will my taking part in the study be kept confidential?  
 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2.  
 
 
 
 
Patients information sheet:  Part 2 
 
 
12. What if relevant new information becomes available?  
 
Sometimes we get new information about the treatment being studied. If this happens, your 
research physiotherapist will tell you and discuss whether you should continue in the study. 
 
  
13. What will happen if I don’t want to carry on with the study?  
 
If you decide to withdraw from the study and we have already collected some information about 
you, you have two choices.  Either you can let us use the data that we have already collected or 
you can ask for it to be destroy 
 
 
14. What if there is a problem 
 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions (0845 155500 ext 3166). If you 
remain unhappy and wish to complain formally, you can do this through the NHS Complaints 
Procedure Details can be obtained from the hospital.  
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In the event that something does go wrong and you are harmed during the research and this is 
due to someone’s negligence then you may have grounds for a legal action for compensation 
against UCLH NHS Foundation Trust but you may have to pay your legal costs. The normal 
National Health Service complaints mechanisms will still be available to you (if appropriate).  
 
 
15. Will my taking part in this study be kept confidential? 
  
The information we collect about you will be collected first on paper and then transferring to a 
computer.  When it is transferred to the computer the information will be anonymised and you 
will be identified by a number unique to this study.  The information will be stored on a single 
computer that is password protected and kept in locked room.  Only those people directly 
involved with the analysis of the information will have access to it.  It will not be made available 
to other people, or for other studies. At the end of seven years the information will be destroyed.  
 
 
16. Involvement of the General Practitioner/Family doctor (GP)  
 
Your GP and your Consultant will both be informed that you are taking part in the study, unless 
you prefer that they are not informed. 
 
 
17. What will happen to the results of the research study? 
 
The preliminary results of the research will be available in the summer/autumn 2010.  They will 
be published in a medical journal the following year.  The stroke association will also publish the 
results of the study through their magazines and websites. You will not be identified in any 
report/publication. 
 
The final results will be available in 2012 and will be published in a medical journal and via the 
Stroke Association 
 
 
18. Who is organising and funding the research? 
 
The Stroke Association is funding the research 
 
 
19. Who has reviewed the study? 
 
All research in the NHS is looked at by independent group of people, called a Research Ethics 
Committee to protect your safety, rights, wellbeing and dignity. This study has been reviewed 
and given favourable opinion by The National Hospital for Neurology and Neurosurgery/Institute 
of Neurology Joint Research Ethics Committee. 
 
 
20. Contact for Further Information 
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If you require any further information please contact Dr Diane Playford, Consultant Neurologist, 
on 08 
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APPENDIX V11 INFORMATION SHEET REGARDING THE INTERVIEWS 
 
RESEARCH PARTICIPANT INFORMATION SHEET 
 
You are being invited to take part in a research study. Before you decide, it is important for you 
to understand why the research is being done and what it will involve. Please take time to read 
the following information carefully and discuss it with others if you wish.  Ask me if there is 
anything that is not clear or if you would like more information.   
Thank you for reading this 
 
 
Title of the study: 
Patients’ and carers’ perceptions of the use of robotics in upper limb rehabilitation after 
stroke. 
 
What is the purpose of the study? 
Robotic aids have been introduced to stroke rehabilitation to allow extra practice of arm 
exercises. Involving patients in the design and planning of therapy programs has been shown 
make rehabilitation more effective. The aim of this study is to find out how stroke patients and 
their carers feel about using robotic aids as part of their rehabilitation. In particular it will look at 
aspects of design, ways in which it is used, and means of improving motivation to participate in 
therapy. 
 
Physiotherapy will not be provided as part of this study. The study is about obtaining your views 
on robotic therapy. It is hoped that the information you provide will influence the development of 
future robotic aids and therapy programs. 
 
Why have I been chosen? 
You have been approached because you or your relative have experience of using a robotic aid 
as part of your stroke rehabilitation program at the National Hospital for Neurology and 
Neurosurgery. You are the best person to describe your experience of using the robotic aid. 
 
 
 
Do I have to take part? 
No, participation is entirely voluntary. You are under no obligation to take part in this study. If 
you decide to participate and then at some point change your mind you are free to withdraw 
from the study at any point and do not need to give a reason for doing so. Declining to 
take part will not impact on any services you are currently receiving or may receive in the future. 
 
What will happen to me if I take part? 
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If you are considering taking part or would like to know more about the study you can either 
phone me on the number listed below or you can speak to Karen Baker, the research 
physiotherapist at the National Hospital for Neurology and Neurosurgery. We can then explain 
the study to you and answer any questions you might have. If you are willing to participate in the 
study then I will arrange a convenient time to visit you in your home to conduct an interview to 
obtain your views on this topic. The interview may take as long as an hour, although this length 
of time may not be required and some interviews will be shorter. I will need to tape record our 
conversation so that I am able to remember all the points you make accurately.  
 
Will my taking part be kept confidential? 
All information and data obtained from you will be treated as privileged and confidential. It will 
be stored in a secure area and not released to any unauthorised person without your 
permission. The consent form will be the only document that has your full name on it and it will 
be stored safely and separately from the other data. When the information is written up I may 
use direct quotes but you will not be identifiable from them. 
 
What are the possible benefits of taking part? 
The benefit of you taking part in this study is that your opinion, together with the opinions of the 
other participants, will hopefully help to influence and inform the development of a new robotic 
aids and rehabilitation programs for other stroke survivors. 
  
What are the risks in taking part? 
It is possible that you may become upset when talking about your stroke and rehabilitation. If I 
feel concerned about your well being because of how unhappy you are feeling then I would 
need to break confidentiality and discuss this with your doctor. I would let you know if I was 
going to do this.  
 
What will happen to the results of the study? 
The information received from you and the other participants will be used to write an MSc 
(Neurorehabilitation) dissertation project. The results will be presented to healthcare 
professionals and engineers who are interested in the development of robotic therapy.  
 
Concerns and Complaints 
Any queries regarding the project can be directed to the research supervisor, her details are 
listed below. If at any point during the study you have any concerns or complaints about the 
study or the student these can be addressed to the Chair of the Research Ethics Committee. 
Contact details have been listed below.  
 
Thank you very much for taking the time to read this information. If you have any 
questions please do not hesitate to ask me or you can contact me on the number below. 
 
 
My Contact Details: My Supervisor’s details: 
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Bríd Spillane 
 
MSc Neurorehabilitation, 
School of Health Sciences & Social 
Care 
Brunel University, UB8 3PH 
 
Tel: 07910344963 
Email:  om09bbs@brunel.ac.uk 
Dr Sally Spencer 
 
Lecturer in Health Studies 
School of Health Sciences & Social Care 
Brunel University, UB8 3PH 
 
Tel: 01895 268843 
Email:  sally.spencer@brunel.ac.uk    
 
Chair of the Research Ethics Committee 
Elizabeth Cassidy 
School of Health Sciences and Social Care 
Brunel University UB8 3PH 
Tel: 01895 268736 
elizabeth.cassidy@brunel.ac.uk 
 
 
Research ethics approval has been obtained from the School of Health Sciences and 
Social Care Research Ethics Committee and the Joint Research Ethics Committee of The 
National Hospital for Neurology and the Institute of Neurology. 
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APPENDIX V111- INTERVIEW TOPIC GUIDE 
 
• Check that the participant is still happy to be involved in the research 
• Check that participant is OK with being recorded. Reassure about confidentiality. 
• Reminder of the purpose of the interview. Indicate length of interview. 
  
Tell me about your experience of using the robot? 
 
General perceptions of robot and expectations.  
Prompts: Expectation 
Comfort  
Pain 
Satisfied 
Safe 
Confusing  
 
Perceptions of the treatment protocol. 
Prompts: Too long, too short 
Challenging 
Meaningful/Functional 
Any changes 
Design of robot 
Prompts Appearance  
Comfort 
Ease of setting up and attachment 
Any changes? 
 
Motivational Aspects?  
Prompts:  Help with motivation to persist with practice? 
Feedback: 
   Helpful? 
Understandable? 
Sufficient? 
Computer games: 
Opinion on using computer games in stroke rehabilitation 
   Enjoyable? Interested? 
  Virtual Reality 
 
Use of Robot in Different Environments 
Prompts:  Using the robot at home: 
   Barriers (assistance, size etc) 
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   Benefits 
Outpatient setting  
Telerehabilitation 
 
Is there anything else you would like to tell me about your experience of the robot? 
 
Thank the participant  
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APPENDIX V1V-EXAMPLE OF FRAMEWORK ANALYSIS CARRIED OUT ON 
INTERVIEW TRANSCRIPTS. 
Robotic Arm interviews 
 
I can leave that between us.  I have got some questions that I have asked everybody  
Ok 
So that I get the same general ideas from everybody.  So the first one is so broad and 
general, can you tell me about your experience of using the robot? 
 Ah well, first of all my experience of using it.  I think at first I didn’t see or feel like I needed to do 
this because I thought it wasn't helping so when I heard about the robot I thought it was just 
something that would do the actual thing for you.  
Yes 
But then, it is not bad.  I mean it is coming.  Gradually I am getting to, you know, sort of like and 
to actually use it.  I try to go to the sessions more often.   
Ok 
At first I was just a bit senseless and just could not be bothered, couldn’t be asked to do 
anything. 
Whereas have you found that it has been a bit helpful for you? 
I think it does because, I think, yeah it does.  Because it has been helping me a lot with my 
reaching and stuff ok? 
(Agrees) 
Although my hand is not you know, my grasping is not as 100% it does help. 
 What did you, what was your first impression of it when you saw it the first time?   
As I said at first my first impression when I heard of the term robot was not going to be, I thought 
it was actually a (pause) programmed machine that actually does something for you like, 
basically it is programmed to do the actual action.  But when I saw it I was like “Ok this is 
actually a computer, actually it is, you  know, set and runs the programme as one” 
And you can interact with it 
Interact with it, hands on. 
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That is good about it isn’t it?  What do you think about the idea of using robotics in 
stroke rehab? 
Actually it is a good idea but I just had one kind of…maybe I shouldn’t say wish.  I was just 
hoping that it would have been more easier to use. 
Ok 
Yes 
Yes 
And maybe benefits are more obvious because I didn’t really get it at first, to be honest. 
 
I think that is fair enough.  In terms of it being easier to use, do you mean easier to get 
yourself set up on it? 
 
Yes user friendly as well and in a sense where you can see a quicker progress in your body. 
Like, it is more effective on the body. 
 
Yes 
 
Yes, I mean in the upcoming researches that the researchers are carrying out they could maybe 
try and come up with something more feasible, something more effective which gives a faster 
result. Yes. 
 
Yes, yes.  That is the difficult thing 
 
It is very frustrating as a patient using it and being, you know, hearing robot.  You are thinking, 
“Ok this is something that is actually designed to, you know, do help” and it…you should see 
quick progress and quick improvement. 
 
So you would have liked to have seen faster progress? 
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Yes faster progress. 
 
Right but you have seen some progress? 
 
I have 
 
Good.  Did you find it enjoyable to use? 
 
Some days yes I guess.  Some days it can be a bit boring.  It all depends on your mood as well 
because if you are going to be like “Ok whatever” it is going to be “Ok whatever”.  
 
Yes it is going to be a boring day.  
 
Yes some days it is really enjoyable because like, you know, you are using your actual…It is like 
it is somewhat similar to, I would say in my version, is a Wii because you are actually interacting 
with your hands on.  You are just testing how much you can score or what your best score can 
be, you know?  Just trying to get it right. 
 
Yes, that idea of it being like a computer game is something that we want to advance and 
make it a little bit better.  But first can I get your opinion on what did you think of the 
graphics? 
 
It is very minimal but I think they can give you a bit more to look at. 
 
Ok 
 
It can be a bit boring just looking at this screen with just this red thing on the screen.  Yes, it can 
be a bit boring.  There could be a bit more to look at, a bit more to be, you know, even could 
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maybe possibly use creatures, like little creatures running around and trying to get them.  You 
know, stuff like that. 
 
Yes, yes.  Did you understand what you needed to do from the graphics?  Did it make 
sense to you? 
 
Yes it did. 
 
It did, good.  So you were able understand them but they were just a bit basic and a bit 
boring 
 
A bit basic yes. 
 
Would you like to have more interesting games incorporated into it? 
 
Incorporated into it, yes definitely.   
 
Did you find the scoring system, did that help in terms of monitoring your progress. 
 
Yes 
 
Yes? 
 
Definitely for me because I am a bit competitive so definitely  
 
So it was good to feel the scores getting better? 
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Yes, getting better and better 
 
 Did you find the movements challenged you? 
 
Yes definitely because I even had a discussion with the actual person who supervised the 
sessions. 
 
Yes 
 
Right and I had said to him that some of the tasks are for more advanced people, you know like 
the grasping because if you don’t have that much range of movement in your hand there is no 
way you can do that because it is going to be frustrating for you as a patient because, you 
know, it is asking you to do this but you are trying to do it and it is not happening.  So it is really 
frustrating sometimes, yes. 
 
Did you find that the reaching movement was easier for you? 
 
The reaching was easier for me. 
 
What about the turning over movement? 
 
Rotating task, that was a bit challenging too. 
 
Ok.  That is a good mix of there still being something that you can use to work on… 
 
Yes the good thing about it is that it can be monitored in you know, for such advanced or 
beginner depending on the range of movement you have in your hand.  But it can get a bit 
frustrating if you don’t have that much range of movement in your hand. 
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Yes, you mentioned earlier about it, making it more user friendly 
 
Yes 
 
What would you like me to do with it? 
 
Well user friendly in the sense that maybe you could get yourself set up and you know get going 
if someone is not there to supervise you, to put you in.   
 
I think that is key to it, that we need to simplify the set up 
 
Simplify the set up, yes 
 
In terms of computers, are you pretty computer savvy?  Are you used to using 
computers? 
 
I am used to them 
 
Yes great, so you wouldn’t have a problem with the interface of a computer? 
 
No it is just the actual set up of the  
 
The physical… 
 
Yes, it is all a bit complex, you strapping yourself in and all that. 
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And it is hard to do with a weak, with a weak arm.  Do the movements that you were 
doing, so the reach, rotate and grasp, do they seem meaningful or functional? 
 
It was meaningful because these are things that we do in daily life activities, the hand is quite 
complex.  It flexes, it adducts, it rotates. 
 
Did you feel those movements you were practicing on the robot, did they tie in with your 
goals, with your rehab goals? 
 
They did 
 
Good 
 
They did because to be honest I have seen big change improvements in my hand.  It is actually 
doing much more so I am happy for that. 
 
Good.  Did you find the set up comfortable or did it cause you any pain? 
 
Just a bit but I think it had to do with sensation problems. 
 
Ok 
 
Yes, within the palm of my hand.  It was just a bit uncomfortable 
 
So is the palm of your hand a bit hyper sensitive? 
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Hyper sensitive, yes 
 
Ok and then when you put your hand and strapped it in that irritated it? 
 
Yes it was just resting against it  
 
You didn’t get any shoulder pain from it? 
 
No 
 
Good, that’s great.  How about the length of time that you were using it for, how long did 
you use it for in general? 
 
I would possibly say, off the top of my head I would say maybe three weeks 
 
Yes, and in each session, were you using it for 10 minutes, 20 minutes, 30 minutes? 
 
Maybe 10-15 minutes 
 
Yes, was that long enough? 
 
It could be longer 
 
You… 
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But as I said before you don’t want to have the sessions too long because sometimes it gets a 
bit boring, yes.  And it is frustrating for you as a patient when you are trying to do something and 
it is not happening. 
 
Yes and it is more the boring and the frustration than being too tired to keep going with 
it? 
 
The frustration  
 
Yes, so fatigue was not really a problem? 
 
No fatigue was not a problem, it was just frustration and not being able to carry out the task 
being asked. 
 
Ok.  Did you find that you were able to maintain your concentration, your attention, while 
you were doing it? 
 
Yes, definitely 
 
Unless you got too bored? 
 
Yes, unless you got too bored.  I mean you have the screen in front of you and you know it is 
just basically you are watching so I was thinking if you had more characters or you know things 
on the screen. 
 
Something like the Wii… 
 
Yes, just to have something more entertaining going on in front of you that wouold just have 
your attention. 
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And that would keep you more in a…? 
 
To keep you focused, engaged. 
 
And then you might feel like using it more often? 
 
A bit more often because it is funny using it 
 
So having something that is fun, interesting and engaging… 
 
Engaging 
 
Would be a priority for you? 
 
Definitely 
 
Great, that is what we, that is what we want to develop in it.  The other thing that we want 
to do is make the robot suitable for use at home.  What would you think, sort of, if I 
offered you, I can’t at the moment, but if I could offer you a robot to take home with you?  
Is it something you would be interested in? 
 
As I said the set up is a bit complex.  First you would have to know how to set it up. 
 
Would you have somebody as home that would help you? 
 
Definitely 
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You do, good.  But you would need assistance to get set up.  How about the size and 
space, would you be willing to make some space? 
 
Yes the size is a bit, yeah.  Just a bit huge. 
 
We would need to make it a bit more compact. 
 
More compact, yes.  That is it. 
 
That makes lots and lots of sense.  Can I just go back?  Where there any other 
movements that you would like to incorporate into it?  Into the robot? 
 
Well, no because I think that is basically it, reaching, grasping, rotating, that is what the arm 
does.  It hyperextends, it flexes so… 
 
You felt it covered the key movements? 
 
I felt it covered the key movements of the arm. 
 
I meant to talk more about the robot at home.  The way that we envisage using it, some 
other robots have been set up like this, whereby you link the robot and the software that 
runs the robot is linked by the internet to me in a central clinic so that I can use, what do 
you call it? A webcam to watch you doing your exercises  and I can monitor your 
progress so that your robot sends me feedback reports as to how often you are doing it, 
whether you are getting better at it, whether I need to turn up the intensity a little bit.  
Those kinds of things.  What do you think of that as an idea? 
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It is a great idea but I don’t think it would be as feasible as having the machine there because it 
is a hands on thing and having it at home would actually help. 
 
This, you would have it at home.  So you would have the robot connected to your 
computer, so it would be just like using it here but the idea behind it is that it would save 
me having to travel out to your house. 
 
Ok 
 
Yes, or save you having to come into the hospital.  So that you would be able to practice 
it at home. 
 
Not bad of an idea, but I mean monitored over the internet there are a lot things that you can do 
because you are concentrating on your posture, you are concentrating about your truncal 
strength, using your body to reach 
 
Yes 
 
You are using your arm.  You know there are a lot of things you have to concentrate on.  So 
having someone who will monitor you actually in the space I think is a better idea than being 
monitored over a webcam.  Because you could be cheating using the wrong muscles and all 
that. 
 
Exactly.  I think we find lots of people do the lean forward instead of doing a nice reach 
from their arm.  Yes that is good if you can identify the cheating postures then that is half 
the battle.  Compared with your regular physio how useful did you find the robot? 
 
I should say average. 
 
So it is not amazingly better than your physio, than your regular physio but it is not.. 
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It is average 
 
Average, ok that makes sense. 
 
If it was an actual, an actual physio you get a lot more feedback and you actually get hands on 
like massages and stuff, you know hands on stuff with actual physios.   
 
And you can’t replace that with a machine? 
 
Right with a machine 
 
And the idea behind the machine is to supplement physio not to replace it but to give you 
the repetitions of the movement because we know that repetitive task specific practice 
which is what the robot gives you is the optimum thing after brain injury or stroke.  So 
that is the idea of it.  Once you go home would you be interested if I had the robot set up 
in out patients here?  Would you be interested in travelling in to use it? 
 
Yes definitely 
 
Yes, it would be something that you would value? 
 
Yes 
 
Or that you would consider would be worth your time, good, good. 
 
If you were progressing I would definitely enjoy it.  If I can see where I was benefiting definitely 
worth my time 
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Do you feel that the robot has contributed to your recovery? 
 
Yes. 
 
Ok, good.  Is there anything else that you would change about the robot? 
 
As I said its size, a little bit more compact and a little bit more user friendly. 
 
Yes 
 
Graphics, games 
 
Yes, those are… 
 
A little bit more interesting, a little bit more playful.   
 
What kind of games would you like to see on it?  What we are thinking of are the sport 
types of games… 
 
Something just a little bit more entertaining.  Something more, everyday activity because we are 
humans and you know we use our hands to do everyday activity, tasks that we are the brain is 
actually familiar with, things that you know can be remembered using the arm.  It can be all like, 
you know send signals and stuff to that affected area. 
 
One of the things that some researchers are looking at with robotics is using virtual 
reality with the robot.  So that you have censors on your hand and some of them have 
you know curved screens, large curved screens, and some of them have goggles and 
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eye pieces.   But instead of playing a game you have an avatar or an image of your hand 
so that when you open and close your hand in the robot in your virtual environment you 
can do things with your hand.  That means that you can do practical things with your 
hand so you could, I don’t know, practice using a screwdriver or that type of, something 
that is real. 
 
Yes real 
 
Do you think that, which would you prefer to do games that are fun or to do the type of 
virtual reality thing which is more functional?   
 
Virtual reality definitely.  It is more functional, just more yes. 
 
I think it is very high tech and the equipment is huge and bulky at the moment so we 
need to wait for some better advances in that technology before it is realistic, I think 
because our idea is to have something small, cheap, portable and easy to use.  Is there 
anything else you want to tell me about the robot? 
 
That is pretty much it. 
 
It’s pretty much it? 
 
Yes  
 
That is fine.  Thanks for taking the time to have a chat with me. 
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